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Autism spectrum disorders (ASDs) are a group of childhood onset neuropsychiatric 
disorders with shared core symptoms but varying severity. Although a strong 
genetic component has been established in ASDs, genetic susceptibility factors 
have largely eluded characterization, despite active research for decades. In this 
study, we have utilized modern molecular genetics methods combined with the 
special characteristics of the isolated Finnish population to identify genetic risk 
factors for ASDs.
The results of this study show that numerous genetic risk factors exist for ASDs 
even within the Finnish population. The lack of founder mutations in a subset of 
distantly related families from an internal subisolate suggests that the majority 
of genetic risk factors are rare, de novo mutations unique to individual nuclear 
families. The results of this study are consistent with other recent studies of 
genetic risk factors for ASDs. The underlying genetic architecture for ASDs has 
emerged to be highly heterogeneous, with common variants accounting for 
only a subset of genetic risk. The majority of identified risk factors have turned 
out to be exceedingly rare, and family specific linkage, homozygosity mapping 
and resequencing efforts are needed to identify this type of genetic risk factors.
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“What does it matter to Science if her passionate servants 
are rich or poor, happy or unhappy, healthy or ill? She 
knows that they have been created to seek and to 
discover, and that they will seek and find until their 
strength dries up at its source. It is not in a scientist‟s 
power to struggle against his vocation: even on his days 
of disgust or rebellion his steps lead him inevitably back 
to his laboratory apparatus.” 
-From Madame Curie – A biography by Eve Curie 
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ABSTRACT 
Positional cloning has made it possible to perform hypothesis-free, genome-wide 
scans for genetic factors affecting a disorder or trait. Traditionally linkage analysis 
using microsatellite markers has been used as a first step in this process to identify 
regions of interest, followed by meticulous fine mapping and candidate gene 
screening using association methods and subsequent sequence analysis. More 
recently, genome-wide association analysis has enabled a more direct approach to 
identify specific genetic variants explaining a part of the variance of the phenotype 
of interest. In addition, data produced for genome-wide association analysis has also 
made it possible to assay small, submicroscopic variation on the chromosomes, 
referred to as copy number variants, which have been shown to confer susceptibility 
to some complex disorders. 
Isolates have proven useful in the identification of genes causing Mendelian, or 
monogenic, disorders. The Finnish population is genetically homogenous, and has 
been molded by founder effect, multiple consecutive bottlenecks and genetic drift. 
These features can be utilized in identification of genetic risk factors for complex 
disorders, although population isolates have not been shown to be as useful for the 
genetic mapping of complex traits as for Mendelian disorders. The genetic risk 
factors for complex disorders in Finland could, however, prove to be less 
heterogeneous due to the limited range of susceptibility alleles carried into the gene 
pool by the original settlers. 
Autism spectrum disorders (ASDs) are a group of childhood onset neuropsychiatric 
disorders with shared core symptoms but varying severity. Although a strong genetic 
component has been established in ASDs, genetic susceptibility factors have largely 
eluded characterization, despite active research for decades. In this study, we have 
utilized modern molecular genetics methods combined with the special 
characteristics of the Finnish population to identify genetic risk factors for ASDs. 
The results of this study show that numerous genetic risk factors exist for ASDs 
even within a population isolate. Stratification based on clinical phenotype resulted 
in encouraging results, as linkage to 3p14-p24 identified in the Finnish genome-wide 
linkage scan for Asperger Syndrome (AS) was replicated in an independent family 
set. The success of linkage mapping of susceptibility regions for AS has interesting 
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implications for the underlying genetic architecture, suggesting that genetic risk 
factors for AS could possibly be less heterogeneous than for the wider spectrum of 
ASDs. 
Fine-mapping of the previously identified linkage peak for ASDs at 3q25-q27 
revealed association between ASDs and a subunit of the 5-hydroxytryptamine 
receptor 3C (HTR3C). The 5-hydroxytryptamine pathway has previously been 
robustly implicated in the etiology of ASDs but this is the first time the 5-
hydroxytryptamine receptors on 3q have been evaluated as risk factors for ASDs. 
However, association to HTR3C only accounted for a part of the observed linkage 
signal, suggesting that other predisposing factors exist at this locus. 
As a part of this study, we used dense, genome-wide single nucleotide 
polymorphism (SNP) data to characterize the population structure. We observed 
significant population substructure caused by the multiple consecutive bottle-necks 
experienced by the Finnish population during the population history. We used this 
information to ascertain a genetically homogenous subset of autism families from 
Central Finland to identify possible rare, enriched risk variants from dense, genome-
wide SNP data. However, no rare enriched genetic risk factors were identified in this 
dataset, although a subset of families could be genealogically linked to form two 
extended pedigrees which would suggest shared susceptibility factors. The lack of 
founder mutations in this isolated population suggests that the majority of genetic 
risk factors are rare, de novo mutations unique to individual nuclear families. We 
also attempted to use gene ontology (GO)-categories to characterize the biological 
pathways involved in ASDs, but found significant heterogeneity in identified GO-
categories among different genome wide SNP and gene expression datasets. 
The results of this study are consistent with other recent studies of genetic risk 
factors for ASDs. The underlying genetic architecture for this group of complex 
disorders seems to be highly heterogeneous, with common variants accounting for 
only a subset of genetic risk. The majority of identified risk factors have turned out 
to be exceedingly rare, and only explain a subset of the genetic risk in the general 
population in spite of their high penetrance within individual families. The results of 
this study, together with other results obtained in this field, indicate that family 
specific linkage, homozygosity mapping and resequencing efforts are needed to 
identify these rare genetic risk factors. 
 
Keywords: Autism spectrum disorder, Asperger syndrome, linkage analysis, 
expression analysis, genome-wide association analysis, isolated population, 
population genetics, serotonin receptor 
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TIIVISTELMÄ  
Paikkaan perustuva geenitunnistus eli positionaalinen kloonaus on mahdollistanut 
hypoteesittomat, koko perimän kattavat tutkimukset joilla voidaan kartoittaa 
tauteihin ja ominaisuuksiin vaikuttavia perinnöllisiä tekijöitä. Kytkentä-analyysi, 
sekä sitä seuraava hienokartoitus ja sekvenssianalyysi ovat kuitenkin suuritöisiä ja 
sairautta aiheuttavan muutoksen tunnistaminen on usein hidasta. Nykyisin 
perimänlaajuiset assosiaatiomenetelmät tarjoavat oikotien sairautta aiheuttavan 
muutoksen tai siihen liittyvän pienen kromosomaalisen alueen tunnistamiseen. 
Lisäksi näistä tutkimuksista saatavaa tietoa voidaan käyttää pienten 
kromosomaalisten poikkeamien, ns. kopiolukuvarianttien, tunnistamiseen. Näiden 
kopiolukuvarianttien on osoitettu lisäävän riskiä joillekin sairauksille. 
Väestöisolaatit ovat osoittautuneet hyödyllisiksi yhden geenin aiheuttamien 
sairauksien geenien tunnistamisessa. Suomalainen väestö on geneettisesti 
yhtenäinen, ja sitä ovat muokanneet perustajavaikutus, genettiset pullonkaulat ja 
sattuma. Suomalaisen väestön erityispiirteitä voidaan käyttää hyväksi myös 
tunnistettaessa riskigeenejä monitekijäisille taudeille, vaikka isolaattien hyöty 
näiden monimutkaisemmin periytyvien tautien geenikartoituksessa ei välttämättä ole 
yhtä suuri kuin monogeenisten tautien kohdalla. Verrattuna sekaväestöihin 
monitekijäisten tautien riskigeenen kirjo saattaa olla Suomessa suppeampi, sillä 
maamme alkuperäiset asuttajat toivat mukanaan vain osan kaikista mahdollisista 
geneettisistä riskitekijöistä. 
Autismikirjon sairaudet ovat ryhmä vakavuudeltaan vaihtelevia, lapsuudessa alkavia 
neuropsykiatrisia sairauksia. Vaikka perintötekijöiden on todettu vaikuttavan 
vahvasti autismikirjon sairauksien syntyyn, aktiivisesta tutkimuksesta huolimatta ei 
sairauksille altistavia geenimuotoja vielä ole tunnistettu kuin kourallinen. Tässä 
tutkimuksessa olemme käyttääneet molekyyligenetiikan uusimpia menetelmiä 
hyödyntäen samalla suomalaisen väestön erityispiirteitä tunnistaaksemme näille 
sairauksille altistavia perinnöllisiä tekijöitä. 
Tämän väitöskirjatutkimuksen tulokset osoittavat, että autismikirjon sairauksille 
altistavat useat eri geenimuodot jopa eristyneessä väestössä. Keskittymällä 
kliinisesti rajattuun ilmiasuun, eli perheisiin joissa esiintyy vain Aspergerin 
oireyhtymää (AS), pystyimme toistamaan aikaisemmin raportoimamme kytkennän 
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kromosomiin 3p14-p24 AS-perheissä. Kytkentäanalyysien tulokset AS:ssä 
herättävätkin kiinnostavan kysymyksen siitä, onko AS:n perinnöllinen riski 
yhtenäisempi kuin muissa autismikirjon sairauksissa. 
Tutkiessamme tarkemmin aiemmin tunnistamaamme kytkentää kromosomissa 3q25-
q27 perheissä, joissa esiintyy autismia ja muita autismikirjon sairauksia tunnistimme 
assosiaation serotoniinireseptorin 3 alayksikön C (HTR3C) ja autismin välillä. Tämä 
löydös on erityisen kiinnostava, koska serotoniini ja siihen liittyvät biologiset 
prosessit on aiemminkin liitetty autismikirjon sairauksiin. Assosiaatio HTR3C:hen 
selitti kumminkin vain osan alueella havaitsemastamme kytkennästä, joten on hyvin 
todennäköistä että alueella sijaitsee myös muita autismille altistavia perintötekijöitä. 
Tutkiessamme Suomalaista väestörakennetta löysimme huomattavia eroja eri 
puolelta Suomea kotoisin olevien ihmisten perimästä. Erot ovat seurausta 
väestöhistorian aikana tapahtuneista useista pullonkauloista, jotka ovat muokanneet 
väestön perimää. Käytimme tutkimuksesta saamaamme tietoa valitessamme 
autismin perimänlaajuista assosiaatiokartoitusta varten geneettisesti yhtenäisen 
joukon perheitä Keski-Suomesta tunnistaaksemme tähän väestöön rikastuneita, 
harvinaisia geenimuotoja. Emme kuitenkaan löytäneet tällaisia, vaikka pystyimme 
yhdistämään osan Keski-Suomalaisista perheistä kahteen suureen sukupuuhun, joka 
puhuisi yhteisten perinnöllisten riskitekijöiden puolesta. Perustajamutaatioiden 
puute suomalaisessa väestössä osoittaa, että todennäköisesti autismikirjon 
perinnöllisistä riskitekijöistä suurin osa on harvinaisia de novo mutaatioita, joita 
esiintyy vain yksittäissä perheissä. Käytimme myös geeniontologia (GO) 
kategorioita tunnistaaksemme biologisia prosesseja jotka liittyvät autismikirjon 
sairauksiin. Tunnistimme runsaasti eri GO-katgorioita eri tutkimusaineistoissa, joka 
omalta osaltaan antavat lisätodisteita siitä että autismille altistavat useat erilaiset 
biologiset prosessit jotka eivät vältämättä ole samoja eri väestöissä. 
Yhteenvetona tutkimuksen tulokset osoittavat että autismikirjon sairauksia 
aiheuttavat muutokset useissa eri geeneissä, ja yleiset geenimuodot selittävät vain 
pienen osan perinnöllisestä riskistä. Suurin osa tunnistetuista perinnöllisistä 
riskitekijöistä on harvinaisia, ja ne selittävät vain pienen osan riskiä väestötasolla, 
mutta vaikuttavat merkittävästi yksittäisten perheiden riskiin. Tämän tutkimuksen 
tulokset, yhdessä muualla saatujen tulosten kanssa osoittavat että perinnöllisiä 
riskejä tulisi etsiä yksittäisistä perheistä käyttäen kytkentä-, homozygotiakartoitus- 
ja sekvensointimenetelmiä. 
 
Avansanat: Autismikirjon sairaus, Aspergerin oireyhtymä, kytkentäanalyysi, 
ekspressioanalyysi, genominlaajuinen assosiaatioanalyysi, isolaatti, populaatio-
genetiikka, serotoniinreseptori  
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ABSTRAKT 
Med termen positionell kloning menar man hypotesfria, genomomfattande 
kartläggningar som har möjliggjort identifikation av genetiska faktorer som inverkar 
på sjukdomar och egenskaper. Traditionell kopplingsanalys följs upp av finskalig 
kartläggning och sekvensanalys, som ofta är bade mödosamt och långsamt. 
Nuförtiden möjliggör genomomfattande associationsanalys ofta en snabbare metod 
för identifikation av genetiska riskfaktorer. Dessutom möjliggör data från 
genomomfattande associationsstudier även analys av små kromosomala avvikelser, 
sk. copy number variants, som medför risk för vissa sjukdomar. 
Isolerade populationer har med framgång använts i kartläggning av gener för 
sjukdomar som orsakas av fel i en gen. Den finländska populationen är genetiskt 
homogen, och har formats av grundareffekt, flaskhalseffekter och genetisk drift. Den 
finländska befolkningens särdrag kan också utnyttjas i kartläggning av riskgener för 
komplexa sjukdomar. Det är dock oklart om isolerade populationer medför lika stor 
fördel i genkartläggning av komplexa sjukdomar jämfört med monogena sjukdomar. 
Jämfört med blandade befolkningar är det sannolikt att de genetiska riskfaktorerna 
för komplexa sjukdomar är färre, eftersom den ursprungliga grundarpopulationen 
endast bar på en liten del av alla genetiska riskvarianter för en viss sjukdom. 
Autismspektrets sjukdomar är en grupp neuropsykiatriska sjukdomar med liknande 
symptom men varierande svårhetsgrad som manifesterar i tidig barndom. Trots att 
genetiska faktorer har påvisats spela en viktig roll i risken för dessa sjukdomar, har 
endast ett fåtal sällsynta genetiska riskfaktorer identifierats trots aktiv forskning 
inom området. I denna studie har vi använt moderna molekylärgenetiska metoder 
och samtidigt utnyttjat den finländska populationens särdrag för att identifiera 
genetiska riskfaktorer för autismspektrets sjukdomar. 
Vi använde kopplingsanalys för att identifiera genetiska riskfaktorer i familjer med 
Aspergers syndrom (AS). Vi har tidigare identifierat koppling till 3p14-p24 i en 
genomomfattande kopplingsstudie av AS-familjer i Finland, och lyckades nu 
upprepa detta resultat i nya familjer. Framgången av genetisk kartläggning i familjer 
med AS väcker intressanta frågor gällande strukturen av de genetiska riskfaktorerna. 
Kanske är det så att risk för AS styrs av färre riskfaktorer än för autismspektrets 
sjukdomar i allmänhet. 
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Vi har tidigare även rapporterat koppling till 3q25-q27 i Finlandska familjer med 
autism samt andra autismspektrets sjukdomar. I finskalig kartläggning av området 
identifierade vi association mellan underenhet C av serotoninreceptor 3 (HTR3C) 
och autism. Biologiska processer kopplade till serotonin har tidigare förknippats 
med autism, vilket gör vårt fynd intressant. Associationsresultaten påvisade dock att 
association till HTR3C endast förklarar en del av kopplingsresultatet, så det är 
sannolikt att även andra genetiska riskfaktorer för autism är belägna i regionen. 
Inom ramen för denna studie ville vi även undersöka populationsstrukturen i 
Finland, och observerade signifikanta skillnader mellan individer från olika delar av 
landet. Detta är en följd av de flertal genetiska flaskhalsar den finländska 
populationen har upplevt under sin historia. Vi använde denna information för att 
välja ut en genetiskt homogen grupp autism-familjer från Centrala Finland för att 
identifiera sällsynta genetiska riskfaktorer som anrikats i dessa familjer med hjälp av 
genomomfattande associationsanalys. Vi identifierade inga anrikade genetiska 
riskfaktorer, även om vi genom släktforskning kunde koppla ihop en del av 
familjerna till två stora släktträd, vilket skulle tyda på gemensamma genetiska 
riskfaktorer i dessa familjer. Avsaknaden av grundarmutationer i den finländska 
befolkningen tyder på att de genetiska riskfaktorerna för autismspektrets sjukdomar 
huvudsakligen består av sällsynta de novo mutationer som endast förekommer 
enstaka familjer. Vi analyserade även genontologi (GO) kategorier för att identifiera 
biologiska processer som är kopplade med autismspektrets sjukdomar. Vi 
identifierade en heterogen grupp kategorier, som tillsammans med resultaten från 
associationsanalysen tyder på ett stort antal genetiska riskfaktorer för autism. 
Resultaten av denna studie instämmer med resultat från andra studier, och tyder på 
att ett stort antal genetiska riskfaktorer för autismspektrets sjukdomar finns även 
inom en isolerad population. Allmänna riskfaktorer inverkar endast i liten mån på 
risken att insjukna, och de flesta genetiska riskfaktorer som har identifierats är 
sällsynta. Även om de sällsynta genetiska riskfaktorerna har en väldigt liten 
inverkan på risk för autismspektrets sjukdomar på populationsnivå, spelar de en 
betydlig roll inom enstaka familjer. Resultaten av denna studie påvisar att metoder 
som kopplings-, homozygoti- samt sekvensanalys behövs för att identifiera dessa 
sällsynta riskfaktorer. 
 
 
Nyckelord: Autismspektrets sjukdom, Aspergers syndrom, kopplingsanalys, 
expressionsanalys, genomomfattande associationsanalys, isolerad population, 
populationsgenetik, serotoninreceptor 
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NPL Non-parametric Linkage 
nsSNP Non-synonymous SNP 
OR Odds Ratio 
PCR Polymerase Chain Reaction 
PDD-NOS Pervasive Developmental Disorder Not Otherwise Specified 
QTL Quantitative Trait Locus 
r2 Square correlation coefficient 
RNA Ribonucleic Acid 
ROH Region Of Homozygosity 
RTT Rett Syndrome 
SNP Single Nucleotide Polymorphism 
θ Recombination fraction 
TDT Transmission Disequilibrium Test 
WTCC Wellcome Trust Case Control Consortium 
Zmax Maximum LOD score 
 
In addition, standard one letter abbreviations of nucleotides and amino acids are 
used. 
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1 INTRODUCTION 
Positional cloning has provided a hypothesis-free, genome-spanning method for the 
identification of genes affecting traits and other phenotypes. Usually positional 
cloning involves identification of families where the same disorder occur, followed 
by linkage analysis using microsatellites and fine mapping in a larger dataset to 
improve resolution before performing laborious sequencing and functional analysis. 
However, recently genome-wide association studies have provided a shortcut to 
identify finite regions harboring genetic variants affecting traits of interest. The 
drawback with respect to linkage studies is that a large number of markers, often up 
to a million, need to be genotyped in a large study sample consisting of thousands of 
cases and controls. Genome-wide association analysis has revealed a vast number of 
new risk variants for many disorders. In some studies the positional cloning effort 
has been facilitated by the innovative use of special populations, such as isolates. 
Isolated populations have traditionally been linked with successful gene mapping 
efforts in monogenic diseases, but have recently also proven successful in the 
identification of risk genes for complex disorders in limited datasets for a subset of 
phenotypes. 
The genetic architecture of traits and diseases vary from monogenic to complex. 
Monogenic disorders are caused by mutations in just one gene, whereas complex 
disorders are controlled by a large number of genetic variants with small effects on 
the phenotype which often interact with environmental factors. Autism spectrum 
disorders are a group of early onset, highly heritable neuropsychiatric disorders, 
such as autism and Asperger syndrome. The genetic determinants for these disorders 
have remained poorly characterized despite decades of intensive research. A fraction 
of cases have however been linked to syndromic forms of the disorder for which the 
genetic variants are known, such as Fragile X syndrome and partial duplication of 
the maternal chromosome 15. Recent large-scale and high resolution efforts using 
modern methodologies have finally shed some light also on idiopathic forms of 
these disorders revealing biological processes linked to altered regulation and 
connectivity at the synapse. In general, most of the identified genetic variants for 
these disorders seem to be rare, family specific mutations, but incomplete 
penetrance indicates a role of more common, modifying factors in the etiology as 
well.
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2 REVIEW OF THE LITERATURE 
2.1 Genetics of complex traits 
The Austrian monk Gregor Mendel was the first scientist to formally describe the 
laws governing inheritance of traits from parents to offspring. A subset of human 
traits and disorders, caused by mutations in a single gene, are referred to as 
Mendelian disorders to highlight the groundbreaking role Mendel‟s insight have had 
on modern genetics. However, Mendelian disorders are mostly rare, whereas 
common disorders, which have the most impact on public health, are caused by the 
interaction of several genetic risk variants. These disorders are often referred to as 
complex disorders, and are caused by numerous genetic variants. These genetic risk 
variants individually increase the disease risk only marginally, but together with 
other genetic and environmental factors result in the disorder. After the structure of 
deoxyribonucleic acid (DNA) was deduced by James Watson, Francis Crick, 
Rosalind Franklin and Maurice Wilkins, Mendel‟s observations could finally be 
explained at the molecular level, and the groundwork was laid for identification of 
genetics risk factors for human disorders. Although the identification of genetic risk 
factors for Mendelian disorders has been more successful, recent technological 
advances as well as greater understanding of the human genome‟s properties have 
led to breakthroughs in the identification of genetic risk factors involved in complex 
traits. 
2.1.1 Determining the genetic component of a trait 
To assess if a trait or disorder is hereditary, family studies are needed to determine if 
the risk to siblings and relatives of affected individuals is higher than that of the 
general population. If genetic factors confer risk for the disease, a proband‟s closest 
relatives, who share the largest part of their DNA, should display increased risk, 
which decreases toward the population prevalence for more distant relatives. Family 
studies do not reveal if the mechanism of the familial aggregation is due to 
environmental or genetic factors. Twin- and adoption studies are needed to elucidate 
the genetic component. The concordance rate between monozygotic (MZ) twins for 
a trait or disease compared to that for dizygotic (DZ) twins offers an estimate of the 
extent of the genetic variation affecting the phenotype. MZ twin concordance also 
provides a way to estimate the penetrance of complex disorders (Boomsma et al. 
2002).  
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2.1.2 The human genome 
The human genome consists of approximately 3.2 billion base pairs (bp), residing on 
23 pairs of nuclear chromosomes, and in the small, 16.5 kb ring of mitochondrial 
DNA (mtDNA). Two teams of scientists, one publicly and another privately funded, 
competed to finish the sequence of the human genome. The race ended in a tie with 
both groups publishing the draft sequence in 2001 although it took several years to 
finalize the drafts (Lander et al. 2001; Venter et al. 2001). The number of genes in 
the human genome is currently approximated to be around 20 000 (Clamp et al. 
2007), but the discovery of novel classes of genes coding for small RNA molecules, 
such as microRNAs have resulted in a need to further refine the definition of a gene. 
Although human genomes are 99.9% identical, there are several forms of variation 
present between individuals. These consist of repeated sequences of varying length, 
single nucleotide polymorphisms (SNPs), and copy number variants (CNVs, see 
section 2.1.4). These variable sites, although representing a small portion of the 
human genome are responsible for the differences among individuals. These 
variable sites serve as genetic markers, which can be used in the mapping of genetic 
factors affecting disorders and traits. 
Several classes of repeat polymorphisms exist in the human genome. They can be 
divided into different classes based on their length and origin. However, only a few 
are of interest in modern genetic mapping studies. The class of repeat 
polymorphisms called microsatellites consists of highly polymorphic repeats of 1-10 
nucleotides. The microsatellites used in genetic mapping consist of 10-50 copies of 
di-, tri- or tetranucleotide repeats. The repeat sequences range from tens to hundreds 
of bps and are flanked by unique DNA sequence and can therefore be amplified by 
polymerase chain reaction (PCR). The advantage of microsatellites is that they often 
have up to ten alleles resulting in a high number of different genotypes. 
The majority of well characterized variation in the genome is present as SNPs. The 
International HapMap project, possibly the most important effort in characterizing 
the variation in the human genome after the determination of the genome sequence 
itself has discovered millions of SNPs and characterized their frequencies and 
pairwise correlation in different populations (The International HapMap Consortium 
2005; Frazer et al. 2007). The number of SNPs with a minimum allele frequency of 
1% in the human genome has been estimated to be at least 10 million resulting in a 
high density of common SNPs (Kruglyak and Nickerson 2001). Currently, dbSNP 
contains over 14 million entries, of which 6.5 million are validated. Resequencing of 
individual genomes is bound to uncover a multitude of rare SNPs, as exemplified by 
the detection of 1.3 and 0.6 million novel SNPs in the first two sequenced genomes 
alone (Levy et al. 2007; Wheeler et al. 2008). Only a minority of SNPs, 
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approximately 135 000 currently listed in dbSNP, potentially impact protein 
function by directly changing the amino acid sequence. The effect of SNPs in 
promoters, splice sites and other regulatory regions is still incompletely 
characterized, but will undoubtedly also have an important impact on the genetic 
architecture of traits and disorders. 
In addition to uncovering the sequence of the human genome, the human genome 
project advanced the development of new, more efficient sequencing technologies. 
These have for the first time enabled affordable sequencing of multiple individuals, 
as well as a multitude of different organisms. Currently the Entrez genome project 
contains complete genomes of over 950 species, of which 22 are eukaryotes. 
Another 1180 species have draft assemblies available, and genome sequencing 
efforts for more than 1000 species are in progress. 
The availability of complete genome sequences for a range of species has given rise 
to a new branch of genetics termed comparative genomics. The aim of this discipline 
is to establish the relationship of genome structure and function across species. The 
common evolutionary origin of all species was proposed by Charles Darwin in On 
the Origin of Species exactly 150 years ago. On a molecular scale, the differentiation 
of species has happened through slow accumulation of changes in their genomes. 
Therefore, the genomes of more closely related species are more similar compared 
to more distantly related species. However, comparative genomics can also be used 
to identify regions which are conserved among species. These regions often 
correspond to genes and regulatory sequences. Divergence between genomes can be 
used to determine which genes contribute to the phenotypic differences between 
species. As an example, comparative analysis between humans and chimpanzees, 
our closest evolutionary relatives for which the complete genome sequence is 
available at the moment, have identified genes involved in the evolution of the 
human brain (Vallender et al. 2008). The sequencing of the Neanderthal genome, 
which is currently in progress, will add another close relative to aid analyses. 
Although the comparison of closely related genomes can be useful for some studies, 
it is also important that genomes of more distantly related species are present for 
comparison. It has been shown that mammalian genomes are very similar, and that 
few novel genes have been introduced in the mammalian lineage. For example, there 
are only 168 “human specific” genes compared to other mammals. A study of the 
evolution of the synapse included species from the whole animal kingdom, and 
concluded that the genes needed for the synaptic machinery are present in all stages 
of animal evolution. The evolution of the synaptic machinery has instead taken place 
through the process of paralogous expansion. This means that existing genes have 
duplicated and the resulting genes have slowly accumulated different variants, 
leading the encoded proteins to acquire novel functions (Kosik 2009). 
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2.1.3 Genetic mapping of complex traits 
The aim of genetic mapping is to identify a genetic variant which influences the 
phenotype of interest. Because the predisposing variants are not known, testing can 
only be performed between a marker genotype and a phenotype. Mapping is easy if 
strong linkage or linkage disequilibrium (LD) exists between the marker and the 
variant influencing the phenotype. Mapping is further facilitated if the variant 
strongly affects the phenotype and has a high penetrance. Factors complicating 
genetic mapping are the effects of other genes or non-genetic factors, like the 
environment, on the phenotype (Weiss and Terwilliger 2000). 
Primarily, two opposing but complementary hypotheses exist concerning the 
structure of genetic risk for complex disorders (Reich and Lander 2001). The rare 
variant hypothesis proposes that the disorder is caused by a small number of 
variants, each with a large effect on the phenotype with a low frequency (<1%) in 
the population. Rare variants are often population-specific, as founder effects have 
established different rare variants in each population. A review of 61 rare variants 
identified in complex disorders show that rare variants are associated with odds 
ratios (OR) ranging from 1.1 to over five, with the percentage of variants increasing 
towards the high end of the OR spectrum, and the mean OR is 3.74 (Bodmer and 
Bonilla 2008). 
The common variant hypothesis proposes that common disorders are caused by the 
interaction of numerous small effect variants common in the population. The 
assumption that common variants comprise risk factors for common disorders has 
been termed the common disease-common variant (CDCV) hypothesis (Lander 
1996; Chakravarti 1999). Of the common variants identified to date, most ORs are 
smaller than two, and the mean OR of 217 common variants from the literature is 
1.36 (Bodmer and Bonilla 2008).  
The separation of risk factors into common and rare is more than theoretical, as the 
optimal gene mapping strategy depends on the underlying genetic architecture of the 
trait of interest. As rare variants are usually family-specific, they can be identified 
using linkage analysis as linkage analysis investigates the co-segregation of 
chromosomal loci with the trait within families. To obtain optimal statistical power 
linkage analysis, large multigeneration families with multiple affected individuals 
should be ascertained, although methodologies for other family structures have also 
been developed. If the trait is thought to be caused by common variants, association 
analysis provides better power to identify genetic risk variants. Although association 
analysis can also be performed in families, usually it is performed in large case-
control cohorts, which are often easier to collect than large pedigrees, especially for 
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phenotypes with a high age of onset, as parents of index cases might not be available 
for the study. 
Positional cloning makes it possible to locate genetic risk factors for diseases and 
traits without an a priori hypothesis of the genes involved by systematically 
scanning the entire genome. The process begins by collecting and carefully 
characterizing a sufficient number of carefully phenotyped families. Subsequently, 
linkage analysis is performed using a sparse set of genetic markers such as 
microsatellites or SNPs covering the entire genome to identify large chromosomal 
regions co-segregating with the trait of interest. The most interesting regions 
identified in the linkage scan are followed up by a more dense set of microsatellite 
markers or SNPs. The inclusion of additional families at this stage helps refine the 
region of interest as more recombinations will be located in the region of interest. 
Finally, when a sufficiently small region has been identified, in silico methods can 
be utilized to identify candidate genes of interest. This involves data mining of the 
various publicly available databases which contain for example information of gene 
expression patterns, gene function, interaction partners, DNA sequence and 
sequence conservation among species. Before any wet-lab experiments are 
performed, data is extracted and from the databases and combined to make it 
possible to predict which genes in the identified regions functionally make the most 
interesting candidates. These interesting candidate genes can then be analyzed by 
resequencing to identify possible risk variants. Sequencing efforts can identify a 
multitude of possible risk variants, and again extensive in silico characterization of 
these variants is usually needed. Subsequently, functional experiments are needed to 
verify the variant‟s role in the etiology of the disease. Although this approach has 
been successful for identifying genes underlying Mendelian disorders, the success 
has been more limited for complex disorders. 
To obtain more power to identify common variants predisposing for common 
disorders, the positional cloning approach has been mostly replaced by large-scale 
genome-wide association analysis where large cohorts of cases and controls are 
genotyped for a high-density SNP marker set. Markers where allele frequencies 
differ between cases and controls identify limited candidate regions, bypassing the 
need for extensive fine mapping. However, although the identification of limited 
candidate regions is more straightforward in this approach, the identification of the 
true risk variant can still be laborious, and resequencing, bioinformatics and 
functional approaches are needed to evaluate the role of the identified variants. 
Previously sequence analysis has only been used after limited regions or genes of 
interest have been identified through linkage or association analysis to identify risk 
variants present in cases but not controls. However, second generation sequencing 
technologies have enabled genome-wide sequencing of large cohorts, and the next 
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step in the genetic mapping will possibly be the sequencing of the whole genome in 
cases and controls. Whole genome resequencing produces a massive amount of data, 
and needs to be followed by bioinformatic analyses and systems biology approaches 
to separate risk variants from benign polymorphisms. 
L i n k a g e  a n a l y s i s  
Linkage analysis is used to localize a chromosomal region co-segregating with, or 
linked to, a nearby marker locus within a pedigree. Recombination during meiosis 
generates novel allele combinations in each generation, and genetic markers can be 
used to detect which chromosomal segments have been inherited from each parent. 
The probability for recombination to occur between any two sites in the genome is 
related to their physical distance, and described in genetic terms by the 
recombination fraction (θ) which ranges from 0 corresponding to the two loci 
always co-segregating, to 0.5 corresponding to independent segregation, as is the 
case for loci residing on different chromosomes. For linkage studies, physical maps 
are replaced by genetic maps relating markers by their probability to be separated by 
recombination. The distance measure used is Morgan (M) which is divided into 100 
centiMorgans (cM). A genetic length of one Morgan corresponds to one expected 
recombination event (crossing over), resulting in one cM corresponding to 1% 
probability for recombination between loci. Over short distances one cM 
corresponds roughly to 1 Mb, but the rate varies across the genome and is sex-
specific, with higher recombination rates in females than in males. For example 
chromosome 5 is 260 cM in females and 151 cM in males, corresponding to the 
expected 2.6 and 1.5 recombination events respectively. The length of the human 
genome is 44.60 M in females and 25.90 M in males (Kong et al. 2002). 
In theory, linkage analysis is simply based on calculating the number of recombinant 
genotypes in a pedigree. However, as recombinations cannot be directly observed, in 
reality a likelihood measure is employed to estimate the probability of co-
segregation of a genetic marker with the trait of interest compared to the null 
hypothesis. The hypothesis is tested by a likelihood quotient where the logarithm of 
odds (LOD) score, Z(θ), is maximized for all values of θ and compared to the null 
hypothesis that the loci are unlinked, i.e. θ=0.5: 
)5.0(
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Different algorithms have been developed for linkage analysis. The Elston-Stewart 
algorithm (Elston and Stewart 1971) is efficient when big pedigrees but few markers 
are used whereas the Lander-Green algorithm (Lander and Green 1987) makes it 
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possible to use many markers but smaller pedigrees. Approximate, simulation-based 
methods are needed if big pedigrees are analyzed with a large number or markers. 
Linkage analysis can be divided in to parametric and non-parametric analyses. In 
parametric linkage analysis, the mode of inheritance has to be determined using 
penetrance parameters and allele frequencies. This is possible for Mendelian 
disorders where the mode of inheritance is known, but is not directly applicable to 
complex traits. Parametric linkage analysis is very powerful if the correct 
inheritance model is known, and has been shown to remain robust to model 
misspecifications as long as the inheritance model is correct (Nyholt 2000). When 
parametric analysis is performed, data can be analyzed under several genetic models 
and the highest LOD-score (Zmax) can be used as test statistic for linkage (Clerget-
Darpoux et al. 1986; Greenberg et al. 1998). The testing of multiple inheritance 
models increases the likelihood of detecting true linkage, but also increases type I 
error (false positives) due to multiple testing. However, if maximizing is only 
performed over one parameter, in this case the inheritance model, and only a few 
models are used, e.g. one recessive and one dominant, the increase in significance 
levels is relatively modest (Hodge et al. 1997). 
Non-parametric or model-free linkage analysis does not require that the inheritance 
pattern of the disease is defined, and is therefore more suitable for complex traits. 
The non-parametric linkage algorithms explore the extent of allele sharing between 
individuals with the same phenotype. Because the non-parametric linkage methods 
do not assume any inheritance model they tend to be more robust than parametric 
analyses, but are less powerful than parametric methods using the correct mode of 
inheritance (Elston 1998). 
A LOD-score of 3 corresponds to an odds ratio of 1000:1 in favor of the alternative 
hypothesis and has traditionally been considered as a genome-wide threshold for 
significant linkage. This corresponds to a pointwise significance of p=1·10-4 and a 
genome-wide significance level of 9% (Chotai 1984). To obtain a genome-wide 
significance level of 5%, corresponding to a point-wise significance of p=5∙10-5, the 
LOD score threshold needs to be raised to 3.3 (Lander and Kruglyak 1995). 
Replication of positive results in independent datasets is important to rule out false 
positive linkage findings. Simulations have shown that the variability of the location 
estimate in linkage studies in complex disorders for a confidence interval of 95% 
consists of dozens of cMs (Roberts et al. 1999). A failure to replicate linkage results 
could imply that the effect of the locus has been overestimated in the original study, 
and a much larger material is needed to replicate the initial finding (Lander and 
Kruglyak 1995). Replication studies can also lead to contradictory results due to 
population heterogeneity, diagnostic differences and/or statistical fluctuation. 
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Because of genetic differences between populations replication is easier in the same 
population where the initial successful mapping study was performed (Goring et al. 
2001). Meta-analysis of several scans can be used to evaluate if the overall evidence 
for linkage is significant providing that the underlying genetic causes can be 
assumed to be shared in all populations included in the meta-analysis. 
A s s o c i a t i o n  a n a l y s i s  a n d  l i n k a g e  d i s e q u i l i b r i u m  
Association analysis in its simplest form consists of comparing allele frequencies at 
genetic markers in regions of interest in two cohorts - one consisting of affected 
individuals and the other of controls. The statistical significance of the difference in 
allele frequencies in the form of a p-value can be assigned using the χ2 distribution 
with one degree of freedom. 
Traditionally association studies have been used to test if polymorphisms in a 
candidate gene are associated with the phenotype of interest. This has required an a 
priori hypothesis concerning the gene of interest, either about the position of the 
gene in a linkage peak, or about its function in a biological process or pathway 
related to the phenotype. Although a few groundbreaking studies pioneered the 
genome-wide association approach in the 1990s (Houwen et al. 1994; Puffenberger 
et al. 1994), mostly linkage-based approaches were used in genetic mapping at that 
time. Linkage analysis is efficient for detecting rare highly penetrant variants, and 
was therefore successful in Mendelian disorders. However, the poor replication of 
results in complex disorders led to a new hypothesis suggesting that susceptibility to 
common disorders could be conferred by a large number of common, small risk loci. 
In a highly influential paper, Risch and Merikangas (1996) proposed that association 
studies would have more power than linkage studies to identify common variants 
with a small effect on the phenotype. 
As the human genome contains millions of points of variation, testing each of these 
variants for association with the trait of interest would be highly impractical and 
result in an overwhelming multiple testing problem. However, not all SNPs are 
independent, and loci close to each other are often inherited together due to a low 
probability that recombination will occur between them. In the absence of crossing 
over, the whole disease-causing chromosome with all its alleles would be 
transmitted as a block to the next generation. Due to recombination this block, or 
haplotype, becomes shorter for every generation. If the locus contains a variant 
which influences the disease phenotype, affected individuals are expected to share 
the same haplotype (combination of alleles) around the disease locus whereas 
unaffected individuals have a random assortment of alleles. Markers that are 
inherited as a group in the described manner are said to be in LD. 
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LD can be observed as block-like structures across the genome. These blocks consist 
of regions with low recombination rate and only a few common haplotypes flanked 
by regions experiencing high recombination rates (The International HapMap 
Consortium 2005; Frazer et al. 2007). A majority of haplotypes are shared between 
different populations, and these common haplotypes account for a vast majority of 
all chromosomes (Jakobsson et al. 2008). This means that within these haplotype 
blocks one, or a few, SNPs can be selected to capture the information of adjacent 
SNPs. Only these „tagging‟ SNPs need to be genotyped, and the common variation 
in the entire genome can be captured using approximately half a million SNPs or 
less. This is referred to as an indirect association approach, where only a subset of 
SNPs need to be genotyped (Collins et al. 1997). The extensive work performed by 
the International HapMap consortium has characterized the patterns of LD across 
the genome in four populations, and the publicly available data has made it easy to 
select tagSNPs for candidate regions or genes of interest. It should be noted that 
approximately 1% of the SNPs in the second phase of the HapMap project were 
reported to be untaggable, i.e. not in LD with any surrounding SNP. Therefore, 
although the LD structure makes it possible to utilize indirect approaches for most of 
the genome, some parts will require a direct approach where each individual SNP 
needs to be genotyped (Frazer et al. 2007). 
The results of the efforts of the International HapMap consortium, together with the 
fast progress in high-throughput genotyping technologies have enabled affordable 
genome-wide SNP genotyping of hundreds of thousands of markers in the last few 
years, making the ideas proposed by Rich and Merikangas in 1996 a reality. Early 
genome-wide association studies often failed to identify statistically significant 
results because of small sample sizes and only replicating known linkage findings. 
Large international collaborations with thousands, or even tens of thousands of 
samples, have lead to well replicated findings of small effect common variants. 
Among the first success stories of genome-wide association studies (GWASs) was 
the identification of complement factor H (CFH) as a risk factor for age-related 
macular degeneration (AMD). Although CFH was identified in a rather small 
GWAS (96 cases vs. 50 controls) (Klein et al. 2005), the two identified SNPs 
remained significant after Bonferroni correction for the large number of tests. As the 
gene was located in a known linkage region, two other studies published 
simultaneously verified CFH as a risk gene for AMD through different approaches 
(Edwards et al. 2005; Haines et al. 2005). Later meta-analysis have verified the 
Y402H variant as a risk factor, heterozygous carriers of the risk haplotype have a 2.5 
fold increased risk, and homozygous carriers 6 fold increased risk of AMD 
(Thakkinstian et al. 2006). However, fine mapping studies have revealed other 
variants showing stronger association to AMD than the non-synonymous variant 
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suggesting that the identified susceptibility variants in complex disorders are not 
always similar to those identified in Mendelian disorders (Li et al. 2006). In 2007, 
the large Wellcome Trust Case Control Consortium (WTCCC) reported results of 
GWASs for seven phenotypes using 2000 cases and 3000 shared controls across all 
phenotypes. Interestingly, the results for different phenotypes were very different, 
with significant peaks identified for coronary artery disease, Crohn‟s disease (CD), 
rheumatoid arthritis, and type 1 and type 2 diabetes, but much less significant results 
for bipolar disorder and hypertension suggesting different underlying architecture of 
the genetic susceptibility variants (WTCCC 2007). 
Gibson and Goldstein (2007) outlined three primary goals for GWASs. The first is 
to predict risk and allow for interventions for individuals with high risk. The second 
is to improve understanding of the biological processes underlying the disease and 
the third is to identify subclasses of clinically similar diseases that have a different 
etiology and therefore respond to different treatment. In light of these goals, right 
now GWASs fulfill the expectations of the second goal, but have had only limited 
success with the other two. Also, with regard to the second goal, the identification of 
novel genetic risk factors is only the beginning of the characterization of the 
biological processes underlying the disorders, and a wide range of functional studies 
are needed to characterize the role of these variants in disease etiology. Progress on 
this part will further the two other goals, as understanding the biological mechanism 
of action is required for devising new treatment and interventions. 
Although GWASs suffer from the same problems as association studies of candidate 
genes, in that cases and controls need to be well matched for ethnicity to prevent 
spurious associations, GWASs actually contain their own internal control for this, 
which could not be obtained using only a small number of markers. In GWASs, the 
p-values are expected to follow the null distribution, and differ from the expected 
only for a small number of loci with highly significant p-values. If cases and 
controls differ significantly from each other, this can be observed as a large number 
of associated loci, which cannot all be linked to the etiology of the trait of interest. 
Statistical approaches have been developed to deal with inflation of the test statistic 
due to population substructure making it possible to combine data from different 
populations to obtain large sample sizes without inflating the false positive rates of 
the studies (Devlin and Roeder 1999; Price et al. 2006). However, it should be noted 
that combination of different cohorts is only beneficial if the underlying genetic risk 
factors can be assumed to be shared across the populations. 
Although both the CDCV theory and the International HapMap project have been 
criticized, (Pritchard and Przeworski 2001; Terwilliger and Hiekkalinna 2006), 
results of the project have proven useful for at least a subset of phenotypes. To date, 
GWASs have identified several hundred novel susceptibility loci for both clinical 
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conditions as well as disease-related or normal traits (Altshuler et al. 2008). GWASs 
have uncovered numerous new risk variants for many phenotypes, when large 
samples providing adequate statistical power are used in concert with appropriate 
and stringent data analysis suitable for excluding false positives due to population 
stratification and other artifacts. Properly designed studies have also shown that the 
susceptibility variants confer at best modest risk, with effect sizes in the range of 
1.1-1.5. It is likely, that large meta-analysis and collaborations will reveal further 
variants with even smaller effects. 
2.1.4 Copy number variants  
Although the role of chromosomal rearrangements in some disorders, including 
mental retardation and cancer among many others have been recognized for a long 
time, small deletions and duplications have only recently been recognized to be a 
commonly segregating form of genetic variation in the general population. The first 
studies were performed using array comparative genomic hybridization (aCGH). 
Despite a relatively low density of probes, these studies revealed numerous 
differences between phenotypically normal individuals (Iafrate et al. 2004; Sebat et 
al. 2004). Thereafter, a wave of studies confirmed and extended the original finding 
using varying methods (Estivill and Armengol 2007). 
The term CNV has come to mean a variable site exceeding approximately 1kb in 
size and ranging up to several Mb (Feuk et al. 2006). Size-wise this places CNVs 
between chromosomal rearrangements which can be seen by light microscopy, and 
microsatellites and other small indels which can be assessed by traditional sequence-
based approaches. Variant sites with a frequency of 1% in the population are 
referred to as copy number polymorphisms (CNPs). However, it should be noted 
that in order to determine allele frequencies of CNVs, large studies and reliable 
calling algorithms are needed and thus, the determination of allele frequencies is still 
a work in progress. The majority of CNVs are inherited in a Mendelian manner 
(Locke et al. 2006; McCarroll et al. 2006). A large scale, high resolution study 
reported that  less than 1% of CNVs did not correspond to a Mendelian inheritance 
pattern (McCarroll et al. 2008b). The same study also concluded that previous 
studies have tended to overestimate the sizes of CNVs and that most CNVs fall into 
discrete CVN regions with defined boundaries.  
There are several ways in which CNVs could confer risk for disorders. The most 
obvious mechanism is gene dosage, as deletions could result in a diminished and 
duplications to an increased gene dosage. Further, homozygosity for deletion alleles 
of genes results in null expression of the gene or of the exons encompassed by the 
deletion. CNVs in regulatory regions of genes could also have an impact on gene 
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expression levels. A study of the role of CNVs in gene expression concludes that 
18% of the variation in expression levels of 15,000 genes is attributable to copy 
number differences (Stranger et al. 2007). In rare cases, deletion alleles could also 
uncover deleterious alleles in the remaining gene copy. 
Rare, large, often de novo CNVs have been linked to varying phenotypes including 
autism, developmental disorders and schizophrenia (de Vries et al. 2005; Sebat et al. 
2007; Stefansson et al. 2008). However, it should be noted that in most studies, data 
was not collected specifically for the purpose of CNV identification. SNP intensity 
data from GWASs have been used in several studies to identify CNVs as a spin-off 
project from the original GWAS. This could introduce biases, notably the lack of 
control for intelligence quotient (IQ) differences in patients versus controls. As 
CNVs and larger chromosomal abnormalities have been commonly identified as 
causative for intellectual disability, the lack of control for patient IQ could result in 
increased CNV rate estimates as well as frequency estimates for CNP alleles in 
cases (Joober and Boksa 2009). In a schizophrenia study where IQ data was 
available, association was detected between CNVs and low IQ (Walsh et al. 2008). 
In the general population, CNVs exceeding 500kb have been identified in 5-10% of 
individuals, and CNVs exceeding 1 Mb in 1-2% (Itsara et al. 2009). 
Recently, reports have also emerged of CNPs associated with common disorders. A 
20kb deletion polymorphism located upstream of IRGM and in full LD with the 
most significantly associated SNP in a GWAS for CD was found to confer 
susceptibility to CD (McCarroll et al. 2008a). The deletion polymorphism was 
shown to regulate the expression of IRGM, a gene involved in autophagy, a cellular 
process known to be involved in CD from earlier studies (Rioux et al. 2007). 
Individuals with a low copy number of the human immunodeficiency virus (HIV)-
suppressing chemokine receptor CCL3L1 have a higher risk for HIV infection and 
more aggressive disease progress (Gonzalez et al. 2005). High copy number at the 
same gene has been associated with increased risk for rheumatoid arthritis and type I 
diabetes (McKinney et al. 2008). A low copy number of FCGR3B, a receptor for 
IgG Fc-fragment, has been associated with systemic organ-specific autoimmune 
disease (Fanciulli et al. 2007). However, the association results were not consistent 
across all cohorts, as a French cohort of Wegener‟s granulomatosis showed 
association to high copy number of FCGR3B. High copy number of DEFB and lack 
of LCE3B and LCE3C have been shown to confer risk for psoriasis (Hollox et al. 
2008; de Cid et al. 2009). The high number of disorders involving immunological 
processes can be explained by the fact that the distribution of CNVs overlapping 
with genes is not random across the genome. CNVs are enriched in genes encoding 
secreted, olfactory, and immunity proteins, explaining the strong link between 
CNVs and immunological disorders (Nguyen et al. 2006). In addition to increased 
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CNV rates in these genes, significantly elevated synonymous and nonsynonymous 
nucleotide substitution rates were observed in these genes as well. These genes 
mediate processes that are involved in the adaptation to new environmental niches, 
and results suggest that at least CNVs with high frequency have been retained in the 
human population due to positive selection. 
2.1.5 Identification of risk variants through analysis of gene expression 
Variants in DNA can modify the encoded protein, if the variants are located in 
coding regions. However, variants in promoters or other functional elements can 
modify the level of expression. Gene expression level cannot be directly assayed 
from the DNA, as each cell contains one copy of the genome. However, the amount 
of ribonucleic acid (RNA) transcribed from the genes can vary in different 
individuals and cell types, and correlates with the expression level of proteins. 
Genes encoding proteins with different expression levels in cases versus controls 
could influence the phenotype studied. 
The expression levels of single genes of interest can be determined using reverse 
transcription-PCR. However, this method is laborious when there are multiple genes 
of interest. Furthermore, a prior hypothesis is needed to identify genes linked with 
the phenotype of interest. Microarrays containing probes for all known genes enable 
determination of expression levels for all RNA molecules in a single experiment, 
and have become a mainstream application in molecular genetics over the last 
decade. Early microarrays used partial complementary DNAs or expressed sequence 
tags as probes for genes, but virtually all commercially available gene-expression 
microarrays today contain short synthesized oligonucleotide probes. 
As the expression patterns of genes are distinctive for each tissue, expression 
profiling of disorders involving the brain poses specific problems. In studies of 
human gene expression, usually only postmortem brain samples are available. These 
samples often represent the state of the brain years or even decades after disease 
onset. However, gene expression profiling in animal models, such as mice can be 
used to identify differentially expressed genes, which can be further investigated in 
humans. Using this approach an elegant study design was used to identify genes 
associated with anxiety first in mice and then in man (Hovatta et al. 2005). RNA 
was extracted from brain regions previously shown to be involved in anxiety from 
mouse strains differing in anxiety-like behavior. A total of 17 genes with expression 
patterns correlating with the level of anxiety in the different mouse strains were 
identified. Two enzymes, glyoxalase I (Glo1) and glutathione reductase 1 (Gsr) 
were further investigated, and were shown to influence anxiety-like behavior in the 
mice. An association study in 13 human homologues of the anxiety-related genes 
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identified in mice revealed that some of the SNPs in a subset of these genes confer 
risk for anxiety in humans as well (Donner et al. 2008). 
Microarray expression studies produce large amounts of data, as the expression 
levels of tens of thousands of genes is investigated. For some phenotypes, the 
identification of transcripts that are differentially expressed in cases and controls 
using stringent statistical criteria for differential expression can reveal candidate 
genes. These genes can be studied further using functional assays as well as DNA-
sequence-based approaches to reveal new information of the disease pathology or 
DNA risk variants. However, for complex disorders, the difference in expression 
levels between cases and controls can be subtle. In these cases few or possibly no 
genes display significant differences in expression level, but there is a large set of 
suggestively differentially expressed genes. Often these sets of genes are too large to 
draw conclusion of unifying biological processes by manual annotation of the 
identified genes. 
Gene Ontology (GO) is a controlled vocabulary describing the functions and 
relationships of genes and biological function a hierarchical manner (Ashburner et 
al. 2000). GO can be used to assign functional annotations to genes, such as large 
lists of differentially expressed genes identified in expression studies. By comparing 
the relationship of these annotations, large gene lists can be reduced to lists of 
related functions, facilitating the identification of biological processes related to the 
genes. Algorithms have been developed to test if differentially expressed genes are 
enriched in certain GO-categories compared to expected distributions (Breitling et 
al. 2004a; Breslin et al. 2004). Analysis of enriched GO-categories was used in an 
expression study of monozygotic twins, discordant for body mass index in order to 
identify genes involved in acquired obesity. RNA profiling was performed in fat 
biopsies, and downregulated genes were identified to be enriched in mitochondrial 
branched chain family amino acid metabolism (Pietilainen et al. 2008). Furthermore, 
a reduced number of mitochondria and increased serum levels of branched chain 
amino acids, which increase the secretion of insulin, were identified in the obese co-
twin. These results strongly implicate a novel biological process, the mitochondrial 
amino acid metabolism, in acquired obesity. 
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2.2 Population substructure in genetic studies 
Association analysis requires that the cases and controls included in the study are 
appropriately matched to avoid false positive results due to the differential 
distribution of alleles at marker loci in different populations. This effect can remain 
undetected in candidate gene studies, where only tens or hundreds of SNPs are 
tested. However in GWASs, a biased selection of cases and controls will be 
detectable as inflation in the expected distribution of test statistics. Genome-wide 
association datasets have enabled the characterization of population structure, and 
recently a multitude of studies investigating the population substructure locally, 
internationally and even globally have been published. The detailed characterization 
will allow even better study design of GWASs in the future, and at the same time 
also provide information concerning historical migrations and the relationship and 
admixture of current populations. 
2.2.1 Finnish population history 
Finland has been inhabited since the Pleistocene ice withdrew and the land rose 
from the sea approximately 10 000 years ago to form the Finnish peninsula. 
Evidence of both eastern-derived comb ceramic culture as well as western derived 
corded ware culture has been observed in archeological finds from around 5000-
6000 years and 4000 years ago, respectively. These two populations form the major 
contributions to the genomes of Finns today, and represent classic examples of 
bottlenecks in the Finnish population history. Later smaller additions to the 
population have come from Germanic, Scandinavian and Baltic peoples. The 
population size in Finland has remained small, and immigration during the last 
thousand years has been low. The main language spoken in Finland today, Finnish, 
is a member of the Fenno-Ugrian family of languages that includes languages such 
as Estonian and Hungarian, in contrast to most other European languages that 
belong to the Indo-European language group. Although linguistic information and 
genetic origin do not necessarily coincide, this difference provides supporting 
evidence of an eastern immigration. 
For millennia, only southern Finland and the coastal regions, referred to as the early 
settlement region, were inhabited. In the 16th century, the eastern and northern parts 
of the country, referred to as the late settlement, were inhabited by an internal 
migration starting from the South Savo region in southeastern Finland. There are 
several reasons for this migration, including the taxation benefits bestowed upon 
individuals who moved to the uninhabited eastern regions to reinforce the border 
against Russia. In addition, the rapidly growing population needed more land to 
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cultivate, and burn beating enabled the population to move into new regions. New 
settlements consisted of a small number of individuals, which together with 
geographical isolation resulted in severe bottleneck effects and genetic drift. By the 
end of the 17th century, most of Finland was inhabited and the population had 
increased to 400 000. However, the great famine during 1696-1968 killed almost a 
third of the population, forming one more bottleneck in the population. Since then, 
the population has rapidly expanded from 250 000 to over 5 million inhabitants 
today (Varilo 1999). 
2.2.2 Finnish population genetics 
Until recently, population genetics studies have been based on uniparentally 
inherited mitochondrial- or Y chromosomal markers. The Y chromosome is useful 
for population genetic studies due to its paternal and haploid mode of inheritance 
which result in a four times reduced effective population compared to nuclear loci. 
In addition, the Y chromosome only undergoes recombination in the most telomeric 
parts of the chromosome, and thereby all observed variation on the chromosome 
arises as a consequence of new mutations. Two main lineages can be detected in 
Finnish Y chromosomal studies, one of eastern and one of western origin (Sajantila 
et al. 1996; Kittles et al. 1998; Lappalainen et al. 2006). 
The presence of both eastern and western Y chromosomal haplogroups support the 
hypothesis that the Finnish population has been founded by at least two major 
waves, one of western and another of eastern origin. Similar distinction of east and 
west can be observed in other phenomena, such as dialectal groups and disorder 
prevalence. The divisions closely follow the historical border between Swedish-
ruled Finland and Russia established in 1323 (Norio 2003c) The expansion of the 
eastern haplogroup has been dated 2000 years prior to the expansion of the western 
haplogroup, supporting archeological data (Kittles et al. 1998). Finnish Y 
chromosomes show a reduction in genetic diversity when compared to other 
populations, including the neighboring populations, such as Estonians and Swedes, 
suggesting a bottleneck in the population (Sajantila et al. 1996; Lappalainen et al. 
2006). 
Maternal ancestry can be tracked using mtDNA, which does not undergo 
recombination and has a higher mutation rate compared to nuclear DNA. The 
distribution of mitochondrial haplogroups in Finns, excluding the Saami people in 
Northern Finland, resemble that of the rest of Europe (Sajantila et al. 1995; Kittles et 
al. 1999; Finnila et al. 2001). In contrast to results obtained in Y chromosomal 
studies, mtDNA does not display significantly reduced genetic diversity which could 
be explained by different mutation rates in the Y chromosome and mitochondria, or 
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by different effective population sizes in males and females (Hedman et al. 2007). 
However, if only slowly evolving positions are considered, a bottleneck can be dated 
approximately 4000 years ago using mitochondrial data. This is in agreement with 
the archeological evidence of the introduction of agriculture 4900-4000 years ago 
(Sajantila et al. 1996). 
The unique population history of Finland has led to enrichment of certain alleles and 
extinction of others by genetic drift. This has resulted in a unique pattern of 
disorders consisting of 36 mostly recessive disorders that are overrepresented in 
Finland compared to any other population. This set of diseases is often referred to as 
the Finnish disease heritage. The birthplaces of grandparents of individuals affected 
with these diseases are often not located in areas of high population density, but 
rather in areas of the late settlement, or in geographically isolated regions (Norio 
2003b). Some Mendelian disorders common in European populations, such as 
phenylketonuria and cystic fibrosis, are absent from Finland, consistent with the 
principles of genetic drift (Norio 2003a). 
2.2.3 Genome-wide SNP data in population genetic studies 
The abundance of SNP data available from association studies for various 
phenotypes has recently enabled population genetic inferences to be drawn from the 
allele frequencies of dense genetic markers spanning the entire genome. A multitude 
of studies have recently emerged reporting, in essence, the same main results: 
Principal componenet-based analyses show that the distribution of samples strongly 
correlates with geographic distribution and the first two principal components 
correspond to the east-west and north-south gradients, with the east-west gradient 
explaining most of the variation of the data (Heath et al. 2008; Lao et al. 2008; Price 
et al. 2008; Tian et al. 2008; Yamaguchi-Kabata et al. 2008). The dense map of 
markers has been shown to yield similar analysis in single SNP-based and 
haplotype-based analysis, suggesting that unphased SNPs provide the same amount 
of information as phased haplotypes (Jakobsson et al. 2008). It is also evident from 
these studies that the majority of variation resides within populations and that 
between-population variation is smaller. The between-population variation reveal an 
underlying structure which is primarily accounted for by random drift at neutral loci, 
but also some regions under high selection (Voight et al. 2006). 
When the structure of European populations is investigated, Finns cluster separately 
from the rest of the European populations (Lao et al. 2008; Salmela et al. 2008). 
Marker heterozygosity decreases from southwest Europe towards northeast, while 
LD increases over the same trajectory. Therefore, among the European populations 
Finns display the highest LD and the lowest heterozygosity (Lao et al. 2008). A 
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study of genome-wide SNP data from Eastern and Western Finland confirm the east-
west difference which was originally observed using Y chromosomal haplotypes. 
Furthermore, identity-by-state (IBS) sharing was higher within Finland compared to 
other populations in Northern Europe (Salmela et al. 2008). 
2.2.4 Isolated populations in disease gene mapping 
Isolated populations are defined as populations originating from a small number of 
founders that experience little immigration and expand primarily through population 
growth. As a result, they are also known as founder populations. The decreased 
genetic diversity, which can still be observed in isolates today, is a direct 
consequence of the genetic bottleneck caused by the limited number of founders. 
The subsequent rapid population growth is a prerequisite for the population to be 
useful for genetic mapping, as there are sufficient numbers of individuals affected 
with disorders that have a low frequency in the population. The same demographic 
phenomena that have resulted in the decreased genetic diversity have also resulted in 
extended LD and increased homozygosity. The drastic reduction in population size 
during the population history has enabled genetic drift to drastically change allele 
frequencies resulting in distinctive patterns of disorders characteristic for the 
specific population (Morton et al. 2003; Norio 2003a; Charrow 2004). 
In addition to genetic homogeneity, environmental and cultural factors are more 
homogenous in isolates compared to large, admixed populations. Factors such as 
shared language and religion increase social cohesion, whereas education, health 
care and diet minimize the environmental heterogeneity. In many founder 
populations, careful population registries or church parish records are available for 
genealogical studies, and allow construction of extended pedigrees with multiple 
affected individuals. 
The genetic architecture of isolated populations has proven to be extremely useful 
for the identification of genes underlying Mendelian disorders. The bottlenecks 
experienced by the population have enriched a limited number, sometimes only one 
genetic variant resulting in the disorder. Identification of this one risk variant, often 
residing on a large haplotype shared between seemingly unrelated affected 
individuals is relatively easy. However, the use for isolated populations in mapping 
of susceptibility genes for complex disorders is more controversial. Recent studies 
discussed below provide evidence of both successes and failures. However, it seems 
that even if population isolates have proven successful in identification of novel loci 
for a variety of phenotypes, they might not be as useful for complex gene mapping 
as they have been in gene mapping for monogenic disorders. Also, the role of the 
identified loci still need to be further assessed to determine whether they constitute 
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isolate-specific risk factors, or if the results of these studies can be extended to 
outbred populations as well. 
S u c c e s s e s  i n  t h e  i d e n t i f i c a t i o n  o f  r i s k  v a r i a n t s  f o r  
c o m p l e x  t r a i t s  i n  i s o l a t e d  p o p u l a t i o n s  
Isolated populations display increased LD compared to admixed populations. 
Originally, one of the primary benefits envisioned for isolates in the identification of 
genetic risk factors for complex traits was that the increased LD would significantly 
lower the number of markers needed to tag the entire genome (Shifman and Darvasi 
2001; Service et al. 2006). However, today this gain is mostly theoretical, as 
genotyping is performed using pre-designed SNP sets, which have been chosen to 
tag the majority of allelic variation in the genomes of outbred European populations. 
It is therefore not surprising, that tagSNPs chosen using the HapMap European 
population perform well in several isolates (Service et al. 2007). However, it has 
been suggested that the tagging power of these SNPs even for rare haplotypes is 
better in isolated populations, due to the excess of information provided by the off-
the-shelf genotyping chips in populations with high LD.  
The more significant value of isolated populations is the reduced genetic variability, 
which has resulted in enrichment of a subset of susceptibility alleles in the 
population. As isolated populations have undergone bottlenecks, the susceptibility 
variants often reside on a more homogenous haplotypic background compared to 
mixed populations. The genes for all but one disorder of the Finnish disease heritage 
have been identified, and for most disorders, one major mutation accounts for >90% 
of Finnish cases. However, a multitude of other mutations causing the diseases have 
been identified in other populations (Norio 2003b). Another well documented 
example of founder mutations in isolates is the enrichment of only three mutations 
in BRCA1 and BRCA2 conferring risk to familial breast cancer in the Ashkenazi 
Jewish population (King et al. 2003). The enrichment of certain susceptibility 
variants will require fewer individuals to find these shared genetic factors. 
One of the success-stories of genetic mapping of risk variants for complex disorders 
in isolates is provided by data from the Icelandic company deCODE genetics. By 
utilizing extensive genotype and phenotype data combined with genealogical 
information, an unprecedented myriad of susceptibility variants for complex 
disorders and traits have been identified. Linkage, and subsequently association 
mapping have identified common genetic risk variants for various disorders and 
traits, including multiple types of cancer (Gudmundsson et al. 2007a; Gudmundsson 
et al. 2007b; Stacey et al. 2007; Goldstein et al. 2008; Gudmundsson et al. 2008; 
Stacey et al. 2008; Rafnar et al. 2009), pigmentation (Sulem et al. 2008), myocardial 
infarction and aneurysms (Helgadottir et al. 2007; Helgadottir et al. 2008), glaucoma 
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(Thorleifsson et al. 2007) and type 2 diabetes (Grant et al. 2006). In these studies, 
the genomic inflation factor (λ) was used to control for population structure and 
relatedness (Helgason et al. 2005). In some studies, previous linkage findings in the 
same population were used to prioritize regions for follow up if no genome-wide 
significant results were identified in the primary stage of the GWAS. This approach 
has resulted in the identification of susceptibility variants at previously identified 
linkage peaks. 
An elegant study design combining the benefits of enriched risk alleles within a 
subisolate with the power of genealogical information was used to identify risk 
variants for multiple sclerosis (MS). The prevalence of MS is twice as high in an 
internal subisolate of Finland compared to the rest of the country (Sumelahti et al. 
2001). Using genealogical data, and carefully matched controls originating from the 
same geographically limited region, a haplotype shared identical by descent (IBD) 
between affected individuals was identified close to complement component 7 (C7) 
located under a previously identified linkage peak at 5p. The haplotype association 
was replicated in an independent sample from the same subisolate, and the risk 
haplotype correlates with increased expression of C7. A trend toward association 
was also observed in other European populations, suggesting that the risk variant has 
been enriched in the internal isolate, and confers susceptibility to MS in other 
populations as well (Kallio et al. 2009). 
The role of isolate-specific variants for common disorders is still incompletely 
characterized. A recent GWAS of close to 5000 individuals from the late settlement 
region of Finland for metabolic traits replicated numerous loci reported in other 
populations for phenotypes such as blood triglyceride levels, high- and low density 
lipoprotein, blood glucose and C-reactive protein levels. In addition, for some 
phenotypes, such as triglycerides, high density lipoprotein, low density lipoprotein 
and blood insulin levels, novel loci were identified, some of which have shown 
suggestive, but not genome-wide significant association in other populations (Sabatti 
et al. 2008). It remains to be shown whether these findings are isolate-specific or if 
they can be replicated in other populations. 
C h a l l e n g e s  i n  g e n e t i c  m a p p i n g  i n  i s o l a t e s  
Although isolated populations provide excellent opportunities for identification of 
genetic risk factors for genetic disorders, there are some drawbacks using these 
special populations that need to be considered in study design. Given that isolated 
populations are often smaller than mixed population, it should be established that a 
large enough cohort of affected individuals can be assembled from the population 
given the frequency of the trait of the interest and the size of the population. One of 
the drawbacks often encountered when the initial region of interest has been 
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identified is the LD structure. Although extended LD helps identify risk loci, it can 
simultaneously make it harder to identify causative variants within a block of strong 
LD. Therefore, if susceptibility factors are shared across populations, it would be 
beneficial to include a more admixed population in the finemapping stage of the 
study where LD blocks are shorter and LD between markers is less strong. 
Replication of initial findings can prove to be challenging, especially if the isolate is 
small and the disorder is rare, as all available samples have already been used in the 
initial mapping effort. It should also be noted that less strict requirements of 
replication might be relevant if the risk variant is significantly enriched in the 
isolate, and only confers a small risk in the replication population. However, even if 
the effect of the variant is limited to the isolate, characterization of these risk 
variants can prove to be beneficial as it could lead to a greater understanding of the 
trait‟s underlying biology. 
The assumption that rare, high impact variants are enriched in founder populations is 
not always true. A recent study of genetic risk factors with metabolic phenotypes in 
the Kosrae population revealed a similar spectrum of genetic risk variants compared 
to other more outbred populations. The Kosrae, a native population of the Federated 
States of Micronesia, display both decreased genetic diversity and extended LD 
resulting from founder effects and multiple bottlenecks (Bonnen et al. 2006). In 
common with many other populations worldwide, the prevalence of obesity and 
metabolic disorders is increasing in this population (Shmulewitz et al. 2001), and an 
effort was initiated to identify genes for these disorders in this population with the 
hypothesis that founder effects, bottlenecks and genetic drift have concentrated a 
small number of high-impact genetic risk variants in this population. Simulation 
studies showed that the analytic approaches used in the study provided ample power 
to identify alleles explaining ≥5% of the variation in the phenotype. Despite this, no 
high-impact genetic risk factors were identified in this population. The results 
suggest, that depending on the genetic architecture of the trait of interest, low-impact 
common variants shared across populations confer susceptibility for common 
disorders even in isolated populations, where a founder effect could be expected 
(Lowe et al. 2009).  
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2.3  Autism Spectrum Disorders 
Autism Spectrum Disorders (ASDs), also referred to as pervasive developmental 
disorders, are a group of childhood-onset neuropsychiatric disorders with shared 
core deficits but of varying severity. The most common diagnostic categories are 
autism (F84.0, OMIM 209850) and Asperger Syndrome (AS, F84.5, 
OMIM608638). Other disorders include disintegrative disorder (F84.3), atypical 
forms of autism (F84.1), and Rett syndrome (RTT, F84.2). The upcoming new 
editions of both the International Classification of Diseases (ICD) and Diagnostic 
and Statistical Manual of Mental Disorders (DSM) will likely contribute 
substantially modified diagnostic guidelines for ASDs. Suggested changes include 
treating this group of disorders as a continuum of phenotypes. Another proposed 
change is to exclude Rett syndrome, a monogenic form of ASDs, affecting 
predominantly girls and caused by mutations in a single gene (Amir et al. 1999). 
2.3.1 Autism 
Autism was originally described by American psychiatrist Leo Kanner in 1943. His 
work is the basis for the modern definition and diagnostic criteria (Kanner 1943). He 
described 11 children, mostly boys, whose condition differed from mental 
retardation on the basis of their social isolation. He named the syndrome „infantile 
autism‟, because the lack of social interest resembled that described by Swiss 
psychiatrist Eugene Bleuler and termed „autistic psychopathy‟. 
Diagnostic criteria for autism are outlined in ICD-10 and DSM-IV (World Health 
Organization 1993; American Psychiatric Association 1994). Abnormalities in a 
triad of symptoms, consisting of qualitative abnormalities in reciprocal social 
interaction and communication as well as restricted repetitive and stereotyped 
patterns of behavior, interests and activities are required for diagnosis (Table 1). 
Symptoms have to be present before the age of thee years, making autism the most 
severe of all ASDs. In addition, a diagnosis of other ASDs such as specific 
developmental disorder of receptive language, mental retardation (MR) or Rett 
syndrome has to be excluded. MR is present in the majority of individuals with 
autism. Traditionally, 75-80% of individuals with autism have been reported to have 
cognitive impairment, but somewhat lower rates have been reported in more recent 
studies (Chakrabarti and Fombonne 2001; Yeargin-Allsopp et al. 2003). 
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Table 1. Diagnostic criteria for autism, as outlined in ICD-10 (World Health Organization 
1993). 
A. Presence of abnormal or impaired development before the age of three years, in at least 
one out of the following areas: 
(1) receptive or expressive language as used in social communication; 
(2) the development of selective social attachments or of reciprocal social interaction; 
(3) functional or symbolic play. 
B. Qualitative abnormalities in reciprocal social interaction, manifest in at least one of the 
following areas: 
(1) failure adequately to use eye-to-eye gaze, facial expression, body posture and gesture 
to regulate social interaction; 
(2) failure to develop (in a manner appropriate to mental age, and despite ample 
opportunities) peer relationships that involve mutual sharing of interests, activities and 
emotions; 
(3) a lack of socio-emotional reciprocity as shown by an impaired or deviant response to 
other people’s emotions; or lack of modulation of behaviour according to social 
context, or a weak integration of social, emotional and communicative behaviours. 
C. Qualitative abnormalities in communication, manifest in at least two of the following areas: 
(1) a delay in, or total lack of development of spoken language that is not accompanied by 
an attempt to compensate through the use of gesture or mime as alternative modes of 
communication (often preceded by a lack of communicative babbling); 
(2) relative failure to initiate or sustain conversational interchange (at whatever level of 
language skills are present) in which there is reciprocal to and from responsiveness to 
the communications of the other person; 
(3) stereotyped and repetitive use of language or idiosyncratic use of words or phrases; 
(4) abnormalities in pitch, stress, rate, rhythm and intonation of speech. 
D. Restricted repetitive, and stereotyped patterns of behaviour, interests and activities, 
manifest in at least two of the following areas: 
(1) an encompassing preoccupation with one or more stereotyped and restricted patterns 
of interest that are abnormal in content or focus; or one or more interests that are 
abnormal in their intensity and circumscribed nature although not abnormal in their 
content or focus; 
(2) apparently compulsive adherence to specific, non-functional, routines or rituals; 
(3) stereotyped and repetitive motor mannerisms that involve either hand or finger 
flapping or twisting, or complex whole body movements; 
(4) preoccupations with part-objects or non-functional elements of play materials (such as 
their odour, the feel of their surface, or the noise or vibration that they generate); 
(5) distress over changes in small non-functional, details of environment. 
E. The clinical picture is not attributable to other varieties of pervasive developmental 
disorder; specific developmental disorder of receptive language (F80.2) with secondary 
socio-emotional problems; reactive attachment disorder (F94.1) or disinhibited attachment 
disorder (F94.2); mental retardation (F70-72) with some associated emotional or 
behavioural disorder; schizophrenia (F20) of unusually early onset; and Rett’s syndrome 
(F84.2). 
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2.3.2 Asperger syndrome 
In 1944, unaware of Kanner‟s publication, Hans Asperger, a Viennese pediatrician, 
described what he believed to be a new psychiatric disorder. Asperger described 
four boys with normal cognitive and verbal skills, but with difficulties in social 
interactions, unusual and intense interests and motor difficulties (Asperger 1944).  
Asperger‟s work was not widely known in the English-speaking world until it was 
translated into English by Lorna Wing in 1981, who also introduced the term 
„Asperger syndrome‟ (Wing 1981). AS was first granted official recognition in the 
tenth International Classification of Disease (ICD-10, World Health Organization 
1993) and is included as „Asperger‟s disorder‟ in DSM-IV (American Psychiatric 
Association 1994).  
Similar to autism, qualitative abnormalities in social interaction and intense 
circumscribed interests or restricted, repetitive and stereotyped patterns of behavior 
interests and activities are required for a diagnosis of AS (Table 2).The most 
significant differences with autism are the lack of delay in spoken or receptive 
language and normal cognitive development in individuals with AS. However, 
abnormal use of language, such as formalistic speech, unusual use of inflection 
patterns and poor modulation of volume are often present (Volkmar and Klin 2000). 
Motor clumsiness is usual but not required for a diagnosis. 
Table 2. Diagnostic criteria for AS, as outlined in ICD-10 (World Health Organization 
1993). 
A. A lack of any clinically significant general delay in spoken or receptive language or cognitive 
development. Diagnosis requires that single words should have developed by two years of 
age or earlier and that communicative phrases be used by three years of age or earlier. Self-
help skills, adaptive behaviour and curiosity about the environment during the first three 
years should be at a level consistent with normal intellectual development. However, motor 
milestones may be somewhat delayed and motor clumsiness is usual (although not a 
necessary diagnostic feature). Isolated special skills, often related to abnormal 
preoccupations, are common, but are not required for diagnosis. 
B. Qualitative abnormalities in reciprocal social interaction (criteria as for autism). 
C. An unusually intense circumscribed interest or restricted, repetitive, and stereotyped 
patterns of behaviour, interests and activities (criteria as for autism; however it would be 
less usual for these to include either motor mannerisms or preoccupations with part- 
objects or non-functional elements of play materials). 
D. The disorder is not attributable to the other varieties of pervasive developmental disorder; 
schizotypal disorder (F21); simple schizophrenia (F20.6); reactive and  disinhibited 
attachment disorder of childhood (F94.1 and .2); obsessional personality disorder (F60.5); 
obsessive-compulsive disorder (F42). 
2 Review of the Literature 
THL Research 21|2009 42  Genetic Heterogeneity in Autism Spectrum 
 Disorders in a Population Isolate 
 
2.3.3 Prevalence of ASDs 
The most recent comprehensive meta-analysis of ASD prevalence reports a 
consensus prevalence estimate of 60-70/10 000 for all ASDs combined (Fombonne 
2009). Corresponding figures for autism and AS in the same study are 20 and 6, 
respectively. However, prevalence studies have yielded highly discordant findings 
due to methodological differences and differences in diagnostic criteria. Males are 
affected more often than females with approximately 4 affected males per female, 
although the ratio decreases when individuals with severe cognitive impairment are 
included (Fombonne et al. 1997). 
A multitude of studies have reported that the prevalence of ASDs is rising, and 
systematically lower prevalence estimates have been obtained in older studies 
compared to more recent ones (Newschaffer et al. 2005; Wazana et al. 2007). The 
increase has mainly been attributed to improved case ascertainment and changes in 
diagnostic criteria, not to increased incidence. Diagnostic substitution from 
cognitive impairment and learning disability to ASDs have also been suggested to 
partially explain the increase in prevalence (Shattuck 2006; Coo et al. 2008). The 
increase in high-functioning individuals receiving a diagnosis of ASDs has also been 
associated with the increase in ASD prevalence. In addition, the effect of diagnosis 
on the quality of care services, especially in the US has been suggested to increase 
the number of autism diagnoses for high-functioning individuals (Eagle 2004). 
There are only two prevalence studies focused specifically on the prevalence of AS 
(Ehlers and Gillberg 1993; Mattila et al. 2007). In the first study only three affected 
children were identified, resulting in a prevalence estimate of 28.5/10 000 when 
ICD-10 diagnostic criteria were employed. The second study included all children in 
the two most northern provinces of Finland, and a total of 21 individuals affected 
with AS were identified after comprehensive clinical evaluation. These results 
indicate a prevalence estimate of 29/10 000, very close to the result obtained in the 
Swedish study (Ehlers and Gillberg 1993). Prevalence estimates obtained in other 
studies are usually significantly lower, suggesting that AS would be less common 
than autism. Whether this reflects ascertainment bias or different diagnostic 
practices employed in different populations remains unclear. It should also be noted 
that the two AS studies are both relatively small, and a correlation between smaller 
study size and higher prevalence estimates has been reported (Fombonne 2005). 
Furthermore, the age of the group studied is vital when the prevalence of AS is 
estimated, because AS is identified and diagnosed much later than typical autism 
and it is possible that surveys of young children underestimate the prevalence of AS 
(Fombonne 2001). 
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2.3.4 Mode of inheritance of ASDs 
Both Kanner and Asperger reported that parents of individuals with ASDs displayed 
personality traits similar to those observed in their children, even leading Asperger 
to propose a genetic basis of the disorder he described. However, a bias in American 
psychiatry at that time for explaining all psychiatric disorders by deficiencies in 
parenting led to the hypothesis of autism being caused by emotionally cold mothers. 
Later studies showed no differences in parenting skills between parents with 
children affected with autism and healthy children disproving this hypothesis 
(Cantwell et al. 1979). Discovering the connection between autism and mental 
retardation as well as the aggregation of affected individuals in families finally 
established a biological basis of the disorder (Rutter 1968; Lockyer and Rutter 
1969). 
Family studies have reported a 2-6% rate of ASDs among siblings of individuals 
with autism (reviewed in Bailey et al. 1998a). This risk is even higher for siblings of 
female affected individuals, with rates of affected siblings up to 14% having been 
reported (Ritvo et al. 1989). Even using the most conservative frequency estimates, 
a clear increase in the rate of ASDs can be observed in families of affected probands 
compared to the general population. 
Twin studies in autism have reported MZ concordance rates ranging from 36% to 
91% compared to 0% in DZ twins (Folstein and Rutter 1977; Ritvo et al. 1985; 
Steffenburg et al. 1989; Bailey et al. 1995). The zero concordance rate for DZ twins 
can probably be explained by the small number of twin pairs. In all three studies a 
total of 36 MZ twin pairs and 30 DZ twin pairs were included. If a concordance rate 
is considered for a broader phenotype including milder cognitive or social deficits, 
10-30% of DZ twin pairs are concordant in the same three studies. The heritability 
of autism has been estimated to be greater than 90% (Bailey et al. 1995; Szatmari et 
al. 1998). However, as MZ concordance is not 100%, this suggests that 
environmental factors also contribute to disease susceptibility.  
No systematic family or twin studies have been performed in AS. Burgoine and 
Wing (1983) reported a pair of monozygotic triplets with a diagnosis of AS but who 
also displayed some characteristics of infantile autism, especially in one of the 
brothers. Single reports of AS or AS-like features in close relatives of probands with 
AS have been published supporting familial aggregation of AS (Kerbeshian and 
Burd 1986; Gillberg 1994; Kracke 1994). A study by Gillberg (1989) found more 
familial aggregation among families with probands diagnosed with AS compared to 
families with high-functioning autism (HFA), possibly suggesting a stronger genetic 
component of AS or a different inheritance pattern in HFA compared to AS. The 
families in the first genome-wide scan for AS susceptibility loci show strong support 
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of familial aggregation, and some pedigrees resemble autosomal dominant 
inheritance (Ylisaukko-oja et al. 2004). 
Estimates of the number of genes conferring susceptibility to ASDs are variable: 2-
10 (Pickles et al. 1995), 15 (Risch et al. 1999), and as much as 100 (Pritchard 2001; 
Veenstra-Vanderweele et al. 2003). Further studies are needed to elucidate whether 
the triad of impairments in ASDs are modified by separate genetic factors or 
controlled by overlapping risk factors. The correlation between the different 
domains of dysfunction is low, indicating that individuals with severe dysfunction in 
one of the domains do not necessarily display severe symptoms in the other domains 
(Ronald et al. 2006b; Ronald et al. 2006a). Similarly, distinct endophenotypes, often 
reflecting one of the three primary domains of symptoms, have resulted in non-
overlapping linkage regions (Alarcon et al. 2002; Nurmi et al. 2003; Buxbaum et al. 
2004; Chen et al. 2006; Schellenberg et al. 2006). The broader phenotype observed 
in close relatives of probands with ASDs fits best with a model of several interacting 
risk variants for the distinct domains of dysfunction (Jorde et al. 1991), and  
quantitative traits reflecting the three domains of dysfunction have resulted in 
different heritability estimates (Sung et al. 2005). However, other studies have 
reported a single continuously distributed factor contributing to all primary 
symptoms of ASDs (Constantino et al. 2004).  
A related unsolved question is whether risk for ASD is conferred by multiple 
common variants or rare, high penetrance mutations. A statistical analysis of autism 
risk in multiplex families yielded a best fit with a model where ASDs are caused by 
dominantly acting de novo mutations with reduced penetrance in females (Zhao et 
al. 2007). This is consistent with evidence obtained from linkage studies, 
chromosomal abnormalities and the limited number of identified risk variants 
discussed in detail below (see sections 2.3.6-2.3.8). Some studies have also 
suggested that different genetic risk factors exist in simplex versus multiplex 
families (Miles et al. 2005; Campbell et al. 2007; Sebat et al. 2007). Others have 
reported that the broader phenotype is distributed differently in simplex versus 
multiplex families, with family members of multiplex families displaying a higher 
frequency of ASD-like traits (Szatmari et al. 2000; Losh et al. 2008; Virkud et al. 
2009). As outlined in section 2.1.3, knowledge concerning the genetic architecture 
of the trait is vital for appropriate selection of gene mapping strategies, and can 
thereby greatly aid in the identification of genetic risk variants. 
2.3.5 Known genetic etiologies of ASDs 
In 10-15% of cases, autism is occurs together with conditions of known medical 
etiologies (Folstein and Rosen-Sheidley 2001; Fombonne 2003). These include 
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monogenic and complex disorders as well as chromosomal abnormalities, which are 
discussed in more detail in section 2.3.7. ASDs or ASD-like symptoms are present 
in these disorders at a higher frequency than expected by population prevalence. 
Often the symptoms are indistinguishable from idiopathic autism but for some 
genetic etiologies other distinguishing phenotypic features are also present, which 
allow for more specific diagnoses and provide possible clues to biological processes 
of interest. 
The most common medical condition co-occurring with ASDs is cognitive 
impairment, which is present in 75-80% of individuals with ASDs. Some genes have 
already been identified linking these two conditions, such as mutations in NLNG 4 
(see section 2.3.11). Multiple genes involved in the etiology of cognitive impairment 
have been identified and they make up an interesting group of possible candidate 
genes for ASDs. 
Epilepsy is present in approximately a third of individuals with ASDs by adulthood 
(Tuchman and Rapin 2002). The epilepsy can manifest in clinical seizures, or 
subclinically in epileptiform electroencephalography patterns. Individuals with 
infantile spasms are particularly likely to develop autism with nondevelopment of 
language and cognitive impairment (Asano et al. 2001). Stratification based on 
presence or type of epilepsy could be used as an endophenotype providing in 
genetically more homogenous groups for gene mapping. 
Besides MR and epilepsy, the rest of associated conditions are relatively rare, and 
present only in a marginal subset of individuals with ASDs. However, ASDs or 
ASD-like symptoms are present in a significant fraction of individuals affected with 
these disorders. One of the most common of these is Fragile-X syndrome (FXS). 
FXS is the most common genetic cause for mental retardation in males, and is 
caused by mutations in fragile-X mental retardation 1 (FMR1), located on the X 
chromosome. Approximately 20-30% of individuals with FXS show autistic features 
and the frequency is higher in males compared to females (Rogers et al. 2001; 
Hatton et al. 2006). Great variability has been reported in the rate of FXS in 
individuals diagnosed with autism ranging from 1 to 8% (Muhle et al. 2004).  
RTT is currently included in the same diagnostic category with ASDs in ICD-10 and 
DSM-IV. RTT is the most common inherited cause for MR in girls. The role of RTT 
as a part of the ASD continuum is currently being debated, as uncertainty exists 
concerning the true etiological connection between RTT and ASDs. RTT is caused 
predominantly by de novo mutations in MeCP2, which silences transcription of 
methylated genes (Amir et al. 1999). Mutations in MeCP2 have been linked to 
disrupted brain development and abnormal dendritic spine structure, closely 
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resembling anomalies reported in MR syndromes (Kaufmann and Moser 2000; 
Matarazzo et al. 2004).  
An increased rate of ASDs has been reported in a variety of monogenic disorders, 
including Joubert syndrome, Timothy syndrome, Tuberous Sclerosis Complex, 
Smith-Lemli-Optiz syndrome and Potocki-Lupski syndrome. The prevalence these 
disorders in ASDs is hard to determine due to the low frequency of these syndromes, 
but has been estimated to be less than 1% (Abrahams and Geschwind 2008). As 
some of these conditions are multi-organ disorders, they serve as an important 
reminder that if candidate genes are purely identified based on tissue-restricted gene 
expression patterns some interesting candidates could be missed. 
2.3.6 Linkage studies 
Multiple genome-wide linkage scans have been performed to identify chromosomal 
regions linked to ASDs (Yang and Gill 2007). Linkage signals have been obtained 
on almost every chromosome (Figure 1), but only a few loci are replicated in more 
than one study, as with many other complex disorders (Altmuller et al. 2001). 
Differing diagnostic criteria, sample size and statistical analyses used in these 
studies make comparison of linkage signals difficult. 
Significant linkage between autism and the long arm of chromosome 7 has been 
replicated in several studies. This region was also identified as the most significantly 
linked locus to ASDs in a meta-analysis (Trikalinos et al. 2006). Several 
chromosomal rearrangements have been reported in the same region (Folstein and 
Rosen-Sheidley 2001). Other relatively well replicated linkage regions are on 2q, 
16p and 17q. 
Most linkage studies have included 50-150 families, providing only limited power to 
detect linkage regions. However, the Autism Genome Project (AGP) has performed 
a large linkage study including 1168 families with at least two affected sibs. 
Surprisingly, this study revealed no genome-wide significant linkage loci suggesting 
that the lack of replicated linkage loci is not a consequence of a lack of power but 
instead a consequence of underlying genetic heterogeneity (Szatmari et al. 2007). 
When all families were combined, 11p12-13 reached suggestive but not genome-
wide significance. This locus has not been implicated in previous linkage scans. 
Stratification of the sample into male-only and female containing families yielded 
more significant peaks in the female containing families compared to male specific 
families. This could suggest a stronger genetic component in families with female 
affected individuals, or reduced genetic heterogeneity as the number of female 
containing families was 440 compared to 741 male-only families.  
2 Review of the Literature 
THL Research 21|2009 47  Genetic Heterogeneity in Autism Spectrum 
 Disorders in a Population Isolate 
 
The failure of large-scale genome-wide studies to identify common variants 
conferring risk for ASDs has prompted the investigation of linkage within individual 
families to identify rare variants. An elegant example of this approach was a study 
where homozygosity mapping in consanguineous families was used to identify 
family specific genetic risk variants for autism (Morrow et al. 2008). In this study 
104 consanguineous families, 88 of which had cousin marriages, were genotyped 
using a dense, genome-wide SNP array as well as an aCGH platform. The SNP data 
was analyzed for homozygous regions co-segregating with ASDs. Several families 
showed significant but non-overlapping linkage signals with LOD scores ranging 
from 2.4 to 2.96, comparable to the highest LOD scores obtained in linkage studies 
where data from hundreds of unrelated families are pooled. Interestingly, 5 of these 
families showed rare large inherited homozygous deletions ranging from 18 to over 
880 kb within the linkage peaks, depleting whole or parts of genes highly expressed 
in the brain. Genes within or close to the two largest deletions have been shown to 
be regulated by neuronal activity or are the targets of transcription factors induced 
by activity. 
If the lack of replicated linkage signals is due to genetic heterogeneity, increasing 
sample size is not necessarily the best way to increase power in linkage studies. 
Stratification has been performed using clinical phenotypes such as families with AS 
only, gender of proband, the presence or absence of spoken language and 
neurobehavioral features such as regression or obsessive-compulsive behaviors. 
Stratification based on gender has provided increased evidence for linkage (Stone et 
al. 2004; Lamb et al. 2005; Szatmari et al. 2007). Replicated linkage to 2q was 
obtained when a subset of families with delayed onset of phrase speech were 
analyzed (Buxbaum et al. 2001; Shao et al. 2002). 
The use of quantitative traits in linkage analysis have been successful in other 
complex disorders (Kissebah et al. 2000; Fisher et al. 2002; Weiss et al. 2006a). As 
family members often display some mild ASD-like traits, the use of quantitative 
traits such as age of first word provide added power. Analysis of age at first word 
resulted in the identification of a linkage peak on 7q and association with common 
variants in CNTNAP2 in a follow-up study (Alarcon et al. 2002; Alarcon et al. 
2008). 
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Figure 1. Linkage peaks identified on autosomes in genome-wide scans. Vertical bars 
indicate loci where LOD>3 was obtained in at least one study, and LOD>2 in another. Data 
from Abrahams and Geschwind (2008). Horizontal bars indicate loci where significant or 
suggestive linkage has been reported in at least one study. Bars in black indicate genome-
wide significant linkage (LOD>3.3), suggestive linkage in at least two studies (1<LOD<3.3) 
or loci where at least one study has resulted in genome-wide significance and another in 
suggestive linkage. Grey bars indicate markers resulting in suggestive linkage in one study. 
Data from Yang and Gill (2007). 
2.3.7 Genome-wide association studies in ASDs 
Recently, the first GWAS in ASDs was published (Wang et al. 2009). Two datasets 
were used - a cohort of 780 families from the Autism Genetic Resource Exchange 
(AGRE) and a case control cohort of 1204 affected individuals and 6491 controls 
from the US. Although neither cohort alone resulted in any genome-wide significant 
results, when the two cohorts were analyzed together, a genome-wide significant 
signal was obtained on 5p14.1, between cadherin 10 (CDH10) and CDH9. The 
results were replicated in two independent datasets, resulting in combined p-values 
ranging from 10-8 to 10-10 All SNPs showing significant association to ASDs are 
located within the same LD block, suggesting they are tagging the same 
susceptibility variant. Cadherins are neuronal adhesion proteins expressed in the 
developing brain. CDH10 was shown to be highly expressed in the frontal cortex 
and has a similar expression pattern to CNTNAP2, which has been recently 
implicated in ASDs (see section 2.3.9). These results suggest that common variants 
do play a role in the etiology of ASDs. Further autism GWA studies will be 
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published in the near future. A GWA study comprising a more extensive set of over 
1000 AGRE families has resulted in association to SNPs on 5p15, between SEMA5A 
and TAS2R1. The association was replicated in other datasets as well, and the 
combined p-value for the best marker in the region was 6x10-9 (Weiss et al. 2009). 
2.3.8 Chromosomal aberrations and CNVs 
Microscopically visible chromosomal aberrations have been estimated to account for 
6-7% of ASD cases. However the frequency of chromosomal aberrations varies 
widely, ranging from 0-54% (Xu et al. 2004). Higher frequencies have been 
obtained in studies of syndromic ASD cases compared to idiopathic cases 
(Jacquemont et al. 2006). 
The most common cytogenetic abnormality in ASDs, accounting for approximately 
1-2% of cases is maternal duplication of the imprinted 15q11-q13 region (Vorstman 
et al. 2006). This region overlaps with the deletion causing Angelman syndrome and 
Prader-Willi syndrome, both of which also have overlapping clinical symptoms with 
ASDs (Veltman et al. 2004; Bonati et al. 2007). The gene responsible for Angelman 
syndrome, ubiquitin protein ligase E3A (UBE3A), has been identified, whereas the 
specific gene or genes responsible for Prader-Willi syndrome have not been 
identified. A recent expression study reported that gene copy number does not 
directly correlate with gene expression in a female with autism, and that epigenetic 
mechanisms probably controls the expression of genes at the 15q11-13 locus 
(Hogart et al. 2009) Currently, the gamma-aminobutyric acid A receptor B3 
(GABARB3) and UBE3A are the most interesting candidate genes for ASDs in the 
15q11-q13 region. The GABAergic system has also been linked with epilepsy 
(Baulac et al. 2001; Wallace et al. 2001). Candidate gene studies of the three GABA 
receptor genes as well as UBE3A have yielded both positive and negative findings in 
candidate gene studies (Cook et al. 1998; Maestrini et al. 1999; Martin et al. 2000; 
Buxbaum et al. 2002; Nurmi et al. 2003; McCauley et al. 2004; Kim et al. 2006; 
Tochigi et al. 2007). Furthermore, smaller CNVs in several genes involved in 
ubiquitination both at 15q11-q13 as well at other loci have recently been implicated 
in ASDs (Glessner et al. 2009). 
Cytogenetically visible abnormalities have been reported on almost all 
chromosomes in ASDs. Meta-analysis have identified loci where several 
overlapping chromosomal aberrations cluster among unrelated cases, although no 
previous linkage or association results have been reported. These loci were 
suggested to be novel ASD loci. The loci implicated were 2q37, 5p15, 11q25, 
16q22.3, 17p11.2, 18q21.1, 18q23, 22q11.2, 22q13.3 and Xp22.2–p22.3. In 
addition, regions were identified where deletions or duplications overlap with loci 
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identified in linkage studies, such as several loci on 7q, 5p14, 10p14 and 16p13.3 
(Vorstman et al. 2006). The largest number of chromosomal aberrations was 
unsurprisingly reported at the 15q11-13 locus. A large number of chromosomal 
abnormalities were also located at 7q and 22q. 
Deletions in 22q11 and 22q13 are both associated with specific syndromic 
phenotypes (Goizet et al. 2000; Shprintzen 2000). Deletion of 22q11.2 causes 
velocardiofacial syndrome, which is one of the most significant genetic risk factors 
for schizophrenia and has recently been linked to autism as well (Murphy et al. 
1999; Niklasson et al. 2001). The common deletion at 22q13.3 is characterized by 
neonatal hypotonia, global developmental delay, absent to severely delayed speech, 
dysmorphic features and ASD-like behavioral symptoms (Manning et al. 2004). The 
minimal overlapping region identified in 22q13.3 microdeletion syndrome contains 
three genes: ACR, RABL2B and SHANK3. SHANK3 has also been reported to be 
disrupted by a translocation in an individual with clinical symptoms of 22q13.3 
deletion syndrome, implicating SHANK3 as the causative gene (Bonaglia et al. 
2001). However, deletions not overlapping with SHANK3 indicate that other genes 
in the region influence language and cognitive development as well (Wilson et al. 
2008). 
Rare chromosomal abnormalities, identified in only a few individuals, have aided in 
the identification of genes involved in the etiology of ASDs. At Xp22.3, de novo 
chromosomal deletions were identified in three females with autism (Thomas et al. 
1999). A frameshift mutation, resulting in premature termination of the encoded 
protein was identified in neuroligin 4 (NLGN4), located in the deleted region 
(Jamain et al. 2003). The deletion was present in two affected siblings, one with 
autism and one with AS but not in an unaffected brother or 350 healthy controls. 
The mutation was also present in the mother. Another mutation was identified in 
another member of the NLGN family, NLGN3, located at Xq13. The mutation 
resulted in replacement of a conserved Arginine to a Cysteine (R451C) in two 
affected brothers, one with autism and the other with AS. The mother was a carrier 
of the mutation, but no grandparents were available for the study. The role of 
skewed X chromosome inactivation in the mothers was not investigated. 
The first systematic study of submicroscopic chromosomal rearrangements in 
idiopathic ASDs revealed an excess of de novo CNVs in individuals with autism 
(Sebat et al. 2007). The de novo CNVs were particularly enriched in families with 
only one affected individual. The overlap between identified CNVs was small, and 
most CNV were detected only in a single individual. The AGP linkage-study was 
the first autism study where genome-wide SNP data was assessed for variation in 
copy number of submicroscopic regions (Szatmari et al. 2007). Despite a sparse 
marker map, de novo CNVs were identified in cases in 10 families. However, the 
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same CNV was detected in both affected sibs in only three families. In an additional 
18 families, CNVs were identified in regions with previously identified 
chromosomal abnormalities related to autism. The most interesting CNV was a 
deletion in two female affected sibs spanning 300 kb on 2p16, which was not 
detected in either parent. The hemizygous deletion removes coding exons of 
NRXN1, an interesting functional candidate interacting with NLGNs at the synapse. 
A previous study had already reported rare mutations in NRXN1 in autism, making it 
a highly relevant candidate gene (Feng et al. 2006). 
A deletion spanning almost 600 kb on 16p11.2 was identified in five cases using 
dense, genome-wide SNP data in the AGRE families (Weiss et al. 2008). In the 
same study this CNV was also identified in eight individuals from a cohort of 
individuals with ASDs, developmental delay, mental retardation, or suspected ASD. 
Furthermore, the reciprocal duplication was also identified as a risk factor for ASDs 
in the same study. The same CNV was identified in another study using aCGH in 
two AGRE families (Kumar et al. 2008). The CNV has been detected in 
unphenotyped population controls with a frequency of approximately 1%, 
suggesting incomplete penetrance (Weiss et al. 2008). 
Large, genome-wide studies are currently producing massive amounts of data 
concerning the chromosomal rearrangements in ASDs as well as in controls, making 
the review of the available data painstaking. However, resources summarizing the 
extensive information obtained in genome-wide studies of large autism datasets are 
finally emerging, making the use of these large datasets easier. The Autism 
Chromosome Rearrangement database aims to catalogue all chromosomal 
abnormalities associated with ASDs, providing an easy user interface to evaluate the 
significance of novel findings (Xu et al. 2004; Marshall et al. 2008). The 
DECIPHER database contains information on large, rare CNVs identified in 
individuals with cognitive impairments. The database also contains detailed 
phenotype information, allowing for the identification of novel syndromes 
associated with these genomic rearrangements as cases with overlapping 
rearrangements are reported (Firth et al. 2009). The database has already facilitated 
the identification of several novel syndromes, including the 14q11.2, 17q21.3 and 
19q13.11 deletion syndromes (Shaw-Smith et al. 2006; Zahir et al. 2007; Malan et 
al. 2009). 
2.3.9 Candidate gene studies 
An overwhelming multitude of candidate genes studies using both association- and 
resequencing methods have been performed in ASDs. Often studies lack power to 
detect association, and even for the most convincing candidates, both negative and 
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positive results have been published. This likely reflects both the lack of power of 
many studies, and the underlying genetic heterogeneity of the genetic risks of ASDs. 
Some interesting candidate genes are presented in Table 3 and classified according 
to the available evidence for their role in ASD etiology. 
Although approximately half of the candidate genes listed in Table 3 are located at 
linkage peaks, only a few genes have been identified in follow-up studies of linkage 
regions. One example, where positional cloning has been successfully used to 
identify variants influencing risk for ASDs is the identification of CNTNAP2 as a 
susceptibility gene for ASDs. Fine-mapping of the language-related quantitative trait 
locus (QTL)-linkage peak on 7q35 using over 2700 SNPs identified association 
between four genes in the region and age at first word in 170 families (Alarcon et al. 
2002; Alarcon et al. 2005; Alarcon et al. 2008). In the follow-up stage, SNPs in 
these four genes were tested for association in an independent sample of 304 trios. 
The only SNP associated with age at first word in this stage was rs2710102 in 
CNTNAP2, and analysis of families containing only male affected individuals 
resulted in more significant association. In a subsequent study, the link between 
CNTNAP2 and language disorders was reinforced as CNTNAP2 was identified as a 
target of FOXP2, a gene interrupted in rare mendelian speech and language 
disorders (Vernes et al 2008). Mutations in CNTNAP2 have been identified in a 
family with seizures, language regression and ASDs (Strauss et al. 2006). A 
chromosomal translocation disrupting CNTNAP2 has also been identified in a family 
with repetitive behaviors and intellectual disability (Verkerk et al. 2003). 
Chromosomal rearrangements, rare mutations and identification from a genome-
wide linkage study for autism further support the role of CNTNAP2 in the etiology 
of ASDs (Arking et al. 2008; Bakkaloglu et al. 2008). Interestingly, CNTNAP2 is a 
member of the NRXN gene family implicated in ASDs in earlier studies (see section 
2.3.11). 
  
Table 3. Candidate genes with multiple lines of evidence for their role in ASDs 
Gene Pos 
Syndr. 
or 
mutat. 
Repl. 
assoc. 
Analysis 
of 
variant 
Mouse 
model Linkage 
CNV 
in 
ACRD Other evidence 
Total 
score Reference 
AVPR1A 12q14 0 0 0 1 0 0 0 1 Wassink et al. (2004) 
ITGB3 17q21 0 1 0 0 0 0 0 1 Weiss et al (2006b) 
DISC1 1q42 0 0 0 1 1 0 0 2 Kilpinen et al. (2008) 
EN2 7q36 0 1 0 1 0 0 0 2 Gharani et al. (2004) 
GRIK2 6q16 0 1 0 0 0 0 1; mutation in MR 2 Jamain et al. (2002) 
AHI1 6q23 2 0 0 0 1 0 0 3 Ozonoff et al. (1999) 
CACNA1C 12p13 2 0 1 0 0 0 0 3 Splawski et al. (2004) 
NRXN1 2p16 2 0 0 0 0 1 0 3 Feng et al. (2006) 
SLC25A12 2q31 0 1 0 0 1 0 
1; expression upregulated in ASD 
brain 
3 Ramoz et al. (2004) 
CNTNAP2 7q35 2 1 0 0 1 0 0 4 Strauss et al. (2006) 
FMR1 Xq27 2 0 1 1 0 0 0 4 Bailey et al. (1998b) 
NLGN3 Xq13 2 0 1 1 0 0 0 4 Jamain et al. (2003) 
OXTR 3p25 0 1 0 1 1 0 
1; expression reduced in ASD 
blood 
4 
Wu et al. (2005) 
SLC6A4 17q11 0 1 1 0 1 0 1; clinical benefit from inhibitors 4 Cook et al. (1997) 
SHANK3 22q13 2 0 0 0 0 1 
1; modulates dendrite spine 
morphology 
4 Durand et al. (2007) 
DHCR7 11q13 2 0 1 0 1 0 
1; hypocholesterolameia in ASD 
probands 
5 Tierney et al. (2001) 
MECP2 Xq28 2 0 1 1 0 0 
1; controls expression of UBE3A 
and GABRB3 
5 Amir et al. (1999) 
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Gene Pos 
Syndr. 
or 
mutat. 
Repl. 
assoc. 
Analysis 
of 
variant 
Mouse 
model Linkage 
CNV 
in 
ACRD Other evidence 
Total 
score Ref 
MET 7q31 0 1 1 0 1 1 
1; expression reduced in ASD 
brains 
5 
Campbell et al. 
(2006) 
PTEN 10q23 2 0 0 1 1 0 
1; mutations result in synaptic 
abnormalities 
5 Butler et al. (2005) 
TSC2 16p13 2 0 1 0 1 0 1; regulates dendrite morphology 5 Baker et al. (1998) 
CADPS2 7q31 2 0 1 1 1 1 0 6 Sadakata et al. (2007) 
GABRB3 15q12 2 1 0 1 0 1 
1; expression is dysregulated in 
ASDs 
6 Cook et al. (1998) 
NLGN4X Xp22 2 0 1 1 1 1 0 6 Jamain et al. (2003) 
UBE3A 15q11 2 0 1 1 0 1 
1; expression is dysregulated in 
ASDs 
6 Peters et al. (2004) 
RELN 7q22 2 1 1 1 1 0 
1; expression reduced in ASD 
brains 
7 Persico et al. (2001) 
NOTE: To emphasize the role of rare mutations in ASDs, genes associated with ASD-linked syndrome or mutation resulted in 2 points, 
whereas other lines of evidence resulted in one point. To qualify as a mouse model of ASDs, two out of the three clinical core features had 
to be present. Linkage evidence was scored as present if the best marker from a suggestive linkage peak listed in Yang and Gill (2007) 
was located within the same cytogenetic band. ACRD – Autism chromosomal rearrangement database, AH1 – Abelson helper integration 
site 1, AVPR1A – arginine vasopressin receptor 1A, CACNA1C – calcium channel voltage-dependent L type alpha 1C subunit, CADPS2 – 
Ca2+-dependent activator protein for secretion 2, CNTNAP2 – contactin associated protein-like 2, DHCR7 – 7-dehydrocholesterol 
reductase, DISC1 – disrupted in schizophrenia 1, EN2 – engrailed homeobox 2, FMR1 – fragile mental retardation 1, GABRB3 – gamma-
aminobutyric acid A receptor beta 3, GRIK2 – glutamate receptor ionotropic kainite 2 precursor, ITGB3 – integrin beta 3, MECP2 – 
methyl CpG binding protein 2, MET – met proto-oncogene, NLGN3 – neuroligin 3, NLGN4X – neuroligin 4 X-linked, NRXN1 – 
neurexin1, OXTR – oxytocin receptor, PTEN – phophatase and tensin homologue, RELN – reelin, SHANK3 – SH3 and multiple ankyrin 
repeat domains 3, SLC25A12 – solute carrier family 25 member 12, SLC6A4 – solute carrier family 6 member 4, TSC1 – tuberous 
sclerosis 1, TSC2 – tuberous sclerosis 2, UBE3A – ubiquitin protein ligase E3A. Modified from Abrahams and Geschwind (2008). 
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2.3.10 Expression studies in ASDs 
To date, only five studies profiling genome-wide gene expression in ASDs have 
been published (Table 4). Four studies used lymphoblastoid cell lines (LCLs) as 
models for gene expression in the brain and one study used postmortem brain 
samples. The value of LCLs as model systems for gene expression remains unclear. 
Proof-of-principle studies have been performed in animals where gene expression 
profiles from blood cells were able to differentiate between different neurological 
diseases (Tang et al. 2001). In a study of bipolar disorder, a subset of differentially 
expressed genes in postmortem brain tissue were also found to be differentially 
expressed in LCLs, although the direction of expression changes were not consistent 
between the two tissues (Iwamoto et al. 2004). In ASDs, LCLs have been reported 
to differentiate between affected individuals and their healthy siblings (Baron et al. 
2006), and individuals having autism with regression from individuals with early 
onset autism without regression (Gregg et al. 2008). They have also been able to 
separate individuals with the FMR1 mutation from individuals with duplication of 
15q (Nishimura et al. 2007). Taken together, these results suggest that at least some 
of the gene expression changes characterizing neurological and neuropsychiatric 
conditions are reflected in LCLs. Another argument for the use of LCLs is that 
expression studies could result in a combination of biomarkers which could be used 
as diagnostic assays in the future. Possible uses of gene expression profiling from 
blood could be used to confirm diagnosis or to classify affected individuals. The 
distinction into diagnostic subclasses could have impact on choice of treatment. 
Although the use of post-mortem brain samples would seem like a more optimal 
tissue for expression studies, it also poses problem. Access to ASD brain samples is 
limited, and as RNA is seldom extracted immediately upon organ retrieval, the 
quality of RNA is rarely optimal for expression studies. More importantly however, 
death often occurs long after disease onset and the observed gene expression 
changes do not necessarily reflect the processes involved at that time. 
Of the approximately 900 genes identified as differentially expressed on a 
suggestive level in these studies, less than 1% have been identified by more than one 
study. However, for the small group of genes identified in more than one study, 
there are several genes residing on 15q, including CYFIP1, NIPA2 and UBE3A. The 
group of differentially expressed genes identifies significant enrichment in 
categories including ubiquitin conjugation, SH3 domain containing proteins, 
GTPase regulator activity, α-protocadherin genes and alternative splicing (Abrahams 
and Geschwind 2008). Larger gene-expression studies are needed to verify the role 
of these genes and biological processes in ASDs. 
  
Table 4. Genome-wide gene expression profiling studies in ASDs. 
Tissue  Cases Ctrls Platform 
Diff. expr. 
probes Stat. Identified pathways Reference 
Brain 9 4 
cDNA Atlas Human 
Neurobiology and 
UniGEM V2 
NS NS Glutamate neurotransmission 
Purcell et al. 
(2001) 
LCL 10
1
 4 
cDNA TIGR 40K 
Human set 
26 up 15 
down 
|FC|> 1.5 
Nervous system development and function, 
cell death, immune and lymphatic system 
development and function 
Hu et al. 
(2006) 
LCL 3 3
2
 
Affymetrix HG-
U95Av2 
30 up 18 
down 
p<0.05 & 
|FC|>1.3 
Immune system, signal transduction, cell 
growth, response to external stimuli, 
development 
Baron et al. 
(2006) 
LCL 15
3
 15 
Agilent Whole 
Human Genome 
Array G41124A 
43 up 25 
down 
FDR<5% in 
SAM, RankProd 
and ANOVA 
Cell communication, signal transduction, 
immune response, defense response 
Nishimura 
et al. (2007) 
LCL 35 12 
Affymetrix HG-
U133Plus 2.0 
45 up 10 
down 
FDR<5%, 
|FC|>1.5 
Keratan sulfate biosynthesis, folate 
biosynthesis, galactose metabolism, 
serotonin receptor signaling 
Gregg et al. 
(2008) 
NOTE: Ctrls – Controls, Diff. expr. Probes – Number of differentially expressed probes, Stat. – Statistical significance used for 
differential expression, LCL – Lymphoblastoid cell line, NS – Not stated, FC – Fold change, FDR – False discovery rate, SAM – 
Significant Analysis of Microarray Analysis (Tusher et al. 2001), RankProd – Rank Product analysis (Breitling et al. 2004b), ANOVA – 
Analysis of variance, 1 – Five MZ twin pairs, two which were concordant for autism, and two where the co-twin had a Broad Spectrum 
ASD, 2 – Sibs of the affected individuals, 3 – 8 males with FMR1 mutation and 7 with dup(15q). 
 
T
H
L
 R
esearch 21|2009 
                           56 
         G
enetic H
eterogeneity in A
utism
 Spectrum
 
D
isorders in a P
opulation Isolate 
   2 R
eview
 of the L
iterature 
2 Review of the Literature 
THL Research 21|2009  57 Genetic Heterogeneity in Autism Spectrum 
 Disorders in a Population Isolate 
 
2.3.11 Biological pathways identified in ASDs 
The numerous findings from linkage, association, expression and chromosomal 
rearrangement studies in ASDs are almost overwhelming. However, a subset of the 
findings can be linked to common molecular pathways, revealing biological 
processes implicated in the etiology of these diseases. Although findings for 
individual genes are not convincing by themselves, the disruption or dysregulation 
of several genes in the same biological pathway provide convincing evidence that 
the process is involved in the etiology of the trait. 
S e r o t o n i n  a n d  a u t i s m  
One of the most common biological finding in ASDs is elevated blood serotonin in 
20-30% of individuals with ASDs as well as in a subset of healthy relatives (Schain 
and Freedman 1961; Anderson et al. 1987; Abramson et al. 1989; Leboyer et al. 
1999). The observed increase in cases compared to controls has ranged from 20% to 
over 300% (Anderson et al. 1990). However, the prevalence of hyperserotonemia in 
autism may have been overestimated in these studies due to failure to control for 
race and pubertal status (McBride et al. 1998). Blood levels of serotonin correlate 
inversely with verbal IQ and positively with severity of autism (Kuperman et al. 
1987; Cook et al. 1990). Position emission tomography have indicated significant 
differences in serotonin synthesis capacity between children with autism and healthy 
controls (Chugani et al. 1999). 
Pharmacologic studies have further implicated the serotonin system in ASDs. 
Symptoms of ASDs were ameliorated by the administration of selective serotonin 
reuptake inhibitors in individuals with autism (McDougle et al. 1996b). Moreover, 
depletion of tryptophan, a precursor in serotonin synthesis, resulted in the worsening 
of symptoms in a group of adult ASD patients (McDougle et al. 1996a). A review of 
studies of selective serotonin reuptake inhibitors in ASDs concluded that most 
studies demonstrated significant improvement in global functioning and an 
amelioration of symptoms, especially those linked to anxiety and repetitive 
behaviors. However, the review also reported methodological weaknesses in several 
of the clinical trials highlighting the need for additional randomized control trials 
(Kolevzon et al. 2006). 
Serotonin has been shown to play a key role in a variety of behaviours and processes 
such as behavioural inhibition, appetite, aggression, sleep and mood. It also plays a 
vital role in neurodevelopment, having critical effects on neurogenesis, 
morphogenesis and synaptogenesis in the developing brain (Scott and Deneris 
2005). Serotonergic neurons are widely distributed across the mammalian brain, and 
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display rich innervation of limbic areas critical for emotional expression and social 
behavior, reflecting the core defects in ASDs (Anderson 2002). The serotonin 
system has also been linked to epilepsy, and variants in the genes involved in the 
serotonin pathway could explain the co-occurrence of autism and epilepsy (Chugani 
2004). 
The biological evidence linking the serotonin pathway to autism has led to intense 
scrutiny of genes involved in serotonin signaling and metabolism. The most 
intensely investigated gene is the serotonin transporter SLC6A4 also known as 5-
HTT, which is the site of action of selective serotonin reuptake inhibitors. SLC6A4 
modulates serotonergic neurotransmission by transporting serotonin from the 
synaptic cleft into presynaptic nerves (Amara and Pacholczyk 1991). Early reports 
of association between the short allele of a polymorphism in the promoter of 
SLC6A4 with autism was followed by a number of replications as well as non-
replications (Cook et al. 1997; Devlin et al. 2005). A recent meta-analysis of the 
studies of the promoter polymorphism as well as another microsatellite marker in 
intron two of SLC6A4 concluded that there is no evidence for association between 
any of these markers and ASDs. However, when only US populations were 
analyzed, the short allele of the promoter polymorphism was overtransmitted to 
affected individuals (Huang and Santangelo 2008). A study reported magnesium 
concentration-dependent genotyping errors at the SLC6A4 promoter polymorphism 
resulting in a false increased frequency of the short allele. Corrected genotypes 
resulted in no association of this locus with ASDs and evidence for deviation from 
Hardy-Weinberg equilibrium (HWE) in published studies was reported (Yonan et al. 
2006). In light of this finding combined with the meta-analysis of SLC6A4, the role 
of this gene in the etiology of ASDs remains highly uncertain. 
Tryptophan 2,3-dioxygenase (TDO2) is a rate-limiting enzyme in the catabolism of 
tryptophan. Association between a SNP in the promoter of TDO2 has been reported 
in 196 AGRE families with ASDs (Nabi et al. 2004). Decreased activity of this 
enzyme could slow the metabolism of tryptophan and thereby lead to increased 
levels of serotonin. No other studies have been published assessing the role of TDO2 
in ASDs. 
Another gene involved in the metabolism of serotonin is monoamine oxidase-A 
(MAO-A), which regulates the level of serotonin as well as dopamine in the brain. 
Maternal genotypes of a non-synonymous (ns)SNP in MAO-A have been reported to 
be correlated with IQ in children with autism (Jones et al. 2004). Haplotypes in 
MAO-A have also been associated with ASDs in the Korean population (Yoo et al. 
2009). A promoter polymorphism linked to lower activity of MAO-A (Sabol et al. 
1998; Denney et al. 1999) has been linked with lower IQ, more severe symptoms 
and larger brain volume in children with ASDs (Yirmiya et al. 2002; Cohen et al. 
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2003; Davis et al. 2008). The MAO-A genotype can be linked with neurobiological 
findings in autism as early cortical enlargement has been associated with ASDs 
(Courchesne et al. 2001; Dissanayake et al. 2006; Dawson et al. 2007), and the 
authors suggested that the effects of MAO-A variants on brain volume would be 
mediated through serotonin and dopamine (Davis et al. 2008). To date, no negative 
candidate gene studies of MAO-A in ASDs have been published. 
The b3-integrin gene (ITGB3) has been identified as a QTL for whole blood 
serotonin levels in males (Weiss et al. 2004). Association was observed between a 
coding variant in ITGB3 and autism, however, the allele associated with autism was 
associated with lower whole-blood serotonin in population samples, contradictory to 
reports of elevated serotonin in ASDs (Weiss et al. 2006b). The authors suggested 
that ITGB3 is not responsible for hyperserotonemia, but rather perturbation of the 
serotonin system in general in individuals with ASDs. 
S y n a p t i c  d y s f u n c t i o n  
The role of the serotonin system in autism was originally suggested by the biological 
finding of elevated whole-blood serotonin, which led to the identification of several 
candidate genes for ASDs. The opposite route, starting from rare genetic mutations 
and CNVs merging to reveal a shared biological function, has pointed to synaptic 
dysfunction in the etiology of ASDs. 
CNVs and mutations have implicated NLGNs and NRXNs in the etiology of autism 
(see section 2.3.7). Following the initial report of one mutation in NLNG3 and one in 
NLGN4X, several mutations in NLGN4 have been identified. Mutations have been 
identified in both NLGN4X and the Y chromosomal homolog NGLN4Y. NLGN4 
mutations have been linked with a wide range of phenotypes, ranging from autism 
and Asperger syndrome to mental retardation with or without autism (Laumonnier et 
al. 2004), and to Tourette syndrome and attention-deficit hyperactivity disorder in 
another study (Lawson-Yuen et al. 2008). In some families, the carrier mother also 
had learning disabilities (Yan et al. 2005; Lawson-Yuen et al. 2008). Interestingly, 
deletion of NLGN4X has also been linked with normal intellectual function and mild 
MR in one study, suggesting that deletion of NLGN4X is compatible with normal 
intellectual function (Macarov et al. 2007). 
Altogether these studies along with a number of negative screening studies bring the 
total number of individuals with ASDs screened for mutations in the coding regions 
of NLGN4X to over 1000. The resulting frequency of mutations in NLGNs is below 
0.6%, which is probably an overestimate as not all variants identified in these 
studies are necessarily causative. Interestingly, although the original report 
identified a mutation in both NLGN3 and NLGN4X, subsequent reports have only 
identified mutations in NLGN4. NLGN1, located at 3q26 has only been investigated 
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in one study (Ylisaukko-oja et al.). NLGN2, which is predominantly located at 
inhibitory (GABAergic) synapses has not been investigated in ASDs. 
When CNVs and mutations were identified in NRXN1, a postsynaptic binding 
partner of NLGNs, great interest was sparked in the role of the synapse in ASDs. 
Several CNVs spanning the shorter isoform, α-NRXN1 and the longer β-NRXN1 
isoform have been identified (Kim et al. 2008, Szatmari et al. 2007). Rare variants 
have also been identified in both isoforms (Kim et al 2008, Feng et al. 2006, Yan et 
al. 2008). Similarly to NLGN mutations, the NRXN1 variants result in a wide variety 
of phenotypes, ranging from ASDs to schizophrenia (Rujescu et al. 2009). 
Furthermore, the variants do not display complete penetrance, as they have been 
observed in healthy siblings as well (Feng et al. 2006). 
NLGNs and NRXNs are transmembrane proteins, which bind across the synaptic 
cleft. NLGN1 is located exclusively at exitatory (glutamatergic) synapses, whereas 
NLGN2 is located exclusively at inhibitory (GABAergic) synapses. NLGN3 might 
be present in both kinds of synapses. NLGNs are located on the postsynaptic 
membrane of synapses, whereas NRXNs are located at the presynaptic terminals. 
NRXNs are encoded by three genes, but multiple promoters and alternative splicing 
result in thousands of different splice isoforms. The binding affinities between 
different NRXN isoforms controls binding to different NLGNs at different types of 
synapses (Südhof 2008). 
In vitro experiments have shown that expression of NLGNs and NRNXs in non-
neuronal cells induce formation of post- and presynaptic structures, respectively, in 
neurons. However, knockout-mice have shown that NLGNs are not required in vivo 
for synaptic assembly, but are vital for synaptic function. Mice lacking NLGN1, 
NLGN2 and NLGN3 die at birth, and show severe impairment of synaptic 
transmission despite normal number of synapses. Mice lacking only NLGN1 or 
NLGN2 are viable and fertile, but show significant dysfunction at excitatory and 
inhibitory synapses respectively (Südhof 2008). 
NLGNs and NRXNs bind across the synaptic cleft, and interact with several PDZ-
domain containing proteins. The junction formed by NLGNs and NRXNs resemble 
a tight junction, but is asymmetrical with respect to the binding partners on each side 
of the synapse. Interestingly, several proteins linked to the NLGN-NRXN complex 
have been implicated in ASDs or other relevant disorders. NLGNs bind PSD95, 
which recruit glutamate receptors at postsynaptic sites, linking the NLGN-NRXN 
complex to glutamatergic signaling, which has been previously implicated in ASDs 
in both expression and candidate gene studies (Sheng et al. 2007, Purcell et al. 2001, 
Jamain et al 2002). PSD95 also binds SHANK3, which has been implicated in the 
etiology of ASDs by chromosomal rearrangements as well as point mutations 
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(Marshall et al 2008, Durand et al 2007, Moessner et al 2007). PSD95, also known 
as DLG4, has been shown to be regulated by FMRP (Muddashetty et al 2007), and 
belong to the membrane associated guanylate kinase (MAGUK) family. Another 
member of the MAGUK family, DLG3, has been shown to be mutated in MR 
(Tarpey 2004), which links several of the downstream binding partners of the 
NLGN-NRXN complex with phenotypes related to ASDs. A member of the NRXN 
family, CNTNAP2, has recently been implicated in ASDs by multiple lines of 
evidence (see section 2.3.9). 
The interaction of NLGN-NRNX first implicated connectivity problems at synapses 
in the etiology of autism. The findings at the molecular level serve as a link with 
more general observations of possible disease mechanisms. The differential 
expression of NLGN proteins at excitatory and inhibitory synapses modulates 
exitatory and inhibitory synapse development (Levinson and El-Husseini 2005). 
This process is critical for brain function, because alteration in the 
excitatory/inhibitory ratio during brain development can lead to abnormal synaptic 
connectivity and function, thereby resulting in severe neurological impairments 
caused by a number of different genes (Rubinstein and Merzenich 2003). 
Neurobiological findings in ASDs have not identified any major anatomical 
changes, further supporting the notion that ASDs are associated with abnormal brain 
function and not structure. The observed synapse-related dysfunction in ASDs could 
link molecular processes at the synapse with observed disconnection of brain 
regions involved in higher-order processing (Geschwind and Levitt 2007). 
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3  AIMS OF THE STUDY 
When we started this study, two genome-wide linkage scans had been performed in 
the Finnish ASD families, one in families with AS but no other ASDs, and another 
in families with autism, AS and dysphasia. The linkage scans revealed candidate 
regions for both AS and ASDs. In this study, our aim was to use the existing linkage 
data in combination with new families and novel high density genotype data to 
further examine the identified candidate regions to exclude false positive findings, 
replicate true susceptibility loci and identify novel regions and biological pathways 
involved in the etiology of ASDs. 
 
The following specific aims were addressed in the studies included in this thesis: 
I. To evaluate the linkage regions identified in a previous Finnish AS genome-
wide linkage scan in 12 independent families and fine map possible 
replicated linkage regions. 
II. To fine map the 3q26-q29 region previously identified in the Finnish ASD 
linkage scan and to investigate 11 functionally relevant candidate genes at 
this locus. 
III. To investigate whether genetic variants in glyoxalase 1 (GLO1), which had 
previously been implicated in the etiology of ASDs, predisposed to ASDs in 
the Finnish population. 
IV. To investigate to what extent the isolated Finnish population displayed 
population stratification, and what the effects the stratification would have 
on GWASs. 
V. Based on the results of study IV, individuals with ASDs from an internal 
isolate of Finland was selected in an attempt reduce genetic heterogeneity. 
Genome-wide SNP data was used to test if any shared haplotypes carrying 
possible founder mutations could be identified in these distantly related 
individuals. Further, genome-wide SNP data was combined with genome-
wide expression data to test if these complementary methods biological 
pathways involved in the etiology of ASDs using analysis of GO-categories.
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4 MATERIALS AND METHODS 
4.1 Methods 
The methods used in this study have been described in detail in the original articles 
(Table 5). Some of the methods are presented in more detail below. 
 
Table 5. Methods used in this study. 
Method Reference Publication 
Laboratory procedures   
Agarose gel electrophoresis   I, II, III 
Allele-specific primer extension – 
based SNP genotyping  
Pastinen et al. (2000) II 
DNA extraction  
Gentra systems, Minneapolis,  
MN, US 
I, II, III, IV, V 
Electrophoresis, ABI377/ABI3730 
Applied Biosystems, Foster City,  
CA, US 
I, II 
Expression Profiling Affymetrix, Santa Clara, CA, US V 
Genome-wide SNP genotyping  Illumina, San Diego, CA, US IV, V 
iPLEX SNP genotyping Sequenom, San Diego, CA, US II, III 
Polymerase Chain Reaction (PCR)  Kleppe et al. (1971) I, II, III 
Sanger Sequencing  Sanger and Coulson (1975) I, II 
Analysis programs   
Genemapper  
Applied Biosystems, Foster City,  
CA, US 
I 
Illumina BeadStudio Illumina, San Diego, CA, US IV, V 
Sequencher  Gene Codes, Ann Arbor, MI, US I, II 
SNPSnapper  
www.giu.fi/dnn/  
Default.aspx?tabid=177 
II 
Typer Analyzer  Sequenom, San Diego, CA, US II, III 
Statistical methods and software   
ANALYZE Hiekkalinna et al. (2005) I, II 
Downfreq 2.1 
www.genomeutwin.org/member/ 
cores/stat/linkage/downfreq.html 
I, II, III 
Eigensoft 2.0  
Patterson et al. (2006),   
Price et al. (2006) 
IV 
FBAT/HBAT  Horvath et al. (2001) II, III 
Genehunter v.2.1_r5beta Kruglyak et al. (1996) I 
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Method Reference Publication 
Genehunter-Imprinting  Strauch et al. (2000) I 
Genotype-IBD Sharing Test (GIST) Li et al. (2004) II 
Homog 3.35  Ott (1986) I 
LDMAP  Maniatis et al. (2002) IV 
Limma (R-package)  Smyth (2004) V 
MLINK/LINKAGE  
Lathrop et al. (1984),  
Lathrop et al. (1986) 
I 
Pedcheck 1.1  O’Connell and Weeks (1998) I, III 
PennCNV  Wang et al. (2007) V 
PLINK  Purcell et al. (2007) IV, V 
PolyPhen  Ramensky et al. (2002) II 
PSEUDOMARKER  Goring and Terwilliger (2000) I, II, III, V 
SNPiga, Ciga   V 
Tagger/Haploview 
Barrett et al. (2005),  
de Bakker (2005) 
II, III 
 
D N A  e x t r a c t i o n  
Blood was collected in ethylenediaminetetraacetic acid vials. DNA was extracted 
from samples using the Puregene DNA purification system (Qiagen, GmbH, Hilden, 
Germany) according to the manufacturer‟s protocol or using a phenol-chloroform 
protocol modified from Vandenplas and colleagues (1984). 
S e q u e n c i n g  
Regions amplified PCR were sequenced using the BigDye 3.1 terminator (Applied 
Biosystems) according to manufacturer‟s instructions. 
M i c r o s a t e l l i t e  g e n o t y p i n g  
PCR amplified microsatellite markers were electrophoresed on an ABI 3730 
Automatic DNA sequencer (Applied Biosystems, Foster City, CA, USA) as 
described in Ylisaukko-oja et al. (2004). 
S N P  g e n o t y p i n g  
SNPs were genotyped using allele-specific primer extension – based SNP 
genotyping (Pastinen et al. 2000), Sequenom iPLEX technology (Sequenom, San 
Diego, CA, US) or using Illumina BeadChips (Illumina, San Diego, CA, US) 
according to manufacturer's instructions. 
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E x p r e s s i o n  p r o f i l i n g  
Mononuclear lymphocytes were isolated from peripheral blood samples. Total RNA 
was extracted, purified and treated according to standard procedures, and hybridized 
to human Affymetrix U133 Plus 2.0 chips (Affymetrix, Santa Clara, CA, US) 
according to manufacturer‟s instructions. 
L i n k a g e  a n a l y s i s  
Linkage analyses were performed as described in publication I or using the 
dominant and recessive analysis options in PSEUDOMARKER (Goring and 
Terwilliger 2000). In the analysis of the autism-families, a disease allele frequency 
of 0.001 was used. Imprinting analysis was performed using GENEHUNTER 
IMPRINTING (Strauch et al 2000). 
A s s o c i a t i o n  a n a l y s i s  
Association analyses were conducted using PSEUDOMARKER (Goring and 
Terwilliger 2000) or PLINK (Purcell et al. 2007). 
P o p u l a t i o n  g e n e t i c  a n a l y s i s  
Population genetic analyses were performed as described in publication IV. 
D i f f e r e n t i a l l y  e x p r e s s e d  g e n e s  
Re-annotation of the Affymetrix probes was performed according to the latest 
release of the Entrez gene database. Raw data were preprocessed and analyzed using 
Bioconductor 2.3 implemented in R 2.8.0 software. 
P a t h w a y  a n a l y s i s  
Pathway analysis was performed with a non-parametric pathway analysis algorithm 
for global gene expression (CIGA) and GWA data (GWANA) developed in-house. 
The algorithm utilizes the Gene Ontology (GO) classification and aims to find the 
optimal regulated pathway compositions without a priori criteria for significance of 
individual genes. The algorithm uses an iterative cumulative hypergeometric 
distribution p-value based calculation. 
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4.2 Study subjects 
Families and individuals included in this study are summarized in Figure 2 and 
Table 6. The datasets are described in more detail below, and in the original articles 
(I-V). 
 
Figure 2. Finnish ASD datasets. Overview of Finnish ASD families, and the overlap between 
the datasets used in this study. The studies in which the datasets are used are given in roman 
numerals in parenthesis. 
4.2.1 Finnish ASD datasets 
A u t i s m  f a m i l i e s  ( I I ,  I I I ,  V )  
The families were recruited via Finnish university and central hospitals, mainly 
Helsinki University Hospital, Jyväskylä Central Hospital and Kuopio University 
Hospital. All families have at least one child diagnosed with autism and in some 
families siblings diagnosed with AS. Diagnostic evaluations were made by a 
multidisciplinary group of clinicians at the neurological department of hospitals. 
Data was collected from extensive diagnostic examinations including neurological 
examinations, assessment of developmental history as well as psychological and 
neuropsychological examinations. Final diagnoses were based on ICD-10 (World 
Health Organization 1993) and DSM-IV (American Psychiatric Association 1994) 
diagnostic nomenclatures. Families with known associated medical conditions or 
chromosomal  abnormalities  such  as fragile  X  syndrome were excluded  from the 
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Table 6. Summary of family sets and individuals used in this study. 
 N fams N inds 
N inds,  
LC1 
N inds,  
LC2 
N inds,  
LC3 Study 
ASD families       
Autism 97 356 118 126 - II, III 
AS combined 29 210 114 136 - I, III 
AS original (part of AS-comb) 17 119 72 82 - I 
AS new (part of AS-comb) 12 91 42 54 - I 
Autism-AS combined 123 540 - 232 - III 
CF-GWAS 51 51 45 49 51 V 
Ped1 (part of CF-GWAS) 19 19 15 18 19 V 
Ped2 (part of CF-GWAS) 8 8 6 7 8 V 
CF GWAS Families 50 160* 52* 58* 63* V 
FIN-GWAS 76 76 76 - - V 
FIN-GWAS Families 76 258* 90* 96* 106* V 
GWAS Replication AGRE 859 3960 1529 - - V 
FIN-EXPR 10 10 10 - - V 
GEO-EXPR 35 35 35 - - V 
Controls        
Anonymous blood donors - 100 - - - III 
Subset of H2000 - 646 - - - III 
Finland- subisolates - 1093 - - - IV 
Sweden - MZ twins - 302 - - - IV 
CF-GWAS controls - 181 - - - V 
FIN-GWAS controls - 271 - - - V 
CNV-controls - 5400 - - - V 
FIN-EXPR controls - 10 - - - V 
GEO-EXPR controls - 12 - - - V 
NOTE: N fams – number of families, N inds – number of individuals, ASD – Autism 
Spectrum Disorder, AS – Asperger Syndrome, CF – Central Finland, FIN-GWAS – Finnish 
replication GWAS dataset, FIN-EXPR – Finnish expression dataset, GEO-EXPR – Reference 
expression dataset GSE6575 LC1 – individuals with a diagnosis of autism in the autism 
family set and individuals with a diagnosis of AS in the AS-family set. LC2 – LC1 and 
siblings with a diagnosis of AS in the autism family set, LC1 and individuals not fulfilling all 
diagnostic criteria for AS in the AS family set and all individuals with a diagnosis of autism 
or AS in the autism-AS combined family set. LC3 – LC2 and individuals with a diagnosis of 
PDD-NOS or dysphasia, H2000 – Health 2000 cohort. *Including the individuals from the 
GWAS. 
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study. All families were Finnish except for one family where the father was of 
Turkish origin. 
Subsequently, the Autism Diagnostic Interview – Revised (ADI-R) was 
administered to families willing to continue to participate in the study. The ADI-R 
based diagnosis has been shown to correlate very well with the consensus diagnosis 
of autism (Le Couteur et al. 2008). In a subset of the Finnish autism families a 96% 
concordance rate was observed between hospital and ADI-R diagnosis of autism 
(Katja Lampi, personal communication) making the Finnish autism families 
clinically comparable to international family sets used for genetic studies. 
Individuals with a diagnosis of autism were classified in the narrow diagnostic 
category (liability class (LC) 1). Siblings with a diagnosis of AS were assigned to a 
broader diagnostic category (LC2). A total of 97 families, with one to three 
individuals affected with autism were included in this study. The number of families 
and affected individuals varies slightly in the original publications included in this 
study due to DNA availability limitations, but datasets are fully overlapping in all 
publications.  
A S  f a m i l i e s  ( I ,  I I I )  
Families were recruited via the Hospital for Children and Adolescents, Department 
of Child Neurology, Helsinki University Central Hospital, the Helsinki Asperger 
Center, Helsinki, Finland and Finnish central hospitals. Clinical examination 
included a structured interview based on ICD-10 (World Health Organization 1993) 
and DSM-IV (American Psychiatric Association 1994) diagnostic criteria for AS as 
well as criteria proposed by Gillberg et al. (Gillberg and Gillberg 1989; Ehlers and 
Gillberg 1993). The interview also included questions on hypersensitivity to external 
stimuli, prosopagnosia (face blindness), motor clumsiness and sleeping and eating 
disorders. These are not diagnostic criteria but have been frequently reported to be 
associated with AS (Nieminen-von Wendt 2004; Nieminen-von Wendt et al. 2005; 
Paavonen et al. 2008). In some cases the Asperger Syndrome Screening 
Questionnaire (Ehlers et al. 1999) was used to collect additional information. 
Interviews were performed by a research nurse with long experience of ASDs, and 
final diagnosis was established by a child neurologist. The majority of the 
individuals (80%) with a diagnosis of AS were diagnosed by one of two clinicians 
involved in the study (Prof. Lennart von Wendt, Taina Nieminen-von Wendt, MD, 
PhD). The rest were diagnosed by experienced neurologists at Finnish Central 
hospitals. All consenting family members, including individuals without a diagnosis 
of AS, were also assessed by the structured interview. All individuals who were not 
assessed by the clinicians involved in this study or had a hospital diagnosis of AS 
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were assigned an unknown status in the genetic analyses, but were included in 
genotyping if DNA was available, to provide phase information. 
Individuals fulfilling all ICD-10 criteria for AS were classified in diagnostic 
category 1 (LC1). Individuals with AS like features who did not fulfill all ICD-10 
criteria were classified in a broader diagnostic category (LC2). Families can be 
divided into two groups. The first consists of 17 extended families included in the 
Finnish genome-wide linkage scan for AS (Ylisaukko-oja et al. 2004), and are 
referred to as the original families. The second group consists of 12 independent 
families, referred to as the new families, collected for this study (Table 6, Figure 3). 
Autism was present in one family, in two individuals, a pair of male monozygotic 
twins. None of the families overlap with the autism family set. All families are 
Finnish. 
 
 
 
Figure 3. Pedigree structures for the twelve new AS families used in study I. Black symbols 
indicate AS (LC1), grey symbols indicate AS like features (LC2) and white symbols indicate 
unaffected or unknown status. Individuals marked with asterisks were not included in the 
genotyping.  
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F a m i l i e s  f r o m  C e n t r a l  F i n l a n d  ( V )  
From the autism and AS family sets, genealogical studies revealed links between 
nuclear families living across the country forming two extended pedigrees 
originating from two municipalities in Central Finland (CF, Figure 4). The first 
pedigree, referred to as Autism-pedigree 1 consists of 20 nuclear families, of which 
16 are included in the autism family set, 1 in the AS family set and 3 in neither. One 
affected individual from 19 nuclear families was genotyped. The families can be 
genealogically traced back to two neighboring farms in the 17th century. The other 
extended pedigree, referred to as Autism-pedigree 2 consists of 9 nuclear families, 
of which six are included in the autism family set. Three of the families are not 
included in the autism or AS family set. Two of these had a child diagnosed with 
ASDs, one with AS and one with pervasive developmental disorder not otherwise 
specified (PDD-NOS). The third is a family from the Finnish schizophrenia family 
sample with two individuals affected with schizophrenia. There were no individuals 
diagnosed with ASDs in this nuclear family, and it was not included in this study. In 
Autism-pedigrees 1 and 2 individuals with a diagnosis of PDD-NOS were 
considered affected (LC3). From each family, we selected the individual with the 
most severe phenotype (autism if present, otherwise AS or PDD-NOS) for genome-
wide genotyping using the Illumina HumanHap 300 Beadchip. For families with 
more than one child affected with autism, we selected the individual with more 
DNA available for genotyping. For the genome-wide SNP scan we included a subset 
of 24 autism families with at least two grandparents born in CF. One individual with 
autism from each of these families were included in the genotyping. The region of 
CF was defined using population history and linguistic information. The dataset 
consisting of 51 individuals with ASDs (mostly autism) from CF are referred to as 
CF-GWAS. 
A replication dataset was created consisting of one proband affected with autism 
from all Finnish autism families that were not genealogically connected to CF 
(n=76). Ggenome-wide SNP data was produced using the Illumina HumanHap550 
beadchip. In addition to individuals with autism from families included in studies II 
and III (see above) this dataset includes 29 new families in which diagnosis was 
established using the ADI-R. This dataset is referred to as FIN-GWAS.  
For replication of the best SNPs in the GWAS, we genotyped all available family 
members in the families from which the proband had been included in CF-GWAS. 
This data was used for family-based association analysis of the best SNPs in the 
GWAS, which should provide increased power to detect association as some 
families include more than one affected individual. This dataset is referred to as CF-  
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Figure 4. Pedigree structures of the two extended pedigrees identified by genealogical 
studies used in study V. Black symbols denote individuals diagnosed with autism, grey 
symbols denote individual diagnosed with AS, symbols with diagonal lines denote individuals 
diagnosed with PDD-NOS and symbols with horizontal lines denote individuals with a 
diagnosis of schizophrenia. The nuclear pedigree indicated with an asterisk is part of the 
Finnish schizophrenia family collection, and is not included in this study. The top pedigree is 
referred to as Autism-pedigree 1 and the lower Autism pedigree 2. 
GWAS Families. We also genotyped all available members from the FIN-GWAS 
families including affected siblings, and this dataset is referred to as the FIN-GWAS 
families. 
For genome-wide expression profiling, all families from the Autism-pedigree 1 with 
a male individual affected with autism that consented to RNA sample collection 
were included. This resulted in 8 affected males, which were supplemented by 2 
additional samples from males affected with autism that were not part of the large 
pedigrees. Age at the time of sample collection ranged from 5 years 3 months to 15 
years, with an average age of 10 years 9 months. 
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4.2.2 Non-Finnish ASD datasets 
A G R E  f a m i l i e s  ( V )  
AGRE families were genotyped using the Illumina 550K Beadchip at Children‟s 
hospital in Philadelphia. The dataset is publicly available on the AGRE website. 
Only individuals with a diagnosis of autism were included as affected in 
transmission disequilibrium test (TDT) analysis. This resulted in 859 families with a 
total of 1529 individuals affected with autism. 
E x p r e s s i o n  d a t a s e t  ( V )  
We used an additional expression dataset for pathway analysis. This dataset, 
GSE6575, was obtained from the Gene Expression Omnibus (GEO) database 
(Gregg et al. 2008). It consists of 35 individuals with autism and 12 non-autistic 
controls. Of the cases, 30 were male and 5 were female. 
4.2.3 Population stratification study (IV) 
Samples were collected at several sites across Finland and Sweden as part of larger 
studies. The Swedish samples (n=302) are a subset of the GenomeEUtwin study, and 
consist of female monozygotic twins with no data describing the geographical origin 
of samples (Pedersen et al. 2002). The majority of Finnish samples were drawn from 
two large cohorts: Health2000 and the Northern Finland Birth Cohort 1966 
(NFBC66). The Health2000 cohort is a nationally representative sample of 10 000 
people, originally collected to provide a comprehensive picture of health in the 
population aged over 18 in Finland in the years 2000-2001 (Aromaa et al. 2004). 
NFBC66 is a longitudinal birth cohort of individuals born in the two most northern 
provinces in Finland in 1966 (Rantakallio 1988). In addition, genome-wide SNP 
data, but only limited information about parents‟ birthplaces was available for 
samples from South Ostrobothnia (LSW) and Central Finland (LSC). These two 
groups comprise of individuals living within a particularly geographically limited 
region, as well as individuals from the population-based cohorts whose parents were 
born in these regions. Sample groups for the remaining regions were created using 
samples from NFBC66 and Health2000 limited strictly to individuals with both 
parents born within the same geographically restricted regions. The total number of 
Finnish samples included in the study is 1093. All study samples were anonymized 
with no possibility for identification of individual subjects.  
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4.2.4 Controls (III, V) 
A set of 746 Finnish individuals were used as controls in study III. Of these, 100 
were anonymous blood donors from CF and 646 were from the Health2000 cohort. 
No phenotype data was available for the anonymous blood donors. 
For study V, the controls used in association analysis comprise of two sets. The 
controls used for the CF-GWAS comprise of 181 individuals consisting of 
anonymous blood donors from CF and individuals from the Health2000 cohorts. The 
controls have been matched to the cases using multidimensional scaling (MDS) 
extracted IBS data - no geographical data was available for these individuals. For the 
FIN-GWAS, we used 371 controls from a large set of Finnish GWA samples 
genotyped on the Illumina HumanHap 370 Beadchip. Controls were selected by 
complete linkage agglomerative clustering based on pairwise IBS distance. The 
individuals in the control database originate from several large population cohorts, 
which have not been screened for ASDs. However, with a population prevalence of 
<1%, possible ASD cases in the control cohorts should not result in any inflation of 
allele frequencies (WTCCC 2007). 
For CNV analysis, we used a control dataset comprised of 5400 individuals from the 
NFBC66 population cohort, which have been genotyped using the Illumina 
HumanHap 370. In this population, CNVs had been determined for another study 
following the identical procedure used in this study. 
For the Finnish genome-wide expression profiling, ten age-matched males with no 
diagnosis of ASDs were used as controls. The age of the controls at time of sample 
collection ranged from 9 years 8 months to 17 years 6 months. The average age was 
12 years 3 months. 
Controls for the GEO-datasets were included in the same datasets as the cases 
(GSE6575) and consisted of 12 individuals without a diagnosis of ASDs. The 
controls were age-matched to the cases, 9 were male and 3 female. 
4.3 Ethical considerations 
All samples have been collected and studies have been performed in accordance 
with the Helsinki declaration. The studies have been approved by the appropriate 
ethics committees. Informed written consent was obtained from all individuals or 
their legal guardians. 
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5 RESULTS AND DISCUSSION 
5.1 AS Linkage study (I and unpublished data) 
The first genome-wide linkage scan in families with AS but no other ASDs was 
performed using 17 Finnish multi-generation pedigrees with multiple affected 
individuals (Ylisaukko-oja et al. 2004). Three primary linkage peaks were identified, 
at 1q21–q22 (Zmax dom=3.58), 3p14–p24 (Zmax dom=2.50) and 13q31–q33               
(Zmax dom=1.59). 
In this study, a new, independent family set consisting of 12 families (naff LC1=41, naff 
LC2= 54) was genotyped using microsatellite markers resulting in Zmax>1.5 in the 
initial stage of the Finnish AS genome-wide linkage scan (Ylisaukko-oja et al. 
2004). Two-point analysis under heterogeneity, performed using HOMOG and 
MLINK implemented in the ANALYZE package, resulted in three markers with 
maximum LOD scores (Zmax) exceeding 1. The highest Zmax was obtained using 
D3S1768 at 3p22.3 (Zmax=1.77, LC1, recessive model). In addition, Zmax=1.42 (LC2, 
recessive model) was obtained using D3S3547 located 5 cM distal of D3S1768. 
Results of two-point analysis for all markers on 3p14-p24 using different diagnostic 
criteria are presented in Figure 5. The third marker resulting in Zmax>1 was D4S3001 
(Zmax=1.65, LC1, recessive model) on 4p15.  
Figure 5. Results of two-point analysis of markers at 3p14-p24 in the 12 new AS families.  
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The highest multipoint nonparametric linkage (NPL)-score was obtained on 
chromosome 3p. The highest NPLall was 2.80 (p=0.0055, LC2) obtained at D3S1768 
(61.5 cM), the same marker which resulted in the most significant Zmax in two-point 
analysis (Figure 1 in publication I). The most significant multipoint result was 
obtained only 3.5cM proximal of the peak identified in the original linkage scan 
(Ylisaukko-oja et al. 2004). NPLall >1 was also observed at 4p. At this locus, 
maximum NPLall=1.28 (p=0.087, LC1) was observed at D4S3001 (29.47 cM).  
The data from the original genome-wide screen (Ylisaukko-oja et al. 2004) and the 
current study were analyzed jointly (nfam=29, nLC1=114, nLC2=136). The highest two-
point LOD score (Zmax=3.53, LC1, dominant model) was obtained using D1S484 at 
1q23.3 (Table 3, publication I). Also two flanking markers proximal to D1S484 
resulted in Zmax>2. The new families did not contribute significantly to the linkage at 
this locus. The second highest two-point maximum LOD score was obtained using 
D3S2432 (Zmax=2.94, LC1, dominant model). Altogether five out of six markers in 
the flanking region resulted in Zmax>1. Both datasets contributed to the linkage 
signal. 
Non-parametric multipoint analysis of the joint family set was performed using 
GENEHUNTER, and the most significant result, NPLall=3.83 (p=0.0007, LC1), was 
obtained at 57.92 cM near marker D3S2432 at 3p22.3. The NPL scores of the 
combined material and the contribution of the new material are shown in (Figure 1 
in publication I). The best evidence for linkage at 3p14-24 was obtained using the 
same marker in the original genome-wide screen (Ylisaukko-oja et al. 2004), and the 
most significant evidence for linkage using only the new families was obtained at 
D3S1768, only 3 cM proximal to D3S2432. In addition, NPLall>1 were obtained on 
chromosomes 1q, 4q and 13q. However, at these loci, the new families contributed 
only marginally to the linkage evidence. 
Family-based association analysis of the combined material was performed with 
PSEUDOMARKER 0.9.7 beta using the test of association conditional on linkage 
(LD|linkage) as appropriate in a region where strong linkage has been observed. A 
total of 11 markers resulted in p<0.05 (Table 7). The best evidence for association 
was obtained at D1S2815 (p=0.0024, LC1, dominant model). Results from the 
association analysis show that in general, the best linkage results in this study are 
not due to significant sharing of alleles across families, which is in agreement with 
analyses of haplotype sharing. Haplotypes were phased using GENEHUNTER and 
shared haplotypes on chromosomes 1, 3 and 4 were manually inspected. No 
common shared haplotypes were identified. In addition, the putative shared 
haplotype identified in three families from the genome-wide scan on chromosome 1 
(Ylisaukko-oja 2002) was not identified in any of the new families. Interestingly, the 
1q21-q24 region showing suggestive association in this study also resulted in 
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significant linkage in the combined analysis. It should be noted however, that the 
linkage signal is primarily contributed by the families from the original linkage-
scan. Linkage to this region has been observed in genome-wide linkage scans for 
schizophrenia (Brzustowicz et al. 2000; Gurling et al. 2001; Brzustowicz et al. 
2002). Finemapping of the linkage peak identified by Brzustowicz et al. (2000) 
revealed association between schizophrenia and eight markers in the carboxyl-
terminal PDZ ligand of neuronal nitric oxide synthase (NOS1AP) at 1q23.3 
(Brzustowicz et al. 2004). Regulator of G-protein signaling 4 (RGS4), another gene 
associated with susceptibility to schizophrenia is also located in this region (Mirnics 
et al. 2001; Chowdari et al. 2002; Morris et al. 2004; Williams et al. 2004). The 
1q21-24 region could harbor susceptibility variants shared between different 
neuropsychiatric disorders. Evidence already exists, that there are genes conferring 
risk to several different clinical entities. One such gene is disrupted in schizophrenia 
1 (DISC1), which has been linked to several neuropsychiatric disorders including 
schizophrenia, bipolar disorder, major depression and AS (St Clair et al. 1990; 
Hennah et al. 2003; Hennah et al. 2005; Thomson et al. 2005; Hashimoto et al. 
2006; Zhang et al. 2006; Kilpinen et al. 2008). DISC1 is involved in neuronal 
development, and has been associated with memory functions and other cognitive 
phenotypes making it an interesting and functionally convincing candidate. DISC1 
provides an encouraging example of the presence of common, shared susceptibility 
factors for neuropsychiatric disorders by affecting neurobiological processes.  
Table 7. Markers resulting in p <0.05 in family-based association analysis of the combined 
AS family material consisting of 29 families. 
Marker cM Diagnostic class Model p 
D1S1595 161.05 LC2 dominant 0.0258 
D1S1653 164.09 LC2 recessive 0.0255 
D1S1167 168.52 LC2 dominant 0.0324 
D1S2815 188.85 LC1 dominant 0.0024 
D3S3659 47.44 LC2 dominant 0.0416 
D3S2432  57.92 LC1 dominant 0.0280 
D3S3583 195.6 LC1 recessive 0.0040 
D3S2398 209.41 LC1 dominant 0.0210 
D4S3001 49.47 LC1 dominant 0.0430 
D4S1090 158.65 LC1 recessive 0.0259 
D6S1671 107.88 LC2 recessive 0.0264 
NOTE: cM – centiMorgan, LC1 – narrow diagnostic classification, LC2 – broad diagnostic 
classification. p-values are reported from the PSEUDOMARKER LD|linkage test.  
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To investigate whether the 3p14-p24 locus is subject to imprinting, we used 
GENEHUNTER-IMPRINTING (Strauch et al. 2000) In this analysis, two 
heterozygote penetrance parameters are defined and paternal and maternal origin of 
the disease allele can be treated differently in terms of probability of expression of 
the trait. We found no evidence for parent-of-origin effects at this locus, as the 
maternal imprinting-model resulted in HLOD=0.04 while the paternal imprinting-
model resulted in HLOD=1.81 (both LC1, dominant model). Most significant LOD 
scores were obtained in the original analysis, resulting in multipoint heterogeneity 
LOD=3.71 between markers D3S2432 and D3S1768 using a model with no 
imprinting (LC1, dominant model). 
In an effort to extract all possible linkage information from this set of families, we 
finemapped the region on 3p14-p24 using 13 additional markers in all 29 families. 
Six of the 13 fine mapping markers resulted in Zmax>1 (Figure 6). Family-based 
association analysis revealed two adjacent markers D3S2432 (from the first stage) 
and D3S1619 (finemapping marker) showing suggestive sharing across families 
using the LC1 and dominant model (LD|linkage p=0.028 and p=0.041, respectively, 
Figure 7). The region flanked by these two markers extends 3 cM and contains 13 
known genes. The fine-map did not significantly increase the evidence of linkage in 
the region, suggesting that available linkage information has been extracted from the 
region using the current density of microsatellite markers. Future studies using dense 
SNPs in the region will reveal the LD structure and the haplotype diversity in the 
region in these families, hopefully further specifying the region of interest and 
identifying haplotypes shared between families harboring possible susceptibility 
variants. 
As the best microsatellite marker, D3S2432 is located within the gene glycerol-3-
phosphate dehydrogenase 1-like (GPD1L), we wanted to sequence coding exons and 
exon-intron junctions to rule out possible coding variants as susceptibility variants 
for ASDs. GPD1L shows 72% identity with NAD-dependent glycerol-3-phosphate 
dehydrogenase (GPD1), and is expressed in several tissues including brain (Nagase 
et al. 1995). Mutations in GPD1L have been identified in families with Brugada 
syndrome, a syndrome that causes cardiac arrest due to ventricular fibrillation in 
apparently healthy individuals, and therefore, makes for a very unlikely candidate 
gene for ASDs. We sequenced all 8 coding exons in 13 patients from AS families 
contributing to the linkage peak at 3p. We identified seven variants which had all 
been previously detected, and were present in dbSNP (Table 8). Mutation analysis 
did not reveal any variants likely to contribute to the etiology of ASDs.  
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Figure 6. Results of two-point linkage analysis at 3p14-p24 in the combined AS family 
material consisting of 29 families. Markers indicated by an asterisk were added in the 
finemapping stage. 
 
 
 
Figure 7. Results of family-based association analysis at 3p14-p24 in the combined AS 
family material consisting of 29 families. Results from the PSEUDOMARKER LD|linkage 
test are reported. Markers indicated by an asterisk were added in the finemapping stage. 
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Table 8. Variants identified in the sequencing of GPD1L in 13 individuals with AS from 
families contributing to the linkage signal at 3p. 
Exon Pos SNP 
AA 
change 
N Sequence dbSNP 
ex1-231 -231 G>A - 8 GCGCAGCGACAGGGGGTGAGG rs13095243 
ex1-231 -231 G>R - 4 GCGCAGCGACRGGGGGTGAGG rs13095243 
ex1-168 -168 T>K - 4 GAGCCGGGCCKGGAGGCCGGC rs6805518 
ex1-168 -168 T>G - 9 GAGCCGGGCCGGGAGGCCGGC rs6805518 
ex1-59 -59 C>Y - 1 TGGCCGCGACYATTGGCGGAG rs1077601 
ex4 33 618 C>Y D136D 2 TCATTTCTGAYATCATCCGTG rs9835387 
ex5-218 39 863 G>A - 1 ATCCTATCATAAACATGTTAC rs9839702 
ex5+23 40 106 A>- - 1 TCAGGGGAGG[]GTTCATCAAG rs11351972 
ex8 59 463 A>R - 5 ACATGCAAACRTGTGAATGGT rs6799559 
ex8 59 463 A>G - 2 ACATGCAAACGTGTGAATGGT rs6799559 
NOTE: Pos – Position is given as bp from the start of exon 1 of GPD1L (NM_015141.2), 
corresponding to position chr3:32,123,143 according to NCBI build 36.1. N indicates the 
number of cases with the variant. 
 
In conclusion, we have replicated the linkage finding to the 3p14-p24 region in an 
independent set of AS families. Both the original and the replication family sets 
were relatively small suggesting that the region could contain a susceptibility gene 
with high individual gene-effect. Genome-wide linkage scans for ASDs have not 
identified significant linkage overlapping with the region identified in this study.  
Suggestive linkage to autism has been obtained in two independent studies, 10.5 and 
21.8 cM distal of the best AS region (Auranen et al. 2002; Shao et al. 2002b) (Figure 
8). In a combined analysis of the Finnish autism families and publicly available 
AGRE families from the heterogeneous US population the best linkage signal was 
observed on 3p24-p26. The highest NPLall=2.20 was obtained at D3S3691 located 
28.7 cM distal of the best AS region (Ylisaukko-oja et al. 2006). Simulation studies 
have shown substantial variation in the location of the best evidence for linkage 
even when the linkage is the result of a single genetic signal (Roberts et al. 1999). 
Therefore these non-overlapping but adjacent linkage peaks could be caused by 
shared underlying genetic risk factors. 
In published linkage studies, complementary approaches have been used to untangle 
the genetic constituents of ASDs. One strategy is to include a large sample set to 
increase the information content, but this may also lead to increased phenotypic as 
well as genetic heterogeneity. Another approach is to use individuals with a specific 
trait or endophenotype, which leads to a decreased sample size, but could benefit  
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Figure 8. Findings on the short arm of chromosome 3 in autism and AS. Marker location 
is given in centiMorgan (cM) from the telomere of the short arm. Results obtained in this 
study are presented in bold type. 
from the decreased genetic heterogeneity in the smaller sample. This approach has 
been used successfully in two studies identifying a susceptibility region on 
chromosome 2q in individuals with autism and delayed phrase speech (Buxbaum et 
al. 2001; Shao et al. 2002a). In this study we have attempted to decrease the genetic 
heterogeneity both by selection of AS, an endophenotype of autism, and by 
performing the study using families from the isolated Finnish population which has 
been shown to be genetically more homogenous compared to more outbred 
populations (Sajantila et al. 1996, study IV). Additionally, affected individuals were 
divided into two diagnostic categories, and in many cases better results were 
obtained using only a narrow definition of the phenotype. 
Although linkage has now been established to 3p14-24 in AS in two independent 
studies, this locus needs to be further evaluated in other populations to determine if 
this locus contains genetic variants conferring susceptibility to AS specific to the 
Finnish population, or if the risk factors are common in families with AS. To date, 
no family sets comparable to the ones used here and in the original Finnish genome-
wide linkage scan have been published. The ASD datasets used in other studies have 
traditionally been ascertained through probands affected with autism. We propose 
that large, multigenerational pedigrees affected only with AS serve as a genetically 
more heterogeneous subgroup of families with ASDs, and encourage the collection 
of such families in other studies as well.  
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5.2 3q finemap (II and unpublished data) 
In the Finnish ASD linkage scan strongest linkage was observed at 3q25-q27 
resulting in a maximum two-point LOD score of 4.31 at D3S3037 (Auranen et al. 
2002). Here, we wanted to finemap the region to further restrict the region of 
interest, and to test functionally interesting candidate genes for association with 
autism. 
5.2.1 Finemapping using microsatellites 
We selected microsatellite markers to finemap the distal part of the linkage peak 
identified in the Finnish ASD genome-wide linkage-scan (Auranen et al. 2002). In a 
previous study of three neuroligin family genes, we finemapped the proximal part of 
the linkage peak using six new microsatellites as well as 18 SNPs in and flanking 
the NLGN1 gene (Ylisaukko-oja et al. 2005). Here, further finemapping markers 
were selected from the Marshfield genetic map and UCSC genome browser. 
Intragenic markers, and markers located in the promoter region of genes were 
preferred. Two intergenic markers were also included for a more complete coverage 
of the region. In genes where no microsatellite markers were available, we used the 
RepeatMasker tool to identify intragenic repeats, and genotyped these in a set of 
controls to identify the polymorphic repeats. As a result, 11 new microsatellite 
markers were added in this stage. Together with the microsatellite markers from the 
original linkage-scan and the NLGN1 study, a total of 37 microsatellite markers 
were included in the region between D3S3053 located at 3q26.31 and D3S1311 
located at 3q29, covering a region of approximately 25 Mb. The average marker 
spacing was 1.16 cM. Markers were genotyped in 97 autism families. 
Two-point association analyses were performed using both LC1 corresponding to 
individuals with a diagnosis of autism, and LC2, corresponding to individuals with 
autism and siblings with AS (Figure 9). We used PSEUDOMARKER to test for 
association conditional on linkage (LD|linkage) using both recessive and dominant 
models. Best results were obtained using LC1 and the dominant model, although an 
almost similar level of significance was obtained using LC2. The results are in 
agreement with the genome-wide linkage scan, in that the most significant results 
were obtained using the dominant model. The most significant association was 
obtained with one of the fine-mapping markers, D3S1521 (p=0.01), located 
approximately 5.7 Mb distal of D3S3037, which resulted in the highest two-point 
LOD scores in stage II of the genome-wide linkage scan (Auranen et al. 2002). 
D3S3037 resulted in the second most significant p-value in PSEUDOMARKER 
analysis (p=0.02). 
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Figure 9. Results of the family-based association analysis of 3q26-q29 in 97 Finnish 
autism families. Results from PSEUDOMARKER LD|linkage test using a dominant model 
and TDT-analysis are reported. Markers marked with an asterisk were added in the 
finemapping stage. 
When we used the TDT-test, most significant association was obtained with 
D3S3730, located 1.5 cM distal of D3S3037. However, the results of both tests of 
association suggest that linkage in this region is not due to significant sharing of 
susceptibility alleles across families.  
5.2.2 Association analysis of 11 candidate genes at 3q26-q27 
We used the UCSC genome browser to investigate genes located at the previously 
identified autism linkage peak at 3q2 in silico and selected 11 functionally 
interesting candidate genes (Table 9). A total of 125 SNPs were polymorphic and 
were successfully genotyped in 97 families (naff=112), of which 32 families were 
included in the original genome-wide linkage scan. 
We performed family-based association analysis using PSEUDOMARKER and the 
LD|linkage test. The dominant model resulted overall in more significant results 
compared to the recessive model. Best results were obtained using markers in FXR1 
and HTR3C, but two SNPs in KCMNB2 and one SNP in HTR3E and GNB4 
respectively, also resulted in suggestive association with autism (p<0.05) (Table 10). 
The most significant association was observed with two nsSNPs in HTR3C, 
rs6766410 (N163K) and rs6807362 (G405A), both resulting in p=0.0012. The non-
synonymous variants are common SNPs with minor allele frequencies ranging from 
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0.42 to 0.49. In agreement with the high frequency of these substitutions, in silico 
analysis did not predict the amino acid changes to result in significant structural or 
functional changes according to PolyPhen. We used GIST software to test post hoc 
if the most significantly associated SNPs could partly account for the linkage in the 
families included in the original linkage scan. Both nsSNPs resulted in non-
significant P-values (p=0.15 for rs6766410 and p=0.30 for rs6807362 using a 
dominant model), suggesting these SNPs alone do not account for the linkage signal. 
Table 9. Candidate genes included in the association analysis of 3q26-q27. 
Gene 
symbol  
Gene name Length 
(kb) 
SNPs 
genotyped 
KCNMB2 calcium-activated potassium channel beta 2 308.0 40 
PIK3CA phosphoinositide-3-kinase catalytic alpha 86.2 15 
KCNMB3 calcium-activated potassium channel beta 3 24.2 8 
GNB4 guanine nucleotide-binding protein beta-4 55.5 17 
FXR1 
Fragile X mental retardation related, autosomal 
homolog 
64.5 6 
HTR3D 5' hydroxytryptamine receptor subunit 3D 7.8 
 
 
HTR3C 5' hydroxytryptamine receptor subunit 3C 7.6 13 
HTR3E 5' hydroxytryptamine receptor subunit 3E 6.8  
DVL3 dishevelled 3 18.0 5 
CHRD Chordin 9.8 12 
EPHB3 ephrin receptor B3 20.6 9 
 
Table 10. Results of the family-based association analysis for all markers resulting in 
p<0.05 in the candidate gene study of 3q26-q27 in 97 Finnish autism families. 
SNP Position Gene Description P 
rs9839672 180034391 KCNMB2 Intron 0.026 
rs4542999 180045647 KCNMB2 Downstream 0.007 
rs13087067 180604702 GNB4 Intron 0.008 
rs1607678 182067412 FXR1 Upstream 0.008 
rs7630922 182075054 FXR1 Upstream 0.006 
rs1805567 182121946 FXR1 Intron 0.004 
rs6766410 185257456 HTR3C NS coding (N163K) 0.001 
rs6807362 185260704 HTR3C NS coding (G405A) 0.001 
rs9872968 185285553 HTR3C Downstream 0.029 
rs7627615 185301110 HTR3E NS coding (A86T) 0.036 
NOTE: p-values from PSEUDOMARKER LD|linkage test, dominant model are presented. 
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We used Haploview to determine the haploblock structure within candidate genes, 
and HBAT to test for association within the blocks. The only haplotype resulting in 
suggestive association (p=0.05) was a three-SNP haplotype containing the two 
nsSNPs in HTR3C. The two-marker haplotype consisting only of the two non-
synonymous SNPs in this block also showed suggestive association with autism 
(p=0.020). The haplotype C-C, corresponding to amino acids N163 and A405 was 
overtransmitted to individuals with autism (p=0.006), whereas the haplotype A-G, 
corresponding to amino acids K163 and G405 showed suggestive undertransmission 
to individuals with autism (p=0.014). 
To test if the SNPs associated with ASDs in this study tagged other genetic variants, 
we we sequenced coding regions and splice sites of FXR1 and HTR3C in seven 
individuals with autism. Individuals were probands from families contributing to the 
original linkage finding in the Finnish genome-wide linkage scan for ASDs 
(Auranen et al. 2002). No novel variants were identified in the sequence analysis, 
suggesting either that the associated variants are the true susceptibility variants, or 
that other variants exist but are located in intronic regions which were not covered 
by the sequencing efforts. 
5.2.3 Association analysis of ZIC1 and ZIC4 
Dandy-Walker malformation (DWM, OMIM #220200) is a congenital malformation 
of the cerebellum. Affected individuals display motor deficits such as delayed motor 
development, hypotonia and ataxia, and around half have MR. Recurrence rates of 
1-2% suggest that DWM does not follow Mendelian inheritance, and is likely 
inherited in a polygenic fashion (Murray et al. 1985). Heterozygous deletion of two 
flanking Zinc finger in cerebellum genes, ZIC1 and ZIC4, has been identified in 
individuals with DWM (Grinberg et al. 2004). In the same study, Grinberg and 
colleagues showed that heterozygous loss of Zic1 and Zic4 in mice is sufficient to 
cause cerebellar malformations similar to those found in DWM. In some cases, 
autistic features have been reported as part of DWM (Aldinger 2008). Although 
there have been no reports on consistent structural brain-abnormalities in ASDs, one 
of the most common findings is a decrease in the number of Purkinje cells in the 
cerebellum (Williams et al. 1980; Palmen et al. 2004; Vargas et al. 2005; Whitney et 
al. 2008). In addition, some studies have reported cerebellar vermal hypoplasia in 
ASDs, which is also observed in DWM (Courchesne et al. 1988; Hashimoto et al. 
1995; Courchesne et al. 2001; Kaufmann et al. 2003). Encouraged by these findings 
and the location of ZIC1 and ZIC4 at 3q24, near the best linkage peak identified in 
the Finnish ASD linkage-scan, we wanted to investigate if these two genes were 
involved  in  the  etiology  of ASDs  in Finnish  families. Five  rare  variants  have 
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Table 11. Rare variants identified in ZIC4 in patients with DWM (Grinberg 2005). 
SNP DNA Protein dbSNP Patients Controls 
ZIC4_SNP1 321C>G Y16STOP - 1/176 0/192 
ZIC4_SNP2 568G>C G99R rs34676558 1/176 2/370 
ZIC4_SNP3 779C>G A169G - 1/176 2/384 
ZIC4_SNP4 1113G>T S280S - 1/176 0/192 
ZIC4_SNP5 1480delT 3'UTR - 1/176 0/384 
NOTE: DNA – The position of the SNP in the ZIC4 gene, numbering starts from 1 at the 
transcription start site. 
 
previously been identified in ZIC4 in patients with DWM (Grinberg 2005) (Table 
11), and we included these five variants together with tag-SNPs identified using the 
Tagger algorithm implemented in Haploview to capture the allelic variation in these 
two genes. Altogether 13 SNPs were genotyped in 97 ASD families (naff LC1=118, 
naff LC2=126). The TDT-test was performed using PLINK and a test of association 
conditional on linkage was performed using PSEUDOMARKER. 
No SNPs showed association with autism (p<0.05) in the TDT or 
PSEUDOMARKER analyses (Table 12, Table 13). Three of the rare variant SNPs 
were monomorphic: ZIC_SNP1, ZIC_SNP4 and ZIC_SNP5. For ZIC_SNP2, 
corresponding to rs34676558, a minor allele frequency of 2% was observed in the 
ASD families. None of the individuals were homozygous for the rare allele, but 5% 
(18/357) were heterozygotes. Of these, 7 were affected and 11 were unaffected 
parents. A minor allele frequency of 2% was observed for the ZIC4_SNP3. Again, 
no homozygotes for the rare allele were observed. A total of 15 individuals 
heterozygous for the minor allele were identified, 6 were affected with ASDs, 8 
were unaffected parents and 1 was an unaffected sib, whose affected sibling was 
homozygote for the common allele. 
To conclude, SNPs in ZIC1 and ZIC4 do not show association with ASDs in the 
Finnish families, and rare variants ZIC4_SNP2 and ZIC4_SNP3 appear to be rare 
polymorphisms observed in both affected and unaffected individuals. The role of 
variants ZIC4_SNP1, ZIC4_SNP4 and ZIC4_SNP5 need to be evaluated in larger 
patient cohorts with DWM to establish the role of these variants in the etiology of 
DWM. In addition, as DWM was originally reported to be caused by deletion of the 
ZIC1/ZIC4 locus, CNVs encompassing this locus should be evaluated in cohorts 
with ASDs.  
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Table 12. Results of the TDT analysis of SNPs at the ZIC1-ZIC4 locus in 97 Finnish 
autism families.  
SNP A1 A2 T U OR CHISQ P 
rs3796128 A G 13 6 2.17 2.58 0.11 
rs2279829 A G 43 42 1.02 0.01 0.91 
ZIC4_SNP1 NA NA NA NA NA NA NA 
rs17509456 C G 10 6 1.67 1.00 0.32 
rs34676558 C G 5 4 1.25 0.11 0.74 
ZIC4_SNP3 G C 6 3 2.00 1.00 0.32 
ZIC4_SNP4 NA NA NA NA NA NA NA 
rs3852000 C T 52 60 0.87 0.57 0.45 
rs10804719 C T 31 30 1.03 0.02 0.90 
ZIC4_SNP5 NA NA NA NA NA NA NA 
rs954735 C T 23 29 0.79 0.69 0.41 
rs7614043 T C 14 15 0.93 0.03 0.85 
rs1394042 G A 9 10 0.90 0.05 0.82 
NOTE: A1 – allele 1, A2 – allele 2, T – transmitted minor allele count, U – untransmitted 
minor allele count, OR – odds ratio, CHISQ – chi square test statistic, P – p-value. Markers 
with results indicated by NA were monomorphic. 
 
Table 13. Results of the PSEUDOMARKER analysis of SNPs at the ZIC1-ZIC4 locus in 
97 Finnish autism families.  
Marker LC1, dominant LC1, recessive LC2, dominant LC2, recessive 
rs3796128 0.51 0.26 0.19 0.16 
rs2279829 0.84 0.54 0.96 0.73 
ZIC4_SNP1 NA NA NA NA 
rs17509456 0.24 0.03 0.30 0.05 
rs34676558 0.52 0.96 0.67 0.61 
ZIC4_SNP3 0.81 0.78 0.74 0.71 
ZIC4_SNP4 NA NA NA NA 
rs3852000 0.89 0.40 0.94 0.62 
rs10804719 0.96 0.60 0.77 0.94 
ZIC4_SNP5 NA NA NA NA 
rs954735 0.26 0.36 0.58 0.82 
rs7614043 0.45 0.41 1.00 0.77 
rs1394042 0.71 0.40 1.00 1.00 
NOTE: LC1 – narrow diagnostic classification corresponding to autism only, LC2 – broad 
diagnostic classification corresponding to autism and AS. All results are p-values from 
LD|linkage statistic. Markers with results indicated by NA were monomorphic. 
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5.2.4 Sequence analysis of PEX5L 
Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are homo- or 
heterotetramers consisting of four subunits (HCN1-HCN4). These voltage-gated 
channels mediate the hyperpolarization-activated current (Ih), and characterize the 
integration of incoming synaptic input as well as determine the pattern of action 
potential output (reviewed in Wahl-Schott and Biel 2009). The differential 
expression patterns of the subunits with different biophysical properties contribute to 
differential neuronal excitability in different cell types and brain regions (Notomi 
and Shigemoto 2004). HCN family members interact with different scaffolding 
proteins, among others the tetratricopeptide repeat (TPR)-containing Rab8b-
interacting protein (TRIP8b). TRIP8b results in altered trafficking and reduction in 
cell surface expression of HCN channels (Santoro et al. 2004). It has also been 
recently shown that alternatively spliced isoforms of TRIP8b differentially control 
HCN channel localization function (Lewis et al. 2009). The TRIP8b protein is 
encoded by the peroxisomal biogenesis factor 5-like (PEX5L) gene at 3q26.33, 
located only 2 Mb distal of the linkage peak identified in the Finnish ASD genome-
wide linkage scan (Auranen et al. 2002). As TRIP8b has been shown to regulate 
normal neural function and excitability associated with neurological disease we 
wanted to investigate whether PEX5L contributed to etiology of ASDs in Finnish 
families. 
We sequenced a total of 17 coding exons, of which the first two were alternative 
first exons, present in different splice variants in 83 probands with autism and 11 
controls. The success rate was >97%, ranging from 90.5%-100% per exon. A total 
of 12 variants were identified, of which 3 were not present in dbSNP (Table 14). All 
identified variants were located in introns. 
We identified three novel SNPs, of which one was also identified in controls. Two 
of the variants that were not present in dbSNP were identified in cases but not in 
controls. One variant was identified 39 bp downstream of the end of exon 1a, and 
was found in one case as a heterozygous SNP, and in another case as a homozygous 
C>A SNP. The other SNP identified only in cases was present in three cases as a 
heterozygous SNP. It was located 36 bp upstream of the start of exon 7. As the 
number of controls in this study was very small (n=11) these two SNPs should be 
evaluated in a larger control cohort for accurate estimates of allele frequencies. 
Although we did not identify any SNPs which are likely to modify the protein 
structure, PEX5L remains a positional and functionally interesting candidate gene 
for ASDs. Future work should include the evaluation of different isoforms of PEX5L 
mRNA in autism cases and healthy controls in different brain regions. In addition, 
the locus should be tested for CNVs compassing PEX5L.  
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Table 14. Variants identified in the sequencing of coding exons of PEX5L in 83 probands 
from the Finnish autism families. 
Exon Position* SNP Case Contr Sequence dbSNP 
ex1a+39 190 C>A 1 0 ATTCTTGGGGACTAATTTAAG NA 
ex1a+39 190 C>R 1 0 ATTCTTGGGGRCTAATTTAAG NA 
ex1c 63 424 C>T 3 0 CTGTGGTTCTTTGGTCAGCAA rs12054457 
ex1c 63 424 C>Y 29 2 CTGTGGTTCTYTGGTCAGCAA rs12054457 
ex2+17 65 153 G>A 3 0 GAATACTTACATACATTTTCT rs3774257 
ex2+17 65 153 G>R 29 2 GAATACTTACRTACATTTTCT rs3774257 
ex5-75 148 871 G>T 3 2 TCATTTTGTTTCAAGGCTGCA rs41265425 
ex5-75 148 871 G>K 35 6 TCATTTTGTTKCAAGGCTGCA rs41265425 
ex6-68 156 539 C>T 4 0 CTGTACCCAATTGAAACCTAT rs13067789 
ex6-68 156 539 C>Y 15 1 CTGTACCCAAYTGAAACCTAT rs13067789 
ex7-87 161 166 G>R 33 5 TGCACCACACRCTCCACCCTC rs2302743 
ex7-87 161 166 G>A 22 2 TGCACCACACACTCCACCCTC rs2302743 
ex7-36 161 217 A>R 3 0 CCGCCCTGCCRCCACCTGCCT NA 
ex8-29 162 278 G>A 27 2 TCTAGTGTACATTTAATTTCC rs2339914 
ex8-29 162 278 G>R 37 6 TCTAGTGTACRTTTAATTTCC rs2339914 
ex8+62 162 465 C>T 66 9 AGCATAAATGTTTTATTTTCA rs1609981 
ex8+62 162 465 C>Y 16 2 AGCATAAATGYTTTATTTTCA rs1609981 
ex10-64 216 691 A>R 5 1 TAGGGGGGGARGAAAAACACA rs1001668 
ex11-34 220 693 A>R 6 1 AGAGAAATCARTGGCTCATGC rs17690759 
ex14+34 228 494 G>R 5 1 AAACCACAGCRTTCTCTGTAA NA 
NOTE: Position is given as bp from the star of PEX5L exon 1 (NM_016559.1), 
corresponding to position chr3:181,237,211 according to NCBI build 36.1. Case and Contr 
columns indicate the number of cases or controls carrying the variant. 
5.2.5 Discussion 
In this study, we wanted to finemap the linkage peak at 3q2 identified in the Finnish 
ASD scan. We used microsatellites in an attempt to limit the region of interest, and 
after that, investigated a number of functionally interesting candidate genes to 
identify possible susceptibility genes in the region. For candidate gene analysis, we 
employed both association- and sequence analysis. Together with two previously 
published candidate gene studies, one of NLGN1 located 8 Mb proximal of the 
linkage peak at 3q26.31 (Ylisaukko-oja et al. 2005), and the other of ATP13A4 
located 16 Mb distal of the linkage peak at 3q29, (Kwasnicka-Crawford et al. 2005), 
we have now evaluated 15 genes at 3q2 for association with ASDs.  
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Finemapping using microsatellites did not significantly help limit the region of 
interest, although suggestive evidence of allele sharing between families was 
obtained using flanking markers D3S1521 and D3S3037. Of the candidate genes 
tested here, this region contains KCMNB2, PIK3CA, KCMNB3, GNB4, PEX5L and 
FXR1. 
The linkage finding to 3q2 originally reported in Finnish families has been 
replicated in other populations, making it a highly interesting candidate region. In a 
genome-wide linkage scan of one large ASD family, the most significant linkage 
signal was observed at rs1402229 (p=0.0003), only 2.6 Mb from the best marker 
(D3S3037) in the Finnish genome-wide scan (Coon et al. 2005). A sequence 
analysis of FXR1, which is located in the linkage region, did not reveal any variants 
likely to contribute to ASDs, in line with the results observed in our study. However, 
we observed suggestive association of three SNPs in the promoter and introns of 
FXR1 (p=0.04-0.08), suggesting that possible intronic risk-variants could exist in 
FXR1. 
Further support for linkage between autism and 3q was obtained in a study of 
language QTLs in autism. The strongest evidence for “age at first word” (p<0.001) 
was at 147cM, around 40cM from the best findings in the Finnish genome-wide scan 
(Alarcon et al. 2005). In the same study suggestive evidence for linkage of “age of 
first phrase” (p=0.04) was obtained at 180 cM, only 10 cM proximal to our peak at 
190cM. 
The most promising association results in this study were obtained with two 
common, coding SNPs in HTR3C. This gene is located only 6 Mb distal of D3S3037 
and is the most interesting region identified in the microsatellite finemapping. The 
two SNPs, rs6766410 (N163K) and rs6807362 (G405A), both resulted in p=0.0012 
in family-based association analysis. The SNPs are in high LD (D‟=0.96 in the 
HapMap CEU data) and are located within the same haplotype block. In addition, 
the haplotype consisting of these two SNPs resulted in suggestive evidence for 
association (p=0.02). 
Most serotonin receptors are G-protein-coupled binding proteins and the 5-HT3 
receptor is the only ligand gated ion channel in the family. Subunits HTR3A and 
HTR3B of this receptor are well characterized (Miyake et al. 1995; Davies et al. 
1999) but HTR3C, HTR3D and HTR3E, forming a cluster on 3q27, have only been 
recently discovered and are incompletely characterized (Karnovsky et al. 2003; 
Niesler et al. 2003; Niesler et al. 2008). Subunits C-E display identities of roughly 
70% between each other and a 26-29% identity to HTR3A and HTR3B at the protein 
level. Expression of HTR3E and HTR3D is limited to some internal organs, whereas 
HTR3C displays a wider expression pattern that includes the brain, and therefore, 
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resembles HTR3A and HTR3B more closely. Exon structure of HTR3C is identical to 
HTR3A and HTR3B, while the two other subunits display different exon structures 
(Niesler et al. 2003). It has recently been shown that  that although HTR3C, HTR3D 
or HTR3E cannot form homomeric receptors, these subunits are able to form 
heteromeric receptors with HTR3A and modulate receptor function and properties in 
a similar manner to HTR3B (Davies et al. 1999; Niesler et al. 2007). HTR3C, 
HTR3D and HTR3E are absent in rodents making it necessary to use human cells to 
investigate the function of these subunits (Karnovsky et al. 2003). It has recently 
been shown that HTR3C, HTR3D and HTR3E cannot alone form functional 
receptors. They are, however, able to form heteromeric receptors together with 
HTR3A, and modulate functional properties of these receptors compared with 
homomeric HTR3A receptors (Niesler et al. 2007). 
Elevated whole blood serotonin in individuals with autism and their close relatives is 
the most consistent biological finding in autism (see section 2.3.11 for a summary of 
studies of the serotonergic system in ASDs). Although the HTR3 receptors cannot 
be directly linked to levels of blood serotonin, variants in HTR3A have interestingly 
been shown to modulate neural activation of the amygdala during a face recognition 
task (Iidaka et al. 2005), a process which has repeatedly been implicated as 
abnormal in individuals with ASDs (Klin et al. 1999; Schultz 2005; Kleinhans et al. 
2008)It should be noted, that the results of the linkage analysis do not necessarily 
support the hypothesis of common variants in this region contributing to ASD 
susceptibility. Linkage studies only investigate the co-segregation of a haplotype 
within families, but do not require the haplotype be shared between families as the 
total LOD-score is obtained by summing up the LOD scores in each family. 
Although a haplotype shared between two families at this locus was reported in the 
original linkage study (Auranen et al. 2002), genotyping a dense map of 
microsatellites revealed that the haplotypes differed between the two families (data 
not shown). Therefore it is possible, that the linkage-peak is a not a result of a shared 
susceptibility variant, but rather of multiple rare risk variants not shared between 
families in this region. These kinds of susceptibility factors would not be detectable 
in an association study. Rare variants could all be located in the same gene. It is 
even possible, though less probable, that rare risk factors reside in several genes in 
the region. Most risk factors identified in ASDs to date are rare variants present in 
only one or a few families (Jamain et al. 2003; Feng et al. 2006; Durand et al. 2007; 
Marshall et al. 2008). 
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5.3 GLO1 association study (III) 
In a previous study, a proteomics approach was used to identify protein 
abnormalities in glyoxalase I (GLO1) in brains of individuals with autism (Junaid et 
al. 2004). GLO1, residing at 6p21.2, is part of the glyoxalase system involved in the 
detoxification of methylglyoxal, a cytotoxic byproduct of glycolysis (Thornalley 
2003). A nsSNP (rs2736654, Ala111Glu) resulting in a protein product with lower 
enzymatic activity was identified in the GLOI gene, which was also reported to be 
associated with autism (p=0.0079). In addition to autism, GLO1 has been linked to 
anxiety-like behavior (Hovatta et al. 2005; Kromer et al. 2005), diabetes (Thornalley 
2003), Alzheimer‟s disease (Chen et al. 2004), and the regulation of theta 
oscillations during sleep (Tafti et al. 2003). Oxidative stress has also been implicated 
in neuropsychiatric disorders such as schizophrenia and depression (Bilici et al. 
2001; Yao et al. 2001). The purpose of this study was to carry out a genetic analysis 
to see whether allelic variants of the GLO1 gene predispose to autism or AS in the 
Finnish population. 
We used the PSEUDOMARKER joint test of linkage and association in addition to 
linkage of six tag SNPs in GLO1, which were chosen to capture the majority of 
genetic variation in this gene. AS and autism families were analyzed separately and 
together. We did not observe statistically significant (p<0.05) linkage or association 
for any SNP in GLO1 in the family based analyses (Table 15 and Table 1 in 
publication III). For a more detailed analysis of the functional SNP, one affected 
proband was randomly selected from each family. The frequency of the A allele, 
which was reported to be the risk allele in the original study (Junaid et al. 2004), was 
0.62 for the combined autism and AS cases as well as for controls (Table 16) and the 
frequency of the AA genotype was 0.37 in both cases and controls. 
The nsSNP is located in a block of high LD incorporating three other SNPs included 
in this study. To test if any specific haplotype of this block would confer 
susceptibility to autism, we tested whether haplotypes of these SNPs were associated 
with ASDs. However, no statistically significant association (p<0.05) was observed 
for any haplotype in any set of families using HBAT. The most common haplotype 
for these markers is A-G-G-G, with a frequency of approximately 0.5 in autism and 
AS families, as well as in controls. 
The allele frequencies of the GLO1 nsSNP have been studied in many populations, 
with only small variability across populations observed (Table 16). The frequency 
found in the controls of the Junaid et al. (2004) study is lower than in any other 
population. In addition, controls in that study were related: 33 of the controls were 
from only 6 extended families suggesting that the association arose from a low A-
allele frequency in controls and not an increased frequency in cases. This 
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observation is in agreement with frequencies obtained in population controls and 
negative candidate studies of GLO1. Interestingly, in another study of GLO1 in 
ASDs, no association was observed between markers in GLO1 and ASD, and in 
addition, a protective effect of the A allele in siblings of probands was observed 
(Sacco et al. 2007). We were not able to test if a similar effect was seen in our 
sample, because with only 25 families having genotypes for unaffected siblings, 
power was too low to detect possible overtransmission. 
The results of this study suggest that GLO1 does not represent a susceptibility gene 
for ASDs in the Finnish autism families. We also provide evidence that the study by 
Junaid et al. (2004) overestimated the association between GLO1 and ASDs due to a 
small number of controls that resulted in an underestimation of the A-allele 
frequency. 
Table 15. Results of the family based association analysis of SNPs in GLO1 in 97 Finnish 
autism families, 29 Finnish AS families and the combined analysis of these two family 
materials. 
  AS, LC1   Autism, LC1   Combined 
SNP ID 
LD | 
linkage 
LD + 
Linkage   
LD | 
linkage 
LD + 
Linkage   
LD | 
linkage 
LD + 
Linkage 
rs7604 0.39 0.36  0.22 0.34  0.62 0.71 
rs2736654 0.99 0.20  0.13 0.23  0.70 0.08 
rs9394523 0.4 0.26  0.53 0.68  0.77 0.75 
rs6932648 0.36 0.24  0.62 0.75  0.67 0.70 
rs10484854 0.98 0.11  0.66 0.78  0.68 0.19 
rs1937780 1.00 0.34   0.81 0.26   0.47 0.25 
NOTE: All results are p-values from PSEUDOMARKER analysis. 
 
Table 16. A allele frequencies of the nsSNP rs2736654 in different populations. 
 ASD case  Control  
Population n freq  n freq Reference 
Finland 120 0.62  740 0.62 This study 
HapMap CEU NA NA  60 0.53 Frazer et al. (2007) 
Italy 371 0.58  171 0.54 Sacco et al. (2007) 
US 71 0.61  49 0.44 Junaid et al. (2004) 
African American NA NA  24 0.65 dbSNP (Coriell Cell repository) 
NOTE: ASD – autism spectrum disorder, NA – not available. 
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5.4 Population stratification study (IV) 
In addition to enabling the identification of novel genetic determinants to complex 
disorders and traits, the genome-wide, high-density SNP data generated for GWASs 
also makes it possible to assess population structure in more detail than ever before. 
Most studies of Finnish population genetics have been performed using Y 
chromosomal or mitochondrial data that give only a limited picture of the genomic 
landscape. Here we wanted to explore, in high detail, the Finnish genome using an 
extensive dataset for the first time. Our aim was to characterize whether the Finnish 
population, which has traditionally been thought to have decreased genetic 
heterogeneity, would display stratification similar to other populations, and 
consequently, how this would affect the design of GWASs in the Finnish population. 
We used all available Finnish GWAS data from both large population cohorts and 
smaller disease-specific cohorts. According to parental birthplace information 
samples representing different geographic regions were ascertained. The groups 
were chosen to represent geographical areas which have been inhabited at different 
stages during the population history (Table 17, Figure 11a). We had SNP genotype 
data generated using different Illumina 300K BeadChips, and after rigorous quality 
control, a set of approximately 230K SNPs of high quality were used in this study. 
Table 17. Summary of populations used in the population stratification study (IV). 
Group N % females Chip type 
Success 
rate 
N SNPs with 
HWE p<0.001 
SWE 302 100 318K duo 0.998 0 
HEL 162 56 370K 0.999 166 
ESS 73 41 318K duo, 370K 0.999 126 
ESW1 179 53 370K, 318K duo 0.998 152 
ESW2 145 65 370K, 318K duo 0.998 163 
ESN 76 46 370K 0.998 115 
LSW 48 50 317K, 318K duo, 370K 0.997 115 
LSC 46 52 317K, 370K 0.998 69 
LSN 107 48 370K 0.998 119 
ISS 96 46 318K duo, 370K 0.998 135 
ISC 78 45 318K duo, 370K 0.998 138 
ISN 53 57 370K 0.998 94 
NOTE: SWE – Sweden, HEL – Helsinki, ESS – Early Settlement South, ESW1 – Early 
Settlement West 1, ESW2 – Early Settlement West 2, ESN – Early Settlement North, LSW – 
Late Settlement West, LSC – Late Settlement Central, LSN – Late Settlement North, ISS – 
Isolate South, ISC – Isolate Central, ISN – Isolate North, 317K – Illumina HumanHap 300, 
318K duo – Illumina HumanHap 300 duo, 370K – Illumina HumanCNV370-duo, HWE – 
Hardy Weinberg Equilibrium. 
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Figure 10. The first two dimensions of variation in Finns, Swedes and the HapMap 
populations from genome-wide SNP data. CEU – CEPH individuals of European Ancestry, 
CHB – Han Chinese, FIN – All Finnish individuals included in this study, JPT – Japanese, 
SWE – Sweden, YRI – Yoruba. 
To obtain a measure of distance between samples, we calculated IBS sharing 
between all pairs of individuals and used MDS to extract the primary dimensions of 
the IBS sharing matrix. Finns cluster close to, but not fully overlapping with, the 
European HapMap population and Swedes, Finns also extend toward the HapMap 
Asian populations (HCB, JPT) possibly reflecting the eastern immigration during 
the original settling of the country (Figure 10). Finns have clearly been shown to 
cluster apart from other European populations (Lao et al. 2008). 
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When the HapMap African and Asian samples were removed, the two primary 
dimensions of the MDS correspond closely to east-west and north-south directions. 
The distribution of individuals closely resembles the geographic distribution 
according to grandparents‟ birthplaces (Figure 11). Particularly fine scale separation 
can be achieved in the youngest subisolates in northeastern Finland (Figure 12). This 
is in agreement with studies where similar approaches have been used to delineate 
the relationships among other populations (Heath et al. 2008; Price et al. 2008; 
Salmela et al. 2008), and in a limited region in western Finland (Saxena et al. 2007). 
However, results of a recent study proposed that gradients correlating with 
continuous geographical variation might be artifacts introduced by principal 
component analysis and should be interpreted with caution (Novembre and Stephens 
2008). 
We used the population differentiation test implemented in Eigensoft (Table 18) and 
estimated IBS sharing within and among groups to show that the subgroups differ 
significantly from each other. The variation among groups is mediated by small 
differences in allele frequencies across the entire genome, and not a small number of 
distinct loci (Figure 13). We estimated the fixation index (Fst), and in agreement 
with the MDS-analysis, the largest Fst was observed between the most eastern and 
western subgroups (ISC vs. ESN and ISC vs. LSW both resulting in Fst=0.006, 
Table 18). The Fst-value is significantly larger than those obtained in a study of the 
Icelandic population, which is also an isolate originating from a small number of 
founders, (Helgason et al. 2005). The Fst-value observed between eastern and 
western Finland is of similar magnitude to those observed between South-Western 
and North-Eastern Europeans (Price et al. 2008) 
To illustrate the effect the observed population substructure would have on a case-
control GWAS where cases were from an isolate and controls from the general 
Finnish population, we estimated the genomic inflation factor (λ) for each subisolate 
versus the Helsinki-population (Figure 14). All subisolates, except for the southern 
coastal “early settlement south” subset resulted in significant inflation (λ>1.05). As 
certain complex disorders, such as schizophrenia and MS (Hovatta et al. 1997; 
Sumelahti et al. 2001), are overrepresented in certain subisolates compared with the 
general Finnish population, the proper selection of controls based on careful 
genealogical data could be imperative in preventing spurious false positive 
association signals. 
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Figure 11. Finnish subpopulations. A) Geographic distribution of subisolates representing 
different stages in the inhabitation of the country. B) The first two dimensions of variation in 
the Finnish subgroups compared to Swedes (SWE, yellow) and HapMap CEU (grey). Group 
abbreviations as in Table 17. 
Figure 12. Fine-scale resolution of IBS-similarities in the youngest subisolates. 
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Table 18. Fst values and p-values for the test of population differentiation implemented in 
Eigensoft for the Finnish subpopopulations used in this study. Fst values are indicated 
above the diagnonal, and approximate p-values from the population differentiation test, a 
summary of Anova statistics across the 10 first eigenvectors, are displayed below the 
diagnonal. Group abbreviations as in Table 17. 
  HEL ESS ESW1 ESW2 ESN LSW LSN LSC ISS ISC ISN 
HEL   0.000 0.001 0.001 0.002 0.001 0.002 0.001 0.002 0.004 0.003 
ESS 0.031   0.001 0.001 0.003 0.002 0.002 0.001 0.003 0.004 0.004 
ESW1 10-142 10-103   0.001 0.003 0.002 0.003 0.001 0.003 0.004 0.004 
ESW2 10-93 10-93 10-128   0.003 0.002 0.002 0.001 0.002 0.003 0.003 
ESN 10-197 10-133 10-273 10-213   0.003 0.002 0.004 0.005 0.006 0.005 
LSW 10-61 10-45 10-116 10-151 10-121   0.004 0.003 0.005 0.006 0.005 
LSN 10-123 10-83 10-151 10-89 10-102 10-101   0.003 0.004 0.004 0.002 
LSC 10-27 10-41 10-103 10-57 10-126 10-86 10-57   0.002 0.003 0.004 
ISS 10-168 10-149 10-257 10-133 10-207 10-133 10-131 10-76   0.003 0.004 
ISC 10-217 10-154 10-283 10-227 10-161 10-151 10-147 10-136 10-173   0.004 
ISN 10-195 10-132 10-225 10-159 10-160 10-131 10-60 10-104 10-165 10-146   
 
 
Figure 13. SNP weights for the first three eigenvectors. All Finnish subpopulations were 
included in the analysis. 
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Figure 14. Quantile-quantile plot of the association analyses of each subisolate versus the 
Helsinki (HEL) group. The genomic inflation factor (λ) for each subgroup is indicated in the 
legend. Group abbreviations as in Table 17. 
We used two approaches to characterize LD structure. Chromosome 22 was taken as 
an example as it has been used in a previous study of world-wide population isolates 
(Service et al. 2006). We estimated the pairwise LD for all pairs of SNPs in 70 SNP 
windows using the square correlation coefficient (r2). The lowest number of SNP 
pairs in high LD was observed in the oldest populations, gradually increasing toward 
the younger populations (Figure 15a). To quantitatively describe the effects of 
recombination on LD over the whole chromosome, we constructed LD maps and 
again observed the longest maps, corresponding to least LD in the oldest populations 
with map lengths decreasing gradually towards the younger northeastern subisolates 
(Figure 15b). In addition, we observed that map lengths obtained in this study 
closely correlate with map lengths in another study where corresponding population 
groups were included (Service et al. 2006). We propose that LD map lengths can be 
considered characteristic for a given population. 
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Figure 15. Properties of linkage disequilibrium across chromosome 22. A) Proportion of 
SNP pairs in different LD bins for the different subgroups. B) A linkage disequilibrium map 
across chromosome 22. The genetic map is indicated by open circles, and is scaled according 
to the y-axis on the right-hand side of the figure. Group abbreviations as in Table 17. 
 
We also determined the lengths and numbers of extended regions of homozygosity 
(ROHs) exceeding 1 Mb and 100 SNPs with a SNP density of at least 1 SNP per 50 
kb. Again, both the length and number of ROHs were lowest in the old 
subpopulations and highest in the younger populations (Figure 4, publication IV). 
This is probably due to autozygosity, reflecting the low number of founders and 
subtle increases in the relatedness of individuals from the younger subisolates. The 
effect was even more pronounced for ROHs exceeding 5Mb, observed in 
approximately 50% of individuals in the early settlement groups, 50-70% of 
individuals in the late settlement groups and up to 80-90% of individuals in ISS, ISC 
and ISN. Similar ROHs were observed in only 20% of Swedes, and 9.5% of 
individuals from the US (Simon-Sanchez et al. 2007). In the HapMap samples, 20% 
had ROHs exceeding 3Mb (Frazer et al. 2007). Although the lengths of homozygous 
segments are higher in Finns than in more outbred populations, they are significantly 
lower than in populations where consanguineous marriages are common. Individuals 
with Pakistani and Arab origins whose parents were first cousins have a mean 
genome homozygosity of 11% compared to an average of 1-2% in Finland (Woods 
et al. 2006). Inbreeding coefficients (F) were similar for all Finnish subgroups: only 
1.65% of individuals corresponding to first cousin marriage (F=0.025–0.07), 
whereas 8.7% of individuals had F corresponding to second-cousin marriage 
(F=0.01–0.025), suggesting that the number and length of ROHs is a more sensitive 
measure of relatedness compared to F. 
5 Results and Discussion 
THL Research 21|2009  100 Genetic Heterogeneity in Autism Spectrum 
 Disorders in a Population Isolate 
 
The results of this study show that on a genome-wide level, there are significant 
differences in the genomic landscapes of individuals originating from different parts 
of the country, as seen in other population isolates (Helgason et al. 2005; 
Yamaguchi-Kabata et al. 2008). Although this study was not designed to show that 
the genomic properties observed here are specifically the results of founder 
bottlenecks and drift, the results from several complementary analytic approaches 
agree remarkably well with the carefully documented population history of the 
country, which has been characterized by multiple founding bottlenecks and severe 
isolation. The groups in this study were selected using information on population 
history as well as linguistics and were shown to represent true genetically distinctive 
subgroups using analysis of eigenvectors and IBS similarities.  
Although the population structure reported here would have significant effects on 
GWASs, proper correction of the substructure using quantitative measures such as 
the primary MDS dimensions has proven to be an efficient approach to tackle the 
genetic variability within Finland. In a study of metabolic traits in the NFBC66 
cohort, from which a subset of samples in this study are drawn, the first two MDS 
dimensions were used to correct for population substructure (Sabatti et al. 2008). 
The Sabatti et al. (2008) study replicated most previously reported associations for 
the traits tested and identified several interesting novel risk variants for high- and 
low density lipoprotein and insulin levels. However, p-values obtained in an 
alternative analysis not corrected for population substructure resulted in p-values of 
similar magnitude. It should be noted that we only included individuals with both 
parents born in the defined geographic regions and these individuals represent 
“extremes” of the genetic variability within Finland. Most individuals have parents 
born in different parts of the country, and thereby, display significantly less 
population stratification. Similar effects were reported by the WTCCC, where north-
south gradients were observed for a subset of SNPs, but the authors concluded that 
the effect of population structure is negligible and did not correct for it in association 
analysis (WTCCC 2007).  
Detailed knowledge of the genomic variability within Finland has already proven 
useful in identifying genetic determinants for complex disorders, as exemplified by 
the study of metabolic traits mentioned above. Another example is a GWASs aiming 
to identify susceptibility variants for MS. In these studies, cases from an internal 
isolate revealed two functionally relevant risk factors including complement 
component 7 (Kallio et al. 2009). 
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5.5 GWA and expression study (V) 
Genealogical data has revealed that a subset of the Finnish ASD families, currently 
living across Finland, can be linked to form two extended pedigrees originating from 
two municipalities in CF in the 18th century (Figure 4). We wanted to use these 
unique extended families to identify possible enriched rare genetic susceptibility 
factors shared IBD using dense, genome-wide SNP data. In addition, we included 
individuals diagnosed with autism, and at least 2 grandparents born in Central 
Finland that were not genealogically linked to the extended pedigrees. In study IV, 
we showed that individuals within subisolates in Finland are genetically 
homogenous, and that systematic genetic differences can be observed among 
subisolates.,Therefore we hypothesized that genetic risk factors in the CF autism 
families not linked to the pedigrees could be shared with the families in the extended 
pedigrees. The initial phase of the GWAS was followed up by replication in two 
datasets. Because genes for ASDs have eluded identification using traditional 
methods, we took a systems biology approach in order to combine the power of 
genome-wide genotype data with expression profiling so that biological pathways 
involved in the etiology of ASDs could be identified (Figure 16). 
 
 
Figure 16. Outline for study V. 
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5.5.1 Quality control 
We used Illumina HumanHap 300 and HumanHap 300 Duo beadchips to genotype 
approximately 317 000 SNPs in 51 cases and 181 controls (CF-GWAS). Of the 
cases, 19 were part of Autism-pedigree 1 and 8 were part of Autism pedigree 2. We 
excluded SNPs and individuals with a success rate below 90%. PLINK was used to 
estimate IBD sharing within the genealogically connected pedigrees and for the rest 
of families which were not genealogically linked but had at least two grandparents 
born in Central Finland (Figure 17). Higher IBD sharing was observed within 
pedigree 2 compared to pedigree 1 (mean IBD sharing 0.0057 and 0.0036, 
respectively), in agreement with the more distant genealogical links in pedigree 1. 
Surprisingly, IBD sharing was higher between the non-genealogically linked 
families than within the families in pedigree 1 (mean IBD sharing 0.0046), and as 
expected IBD sharing was lowest in controls (mean IBD sharing 0.0024). 
5.5.2 Homozygosity mapping 
First we analyzed the extended pedigrees for shared ROHs to monitor possible 
recessive susceptibility variants. ROHs exceeding 100kb were identified and 
assessed for overlap between individuals. A minimum overlap cutoff of 50 kb was 
used. Only ROHs shared among more than half of the affected individuals in each 
pedigree(n=5 and n=10 for pedigrees 1 and 2 respectively) were used providing that 
the individuals were homozygous for the same haplotype. We used liberal cutoffs 
for both segment length and frequency to avoid missing regions of interest. To rule 
 
Figure 17. IBD sharing in samples included in the CF-GWAS. The inset shows a more 
detailed view of the distribution of individuals sharing up to 2.5% of their genome IBD. 
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out false positive findings due to the liberal cut-off criteria, we assessed the regions 
of interest in the 180 regionally matched controls as well. 
In the smaller pedigree, we did not identify any ROHs where 6 or more individuals 
would be homozygous for the same haplotype at any locus. We identified 5 shared 
ROHs exceeding 50kb where 5 individuals were homozygous for the same 
haplotype. In the larger pedigree we identified three regions were 11-18 individuals 
were homozygous for the same haplotype (Table 19). However, the ROHs identified 
in cases in both pedigrees were all common in controls as well (frequency 0.3-0.81), 
suggesting that none of the regions contain high-penetrance risk variants. 
Homozygosity analysis did not implicate any loci harboring enriched, recessive 
haplotypes conferring risk for ASDs in either extended pedigree. 
5.5.3 Shared segment analysis 
To identify shared, enriched risk variants inherited in a dominant-like fashion, we 
used the shared segment analysis implemented in PLINK (Purcell et al. 2007). The 
underlying hidden IBD state is estimated by using the observed IBS sharing across 
chromosomes by a Hidden Markov Model. This differs from traditional haplotype 
estimation  of sharing  for rare and long regions,  even  for pairs of distantly related 
 
Table 19. Regions of homozygosity identified in the extended pedigrees. 
Sample Ncase Freqcase Nctrl Freqctrl Chr From-kb To-kb Size NSNP 
Ped2 10(18)* 0.53(0.95) 137 0.76 4 33720 34094 373 23 
Ped1 5 0.63 74 0.41 6 28629 28738 109 6 
Ped1 5 0.63 91 0.50 7 117503 117943 440 48 
Ped1 5 0.63 57 0.32 8 51513 52109 596 38 
Ped2 11 0.58 53 0.30 11 48105 48573 467 29 
Ped1 5 0.63 88 0.49 15 69889 70501 611 47 
Ped2 11 0.58 88 0.49 15 69899 70794 894 57 
Ped1 5(7)* 0.63(0.88) 146 0.81 18 64802 64929 126 37 
NOTE: Ped1 – Autism pedigree 1, Ped2 – Autism pedigree 2, Ncase – number of cases 
homozygous in the region, Freqcase – Frequency of homozygous region in cases, Nctrl – 
number of controls homozygous in the region, Freqctrl – Frequency of homozygous region in 
controls, Chr – Chromosome, From-kb – Start (in kb from ptel) of overlapping homozygous 
region, To-kb – End (in kb from ptel) of shared homozygous region, Size – Size of shared 
homozygous region in kb, NSNP – Number of SNPs in the shared homozygous region. *The 
number of individuals in parenthesis include individuals with an homozygous segment 
<100kb in the region. 
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individuals. For the shared segment analysis, only SNPs in linkage equilibrium are 
used, as regions with high LD result in false positive calls of IBD sharing. 
For shared segment analysis, all SNPs with a genotyping rate <0.99 and a minor 
allele frequency (MAF)<0.05 were filtered out. SNPs were pruned by estimating LD 
in 100 SNP windows, excluding all SNPs with r2>0.2. This resulted in a dataset 
consisting of roughly 56 000 SNPs. Segments larger than 1000 kb were included. 
We required IBD sharing between more than half of the individuals in each 
pedigree, and that the same alleles would be shared between all pairs in the region, 
as this would suggest inheritance IBD from a common ancestor in the risk region. 
No regions of interest were identified using this approach. Regions where more than 
three pairs in Pedigree 1 and two pairs in Pedigree 2 shared chromosomal segments 
IBD are indicated in Table 20. However, in none of these regions did more than 
three individuals share the same allelic combination IBD. 
To ensure we did not miss any shared regions we also performed the same test for 
shorter regions, requiring that the shared segments only span 100kb and 20 SNPs. 
This did not result in any further regions of interest. In summary, this method did 
not identify any shared segments where genetic risk factors enriched in these 
pedigrees would reside. 
5.5.4 Association analysis 
We did not identify any enriched rare risk variants in homozygosity or shared 
segment analysis. Therefore we wanted to test for the presence of common 
susceptibility variants in the entire CF dataset. We used all 54 affected individuals 
and 181 controls in order to identify possible common variants enriched in this 
subisolate. We identified a slight excess of significant p-values suggesting that 
common shared susceptibility variants do exist, but unsurprisingly, our limited 
dataset, designed to identify rare variants did not have sufficient power to detect 
these shared common variants at a genome-wide significant level (Figure 1, 
publication V). A total of 7 p-values less than 0.00001 were observed, compared to 
the 3 expected, and 37 p-values below 0.0001 were observed compared to 31 
expected. There was not significant inflation in the overall distribution of p-values  
(λ = 1.05). One marker, rs9309326 reached genome-wide significance      
(p=8.00·10-09). The minor allele was significantly enriched in cases (MAF=0.28) 
compared to controls (MAF=0.07). The SNP is located at 2p16.1, 60 kb from the 
start of BCL11A. All seven SNPs resulting in p<0.00001 showed much higher minor 
allele frequencies in cases compared to controls, thereby suggesting the enrichment 
of rare variants (Table 21).  
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Table 20. Segments shared IBD between at least four pairs of individuals in Autism 
pedigree 1 or three pairs of individuals in Autism pedigree 2.  
PED ID1 ID2 CHR FROM-BP TO-BP KB NSNP GRP 
PED1 152 110 2 124193101 129117426 4924.32 75 1 
PED1 152 138 2 123182056 130174939 6992.88 98 1 
PED1 110 138 2 120913571 129108475 8194.9 131 1 
PED1 150 113 2 122832236 130174939 7342.7 107 2 
PED1 SHARED SHARED 2 124193101 129108475 4915.37 74 NA 
PED1 5 25 4 172932609 175514110 2581.5 54 1 
PED1 5 138 4 172561090 177328037 4766.95 93 1 
PED1 152 113 4 166392779 177120896 10728.1 202 2 
PED1 150 182 4 173090726 177086340 3995.61 86 3 
PED1 SHARED SHARED 4 173090726 175514110 2423.38 53 NA 
PED1 115 138 7 108116795 117023250 8906.45 108 1 
PED1 152 115 7 106790674 114162055 7371.38 94 1 
PED1 110 112 7 105545460 126072141 20526.7 214 2 
PED1 30 129 7 106170809 114393860 8223.05 99 3 
PED1 SHARED SHARED 7 108116795 114162055 6045.26 72 NA 
PED2 209 218 9 68190904 100219712 32028.8 649 1 
PED2 209 1 9 68190904 72418000 4227.1 68 1 
PED2 204 3 9 68190904 75855194 7664.29 141 2 
PED2 SHARED SHARED 9 68190904 72418000 4227.1 68 NA 
PED1 150 5 10 226452 2419307 2192.86 61 1 
PED1 150 182 10 226452 2079982 1853.53 50 1 
PED1 110 112 10 226452 10228122 10001.7 335 2 
PED1 152 138 10 1433016 2190634 757.618 39 3 
PED1 SHARED SHARED 10 1433016 2079982 646.966 34 NA 
PED2 1 3 16 62312584 71875058 9562.47 101 1 
PED2 132 1 16 69105798 74396097 5290.3 96 2 
PED2 218 3 16 71026964 73066203 2039.24 60 3 
PED2 SHARED SHARED 16 71026964 71875058 848.094 21 NA 
NOTE: PED – PEDIGREE, ID1 – ID of first individual, ID2 – ID of second individual, CHR 
– Chromosome, FROM-BP – Start of shared segment, TO-BP – End of shared segment, KB 
– length of shared segment in kb, NSNP – Number of SNPs in shared segment, GRP – Pairs 
sharing the same homozygous haplotype IBD, SHARED – the regions shared between all 
pairs of individuals. 
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Table 21. SNPs resulting in p<0.00001 in single-SNP association analysis in CF-GWAS. 
CHR SNP POSITION F_A F_U CHISQ P OR 
2 rs9309326 60478443 0.2843 0.07418 33.28 8.00E-09 4.958 
2 rs4076769 192292451 0.4314 0.1951 23.94 9.95E-07 3.131 
5 rs1863984 4264882 0.1569 0.03297 21.66 3.26E-06 5.457 
5 rs1077606 32135698 0.1373 0.02198 23.54 1.23E-06 7.08 
7 rs4724793 6281541 0.2857 0.08659 27.08 1.95E-07 4.219 
7 rs12701440 35617230 0.3235 0.1291 21.18 4.19E-06 3.226 
11 rs10501399 68979039 0.1373 0.02747 19.66 9.27E-06 5.632 
NOTE: CHR – Chromosome, F_A – Minor allele frequency in cases, F_U – Minor allele 
frequency in controls, CHISQ – Chi-square test statistic, P – p-value, OR – Odds ratio. 
5.5.5 Haplotype analysis 
To increase our power to detect shared common risk variants, we performed an 
association analysis using 5 SNP haplotypes in sliding windows across all 
chromosomes. Only two regions resulted in p<1·10-5 in the global test. The first 
region is located at 2p16.1 and overlaps with the best association result from the 
pointwise SNP analysis. Five consecutive 5-SNP haplotypes resulted in 2.02·10-6 
<p<8.24·10-6. One specific haplotype had a frequency of approximately 27% in 
cases and 7% in controls suggesting that the haplotype association result is primarily 
driven by rs9309326. The number of haplotypes, indicated by the degrees of 
freedom of the test statistic, suggests that the associated haplotype is located 
between two recombination hotspots (Figure 18). The other region highlighted by 
haplotype analysis was 2q33, covering parts of ALS2CR11 and ALS2CR4. In the 
region, four consecutive 5-SNP haplotypes resulted in 2.95·10-7<p<5.24·10-6. The 
SNPs in the region are in high LD in the HapMap CEU data, and the haplotype in 
this study set ends in a possible recombination hotspot indicated by a region of low 
LD and a high number of different haplotypes (Figure 19). The best single-SNP p-
value in the region was observed with rs12464623 (p=3.26·10-5), resulting from an 
enrichment of the minor allele in cases (frequency 0.14 in cases versus 0.03 in 
controls). It should be noted that none of the haplotype findings remain significant 
after correction for multiple testing. 
Analysis of single haplotypes revealed four additional loci of interest. Single 
haplotypes resulting in p<10-6 were identified on 2q24.3, 2q32.3, 7p22.1 and 
20q13.2 (Table 22). However, global p-values in these regions all exceeded   
p=1·10-5.  
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Figure 18. A region on 2p16.1 showing association to autism both in single SNP and 
haplotype association analyses. A) Results of association analyses for both single SNP and 5 
SNP sliding window haplotype tests. The red lines and the y-axis on the right hand side 
indicate the degrees of freedom for the haplotype association test, which correspond to the 
number of haplotypes. B) The LD structure of the region in the HapMap CEU population. 
Red bars indicate the corresponding regions in panels A and B. 
A 
B 
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Figure 19. A region on 2q33 showing association to autism both in single SNP and 
haplotype association analysis. A) Results of association analyses for both single SNP and 5 
SNP sliding window haplotype tests. The red lines and the y-axis on the right hand side 
indicate the degrees of freedom for the haplotype association test, which correspond to the 
number of haplotypes. B) The LD structure of the region in the HapMap CEU population. 
Red bars indicate the corresponding regions in panels A and B. 
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Table 22. Results of the haplotype association analysis in the CF-GWAS. 
LOCUS HAPLOTYPE F_A F_U P 
rs243034|rs243027|rs243081|rs243073|rs9309326 8.2E-06 
2p16.1 GAGGA 0.07 0.02 0.012 
2p16.1 AAGGA 0.22 0.06 4.5E-07 
2p16.1 GAGAG 0.18 0.27 0.049 
2p16.1 AAGAG 0.10 0.09 0.775 
2p16.1 GAGGG 0.00 0.01 0.243 
2p16.1 GCAGG 0.06 0.07 0.547 
2p16.1 ACAGG 0.35 0.41 0.221 
2p16.1 AAAGG 0.04 0.06 0.317 
rs243027|rs243081|rs243073|rs9309326|rs8179712 2.2E-06 
2p16.1 AGGGA 0.00 0.01 0.233 
2p16.1 CAGGA 0.06 0.08 0.648 
2p16.1 AAGGA 0.04 0.07 0.412 
2p16.1 AGGAG 0.28 0.07 8.7E-09 
2p16.1 AGAGG 0.27 0.36 0.104 
2p16.1 CAGGG 0.33 0.41 0.175 
rs243081|rs243073|rs9309326|rs8179712|rs1011407  2.1E-06 
2p16.1 AGGGG 0.10 0.08 0.643 
2p16.1 AGGAA 0.11 0.14 0.354 
2p16.1 GGAGA 0.28 0.07 3.2E-08 
2p16.1 GAGGA 0.28 0.37 0.102 
2p16.1 AGGGA 0.24 0.33 0.075 
rs243073|rs9309326|rs8179712|rs1011407|rs10490071 2.0E-06 
2p16.1 GGGAA 0.25 0.30 0.341 
2p16.1 GGGGG 0.09 0.09 0.818 
2p16.1 GGAAG 0.11 0.16 0.236 
2p16.1 GAGAG 0.27 0.07 1.8E-08 
2p16.1 AGGAG 0.28 0.36 0.116 
2p16.1 GGGAG 0.00 0.03 0.095 
rs9309326|rs8179712|rs1011407|rs10490071|rs1012585 2.3E-06 
2p16.1 GGGGA 0.09 0.08 0.814 
2p16.1 GAAGA 0.11 0.16 0.241 
2p16.1 GGAAG 0.25 0.30 0.318 
2p16.1 AGAGG 0.27 0.07 3.1E-08 
2p16.1 GGAGG 0.28 0.39 0.049 
rs7424428|rs10497238|rs4668422|rs10199735|rs16848651 4.13E-05 
2q24.3 AAAAA 0.07 0.10 0.305 
2q24.3 GCAAA 0.01 0.02 0.627 
2q24.3 GCGAG 0.04 0.07 0.270 
2q24.3 AAAAG 0.05 0.06 0.587 
2q24.3 ACAAG 0.08 0.12 0.250 
2q24.3 AAAGG 0.10 0.01 2.4E-07 
2q24.3 GCAGG 0.66 0.62 0.546 
rs4076769|rs6434503|rs4241279|rs7598944|rs6718527 1.2E-04 
2q32.3 GGAGG 0.04 0.04 0.955 
2q32.3 GAAGG 0.02 0.06 0.099 
2q32.3 GAGGG 0.01 0.02 0.519 
2q32.3 GAGGA 0.06 0.06 0.970 
2q32.3 GGGAA 0.00 0.03 0.094 
2q32.3 AAGAA 0.44 0.20 9.2E-07 
2q32.3 GAGAA 0.43 0.59 0.004 
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LOCUS HAPLOTYPE F_A F_U P 
rs10931953|rs4675170|rs4675195|rs10931963|rs12464623 3.0E-07 
2q33 GGGAA 0.00 0.02 0.134 
2q33 GAGGA 0.08 0.01 8.4E-06 
2q33 AGAGA 0.03 0.00 0.007 
2q33 GAGGG 0.53 0.44 0.136 
2q33 AGAGG 0.25 0.25 0.941 
2q33 GGAGG 0.11 0.27 0.001 
rs4675170|rs4675195|rs10931963|rs12464623|rs17384203 6.5E-07 
2q33 AGGGG 0.07 0.07 0.995 
2q33 GGAAA 0.00 0.02 0.132 
2q33 AGGAA 0.07 0.00 2.9E-05 
2q33 GAGAA 0.06 0.01 5.7E-04 
2q33 AGGGA 0.45 0.37 0.175 
2q33 GAGGA 0.35 0.52 0.003 
rs4675195|rs10931963|rs12464623|rs17384203|rs2540450 5.2E-06 
2q33 GGAAA 0.06 0.00 1.6E-04 
2q33 GGGAA 0.36 0.32 0.463 
2q33 GGGGG 0.07 0.07 0.917 
2q33 GAAAG 0.00 0.02 0.133 
2q33 AGAAG 0.07 0.01 4.7E-04 
2q33 GGGAG 0.09 0.06 0.197 
2q33 AGGAG 0.36 0.52 0.004 
rs10931963|rs12464623|rs17384203|rs2540450|rs1914261 5.2E-06 
2q33 GAAGA 0.07 0.01 3.0E-04 
2q33 GGAGA 0.34 0.50 0.006 
2q33 GAAAC 0.06 0.00 1.3E-04 
2q33 GGAAC 0.36 0.33 0.537 
2q33 GGGGC 0.07 0.07 0.963 
2q33 AAAGC 0.00 0.02 0.134 
2q33 GGAGC 0.10 0.08 0.340 
rs10262194|rs1559560|rs10085518|rs7790267|rs4724793 5.0E-05 
7p22.1 GGAGA 0.02 0.01 0.448 
7p22.1 AGGGA 0.24 0.07 9.4E-07 
7p22.1 AGGAG 0.05 0.06 0.882 
7p22.1 GGAGG 0.05 0.09 0.233 
7p22.1 AGAGG 0.05 0.03 0.279 
7p22.1 GGGGG 0.00 0.04 0.074 
7p22.1 AGGGG 0.59 0.72 0.016 
rs7267819|rs6097659|rs6022839|rs2904376|rs6068717 1.0E-04 
20q13.2 AGGAA 0.04 0.05 0.640 
20q13.2 GGGAA 0.14 0.13 0.807 
20q13.2 GGGGA 0.01 0.02 0.379 
20q13.2 GGGAC 0.16 0.03 1.7E-07 
20q13.2 GAAGC 0.04 0.05 0.724 
20q13.2 GAGGC 0.05 0.03 0.365 
20q13.2 AGGGC 0.32 0.41 0.139 
20q13.2 GGGGC 0.24 0.29 0.313 
Note: For each locus, the first line indicates the SNPs included in the haplotype, and a p-
value for the global association test for that haplotype. Indicated in italics are the frequencies 
of each haplotype allele and p-value for association tests for specific haplotypes. F_A – 
Frequency in cases, F_U – Frequency in controls, P – p-value. Indicated in bold are 
haplotypes resulting in p<1·10-5 in the global test or p<1·10-6 for specific haplotypes. 
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5.5.6 Replication of CF-GWAS in two datasets 
We selected the best SNPs from the single SNP and haplotype association analyses 
for replication in two datasets. Our first replication set consisted of one affected 
individual from the Finnish autism families who did not have genealogical roots in 
Central Finland (n=76, FIN-GWAS) along with 271 matched controls. The second 
control dataset was the large AGRE family set from the admixed US population, 
whose genotypes are publicly available from AGRE (AGRE-GWAS). We also 
genotyped all available family members of the individuals included in the CF-
GWAS and the Finnish replication set in order to perform a family-based association 
study, considering some families had more than one affected individual. We selected 
all SNPs resulting in p<1·10-4 in single SNP association analysis, haplotypes 
resulting in p<1·10-5 in a global test, and specific haplotypes resulting in p<1·10-6 in 
the CF-GWAS for replication and family-based analysis. A total of 70 SNPs passed 
these criteria. 
Case-control analysis for the Finnish replication set was performed by logistic 
regression. The position of each individual on the first three dimensions of MDS 
extracted IBS sharing data was used as covariates in the analysis to control for the 
population structure that was evident in the dataset. The TDT-test was used to test 
for association in the AGRE dataset as genotypes for parents were available. PLINK 
was used for all analysis. None of the SNPs resulting in p<10-4 in the CF-GWAS 
resulted in suggestive association in either of the replication study sets (Table 23). 
However, the Finnish replication dataset does not provide sufficient power to detect 
variants with small effects on the phenotype. As family-based association studies 
provide more power to detect association, we used PSEUDOMARKER to perform a 
family-based, nonparametric association analysis using all available family members 
and controls to further assess the role of these variants in autism. In the family-based 
association analysis, suggestive association was observed in the replication and 
combined Finnish datasets for a subset of SNPs (Table 24). Three SNPs, rs2302561 
rs17053011and rs6935315 resulted in p<0.05 in both Finnish datasets. 
 
  
Table 23. Results for the replication of best single-SNP results from the CF-GWAS. 
    
CF-GWAS 
 
FIN-GWAS 
 
AGRE-GWAS 
SNP CHR POSITION GENE F_A F_U P 
 
OR P 
 
T U P 
rs6696977 1 41128813 
 
0.31 0.54 4.0E-05 
 
1.19 0.35 
 
264 246 0.43 
rs7539694 1 48822262 AGBL4 0.25 0.09 4.7E-05 
 
1.15 0.61 
 
148 139 0.60 
rs10911628 1 182916126 
 
0.16 0.04 2.8E-05 
 
NA NA 
 
NA NA NA 
rs1354369 1 193082712 
 
0.45 0.25 6.3E-05 
 
1.18 0.47 
 
214 205 0.66 
rs4658971 1 230174437 DISC1 0.10 0.01 2.0E-05 
 
0.78 0.77 
 
59 63 0.72 
rs12472764 2 338470 
 
0.30 0.53 4.3E-05 
 
0.32 0.75 
 
268 290 0.35 
rs9309326 2 60478443 
 
0.28 0.07 8.0E-09 
 
0.99 0.97 
 
165 NA NA 
rs2302561 2 71075330 TEX261 0.43 0.22 6.9E-05 
 
0.73 0.19 
 
232 274 0.06 
rs4076769 2 192292451 
 
0.43 0.20 1.0E-06 
 
0.84 0.42 
 
126 136 0.54 
rs4483984 2 192366430 
 
0.51 0.29 4.8E-05 
 
0.97 0.90 
 
235 265 0.18 
rs12464623 2 202181323 ALS2CR11 0.14 0.03 3.3E-05 
 
NA NA 
 
46 60 0.17 
rs3819340 3 150097977 
 
0.08 0.01 5.3E-05 
 
1.58 0.29 
 
48 60 0.25 
rs2968671 4 5025571 
 
0.24 0.09 8.1E-05 
 
0.84 0.58 
 
163 157 0.74 
rs1471928 4 140319218 
 
0.37 0.18 7.1E-05 
 
1.15 0.55 
 
178 165 0.48 
rs1863984 5 4264882 
 
0.16 0.03 3.3E-06 
 
0.95 0.88 
 
104 86 0.19 
rs10066063 5 32126051 PDZD2 0.11 0.02 1.5E-05 
 
0.59 0.36 
 
99 88 0.42 
rs1077606 5 32135448 PDZD2 0.14 0.02 1.2E-06 
 
0.83 0.69 
 
111 89 0.12 
rs17053011 5 55293694 SGCD 0.39 0.20 8.8E-05 
 
1.36 0.17 
 
133 118 0.34 
rs1422859 5 166021965 
 
0.35 0.17 4.6E-05 
 
1.10 0.71 
 
126 104 0.15 
rs2988681 6 87016654 
 
0.12 0.31 9.2E-05 
 
0.76 0.23 
 
188 177 0.56 
rs6935315 6 99459993 FBXL4 0.18 0.40 6.5E-05 
 
1.15 0.49 
 
231 248 0.44 
rs4724793 7 6281291 
 
0.29 0.09 2.0E-07 
 
NA NA 
 
73 75 0.87 
rs12701440 7 35617230 
 
0.32 0.13 4.2E-06 
 
1.19 0.47 
 
198 164 0.07 
rs4717992 7 63219204 
 
0.19 0.41 4.6E-05 
 
1.34 0.15 
 
272 262 0.67 
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CF-GWAS 
 
FIN-GWAS 
 
AGRE-GWAS 
SNP CHR POSITION GENE F_A F_U P 
 
OR P 
 
T U P 
rs7009615 8 18617115 PSD3 0.24 0.09 7.3E-05 
 
1.33 0.31 
 
114 113 0.95 
rs10501399 11 68979039 
 
0.14 0.03 9.3E-06 
 
0.47 0.10 
 
87 81 0.64 
rs2564580 12 30288653 
 
0.13 0.03 2.1E-05 
 
1.34 0.58 
 
NA NA NA 
rs12229563 12 89984555 
 
0.21 0.07 3.8E-05 
 
NA NA 
 
67 56 0.32 
rs9576952 13 39626828 
 
0.25 0.09 2.9E-05 
 
0.86 0.59 
 
149 118 0.06 
rs4587895 14 27532119 
 
0.16 0.04 1.7E-05 
 
NA NA 
 
NA NA NA 
rs10484187 14 46802461 MDGA2 0.13 0.02 1.2E-05 
 
0.68 0.38 
 
92 69 0.07 
rs1959033 14 63405339 SYNE2 0.16 0.04 6.7E-05 
 
0.92 0.84 
 
71 84 0.30 
rs16967173 16 16003127 ABCC1 0.16 0.04 7.8E-05 
 
0.13 0.72 
 
84 63 0.08 
rs2042005 17 5674282 
 
0.51 0.30 9.2E-05 
 
1.05 0.83 
 
287 284 0.90 
rs11661310 18 27781882 
 
0.22 0.08 6.3E-05 
 
0.84 0.60 
 
63 56 0.52 
rs5906714 X 48569590 
 
0.46 0.20 3.9E-05 
 
0.98 0.94 
 
87 81 0.64 
rs952422 X 50660814 
 
0.25 0.07 3.8E-05 
 
0.97 0.93 
 
54 44 0.31 
NOTE : SNPs resulting in p<1·10-4 in single-SNP association analysis in the CF-GWAS were included. Analysis was performed using 
PLINK. Case-control association analysis was performed in the CF-GWAS and Finnish replication study sets, whereas TDT analysis was 
performed in the AGRE data set. Position is given according NCBI build 36.1. CHR – Chromosome, F_A – Allele frequency in cases, 
F_U – Allele frequency in controls, P – p-value, T –transmitted minor allele count, U – untransmitted minor allele count. p-values <0.05 
are indicated in bold. 
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Table 24. Results for the linkage and family-based association analysis of replication SNPs in Finnish families. 
     
CF-GWAS FAMILIES 
 
FIN-GWAS FAMILIES 
 
COMBINED 
SNP CHR BP GENE REP Linkage LD|Linkage 
 
Linkage LD|Linkage 
 
Linkage LD|Linkage 
rs6696977 1 41128813 
 
SS 0.321 0.015 
 
0.065 0.904 
 
0.082 0.043 
rs7539694 1 48822262 AGBL4 SS 0.470 1.2E-04 
 
0.488 0.655 
 
0.470 0.037 
rs1354369 1 182916126 
 
SS 0.306 0.001 
 
0.477 0.349 
 
0.470 0.001 
rs4658971 1 230174437 DISC1 SS 0.418 0.155 
 
0.349 0.014 
 
0.319 0.002 
rs12472764 2 338470 
 
SS 0.288 0.003 
 
0.040 0.428 
 
0.064 0.014 
rs243034 2 60456396 
 
GH, SH 0.059 0.048 
 
0.180 0.553 
 
0.037 0.111 
rs243073 2 60472194 
 
GH, SH 0.153 0.050 
 
0.446 0.922 
 
0.263 0.474 
rs9309326 2 60478443 
 
SS 0.335 8.1E-08 
 
0.500 0.173 
 
0.500 0.026 
rs2302561 2 71075330 TEX261 SS 0.500 0.002 
 
0.500 0.019 
 
0.500 0.556 
rs4076769 2 192292451 
 
SS, SH 0.500 3.9E-05 
 
0.237 0.651 
 
0.385 0.002 
rs4241279 2 192317911 
 
SH 0.002 0.160 
 
0.500 0.716 
 
0.075 0.873 
rs4483984 2 192366430 
 
SS 0.446 1.5E-04 
 
0.343 0.957 
 
0.337 0.021 
rs10931963 2 202172222 ALS2CR11 GH 0.382 0.033 
 
0.382 0.452 
 
0.336 0.082 
rs12464623 2 202181323 ALS2CR11 SS, GH 0.365 0.014 
 
0.378 0.242 
 
0.333 0.023 
rs3819340 3 150097977 
 
SS 0.020 0.003 
 
0.500 0.182 
 
0.161 0.123 
rs2968671 4 5025571 
 
SS 0.184 0.001 
 
0.384 0.239 
 
0.171 0.212 
rs1471928 4 140319218 
 
SS 0.466 0.001 
 
0.474 0.399 
 
0.458 0.245 
rs1863984 5 4264882 
 
SS 0.296 9.0E-06 
 
0.140 0.219 
 
0.140 4.0E-04 
rs10066063 5 32126051 PDZD2 SS 0.500 6.7E-05 
 
0.321 0.289 
 
0.500 0.136 
rs1077606 5 32135448 PDZD2 SS 0.500 6.0E-06 
 
0.500 0.374 
 
0.500 0.075 
rs17053011 5 55293694 SGCD SS 0.500 9.0E-06 
 
0.238 0.005 
 
0.500 1.4E-05 
rs1422859 5 166021965 
 
SS 0.471 1.5E-04 
 
0.500 0.153 
 
0.479 0.001 
rs2988681 6 87016654 
 
SS 0.493 1.4E-04 
 
0.448 0.185 
 
0.448 0.001 
rs6935315 6 99459993 FBXL4 SS 0.500 2.7E-04 
 
0.455 0.049 
 
0.472 0.259 
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CF-GWAS FAMILIES 
 
FIN-GWAS FAMILIES 
 
COMBINED 
SNP CHR BP GENE REP Linkage LD|Linkage 
 
Linkage LD|Linkage 
 
Linkage LD|Linkage 
rs10262194 7 6241110 CYTH3 SH 0.500 0.113 
 
0.500 0.013 
 
0.500 0.268 
rs12701440 7 35617230 
 
SS 0.500 1.1E-05 
 
0.446 0.723 
 
0.449 0.012 
rs4717992 7 63219204 
 
SS 0.466 0.002 
 
0.195 0.956 
 
0.458 0.037 
rs7009615 8 18617115 PSD3 SS 0.500 1.0E-05 
 
0.472 0.587 
 
0.500 0.003 
rs10501399 11 68979039 
 
SS 0.207 5.1E-05 
 
0.472 0.195 
 
0.468 0.001 
rs2564580 12 30288653 
 
SS 0.488 9.1E-05 
 
0.479 0.924 
 
0.492 0.006 
rs4587895 14 27532119 
 
SS 0.047 0.496 
 
0.495 0.084 
 
0.318 0.459 
rs10484187 14 46802461 MDGA2 SS 0.476 1.5E-05 
 
0.020 0.744 
 
0.430 0.005 
rs1959033 14 63405339 SYNE2 SS 0.500 0.001 
 
0.500 0.519 
 
0.500 0.008 
rs2042005 17 5674282 
 
SS 0.075 4.9E-04 
 
0.459 0.716 
 
0.455 0.011 
rs11661310 18 27781882 
 
SS 0.500 1.0E-04 
 
0.464 0.667 
 
0.500 0.005 
rs2904376 20 51955127 
 
SH 0.466 0.020 
 
0.477 0.074 
 
0.500 0.007 
NOTE: Only SNPs resulting in p<0.05 in either linkage- or family-based association analyses are shown. In addition to the autism 
families, controls were included in the PSEUDOMARKER analysis. For the CF-GWAS families, the 181 GWAS controls were included, 
and for the replication families, 492 controls from all of Finland were included. Position is given according NCBI build 36.1. CHR – 
chromosome, CRIT – Criteria for inclusion in replication dataset, SS – Single SNP association analysis resulting in p<1·10-4, GH – Global 
haplotype association analysis resulting in p<1·10-5, SH – Single haplotype association analysis resulting in p<1·10-6, Linkage – p-value 
for nonparametric linkage analysis, LD|linkage – p-value for recessive PSEUDOMARKER association test conditional on linkage. p-
values <0.05 are indicated in bold. 
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The first SNP showing suggestive association in family based analysis, rs2302561, 
resulted in p=0.002 in the CF families, and p=0.019 in the Finnish replication 
families. However, although the ancestral G allele is significantly enriched in the CF 
data set (frequency 0.43 in cases versus 0.22 in controls), the G allele frequency is 
actually higher in controls than cases in the replication data set (frequency 0.22 in 
cases versus 0.29 in controls). The SNP also resulted in the most significant 
evidence for association (p=0.06) of all replication SNPs in the AGRE families. In 
the AGRE dataset, the derived G allele is slightly overtransmitted to affected 
individuals in TDT analysis, in agreement with the CF-GWAS results. Frequencies 
in the Finnish controls are similar to those in the European HapMap populations, 
where the derived T allele is the major allele, and the ancestral G allele frequency is 
around 30%. The rs2302561 SNP is a synonymous SNP located in the last coding 
exon of TEX261, a gene linked to NMDA receptors. 
The second SNP, rs17053011, resulted in p=9·10-6 in the family-based association 
analysis of the CF families and in p=0.005 in the replication families. The SNP is 
located in SGCD and encodes a component of the dystrophin-glycoprotein complex, 
which links the F-actin cytoskeleton to the extracellular matrix. As the protein is 
expressed mainly in skeletal and cardiac muscle and has been linked with autosomal 
recessive limb-girdle muscular dystrophy and dilated cardiomyopathy, it is an 
unlikely candidate gene for ASDs (Nigro et al. 1996). 
The third SNP resulting in p<0.05 in the family-based association analysis in both 
the CF and replication families is rs6935315. The SNP is located in an intron of 
FBXL4 encoding a member of the F-box protein family. The F-box proteins 
constitute one of the four subunits of a ubiquitin protein ligase complex, which 
functions in phosphorylation-dependent ubiquitination and is involved in the control 
of the cell cycle (Cenciarelli et al. 1999; Winston et al. 1999). In the CF families, the 
ancestral allele A is overrepresented in cases, whereas in the replication data set the 
derived G allele is more common in cases than controls. 
The SNP rs4658971 did not result in significant evidence for association in the 
family-based association analysis of the CF families, but resulted in p=2·10-5 in the 
case-control association analysis in the CF-GWAS. It also resulted in suggestive 
association in the replication families (p=0.014) as well as in the combined CF and 
replication families (p=0.002). This SNP is located in DISC1, which has been shown 
to be involved in several neuropsychiatric disorders and related traits (see also 5.1). 
We also attempted to replicate the haplotype findings, and performed family-based 
association analysis using FBAT in all the Finnish replication families. We selected 
all SNPs residing in haplotypes resulting in p<1·10-5 in the global association test 
and p<1·10-6 for single haplotypes in the CF-GWAS. The same haplotypes were also 
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analyzed in the AGRE data using the haplotype-TDT test implemented in PLINK. 
Haplotype analysis in the replication data sets provided further support for the role 
of 2p16.1 in ASDs. Three 5-SNP haplotypes were analyzed in this region in the 
Finnish replication families, and the most significant evidence for association 
(global test p=0.017) was obtained for a haplotype comprised of rs243034, 
rs243027, rs243081, rs243073 and rs8179712. Using the same SNPs, a single 
haplotype allele resulted in p=0.004 in the AGRE dataset. The adjacent 5-SNP 
haplotype, comprised of rs243027, rs243081, rs243073, rs8179712 and rs1011407 
also resulted in suggestive evidence for association. The Finnish replication families 
resulted in p=0.038 in the global test and one haplotype allele at this locus resulted 
in p=0.009 in the AGRE families. As mentioned previously, the haplotype 
association results in the CF-GWAS are probably largely due to the effects of the 
large allele frequency differences at rs9309326. However, it should be noted that 
this SNP did not result in significant p-values in the replication data-set, suggesting 
that rs9309326 serves as a proxy for the true susceptibility variant in the CF-dataset, 
that is more efficiently tagged by the 5-SNP haplotype in the replication dataset. 
No haplotypes outside the 2p16.1 locus resulted in p<0.05 in the Finnish replication 
families. In the AGRE dataset, one haplotype at the 2q33 locus resulted in p=0.013 
and another at 20q13.2 in p=0.024. The haplotype alleles associated with ASDs in 
the AGRE dataset are not the same as those observed in the CF-GWAS. 
To summarize the association analysis, both the single SNP and haplotype 
association analysis revealed common variants enriched in the CF dataset compared 
to regionally matched controls. To further assess the role of these variants in the 
etiology of ASDs, we used two replication datasets, one from Finland and another 
from the US. A subset of single SNP and haplotype findings showed suggestive 
evidence for association in the replication datasets, and encouragingly, some of the 
haplotype findings resulted in suggestive p-values in both replication datasets. 
However, for some susceptibility variants, the replication findings were not obtained 
for the same allele as in the CF-GWAS, and these results should be interpreted with 
caution. The haplotype alleles associated with ASDs in the original and replication 
datasets are different, but this could be a result of the presence of different 
susceptibility variants in the different populations. 
5.5.7 CNV analysis 
In addition to genotype information, the SNP probe intensity values from genome-
wide SNP microarrays can be used to detect amplified or deleted segments. We used 
PennCNV (Wang et al. 2007) to identify CNV regions in the entire autism dataset, 
consisting of both the CF-GWAS and FIN-GWAS. PennCNV implements a hidden 
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Markov model to infer CNV states using both the total probe intensity (Log R ratio, 
LRR) and the relative ratio of the fluorescent signals between two alleles at each 
SNP (B allele frequency, BAF). PennCNV also implements a correction for 
wavelike patterns in the intensity spectra by modeling the GC content in the region 
(Diskin et al. 2008). 
As the frequency and distribution of CNVs in the general population still need to be 
further characterized, we wanted to adopt a conservative threshold defining CNV 
regions of interest (CNV-ROIs) and to focus on CNVs in regions which have not 
been reported in controls. In addition to the controls included in this study, we used 
a set of approximately 5400 Finnish individuals from the NFBC66 cohort, which 
have been genotyped using the Illumina HumanHap 370 beadchip, and assessed for 
CNVs using PennCNV. We discarded all samples with large variability in the 
intensity measurements as they did not meet quality control criteria (LRR_SD>0.3, 
BAF_DRIFT>0.0025, WF>0.04 or WF<-0.04). QC resulted in the exclusion of 4 
cases and 848 controls, resulting in a total of 124 cases and 4608 controls for CNV 
analysis. 
We defined CNV-ROIs as CNVs identified in cases but with no more than a 50% 
overlap with a CNV reported in the Database of Genomic Variants. We also 
excluded all regions identified in 2 or more controls in our large Finnish control 
dataset. We excluded all CNV calls containing <10 SNPs, as the variability in the 
intensity data results in a large probability of false positive calls in small regions. 
Only CNVs spanning genes were included in the analysis. A total of 35 CNV-ROIs 
were identified (Table 25).  
We identified five large CNVs, three at 15q11-13, one at 1q and one at 9q. We 
genotyped available family members to investigate the inheritance of these CNVs 
using Illumina HumanHap 370 Beadchip. Both the gain on chromosome 1 as well as 
the gain on chromosome 9 were inherited from the father, who did not have a 
diagnosis of ASDs. Interestingly, in the family with the 1q duplication, the nephew 
of the affected father is undergoing assessment for ASDs at three years of age. In the 
other family, the father has had delayed speech development and difficulties in 
learning to read and write. Two of the 15q11-13 duplications were inherited from an 
unaffected mother. The third 15q11-13 duplication, estimated to have a copy 
number of four and is de novo. In addition to these loci, several smaller regions of 
interest were identified. These include a deletion spanning part of NRXN1, and a 
duplication of 22q13 that includes SHANK3. Nine regions overlapped with CNVs 
reported in the Autism Chromosome Rearrangement Database (ACRD), supporting 
the role of these loci in the etiology of ASDs. In addition, several novel loci were 
identified. 
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Table 25. CNV regions of interest identified in the CF-GWAS and FIN-GWAS. 
CHR From-kb To-kbP NSNP Length CN Nind ACRD Genes 
1 198 896 199 007 26 110 3 1 No DDX59, CAMSAP1L1 
1 226 859 229 343 577 2 482 3 1 No 18 genes 
2 37 031 37 165 30 134 1 1 No STRN, HEATR5B 
2 47 455 47 569 16 115 1 1 No EPCAM, MSH2 
2 51 068 51 189 27 121 1 1 Loss NRXN1 
2 197 079 197 200 16 121 3 1 No HECW2 
2 208 742 208 808 11 66 1 1 Gain C20orf80 
2 230 582 230 633 10 51 1 1 No FBX036, SLC16A14 
2 238 078 238 159 17 70 3 2 Loss MLPH, PRLH, RAB17 
3 129 114 129 172 10 43 1 2 No KLHDC6 
5 43 037 43 248 22 211 1 1 No 
C5orf39, ZNF131, 
MGC42105 
5 59 759 59 795 15 37 3 1 No PDE4D 
6 7 927 8 003 13 76 1 2 No MUTED 
6 10 871 10 937 10 66 1 1 No MAK 
6 72 989 73 382 95 393 3 1 No RIMS1 
6 116 723 116 808 14 85 1 1 Loss DSE 
7 33 098 33 154 10 56 3 1 No RP9, BBS9 
9 87 214 88 935 225 1 721 3 1 No 
AGTPBP1, MAK10, GOLM1, 
C9orf153, ISCA1, ZCCHC6, 
GAS1 
9 106 297 106 874 187 576 3 1 No 
8 olfactory receptors,, 
NIPSNAP3A, NIPSNAP3B, 
ABCA1 
9 135 459 135 533 42 74 3 1 No DBH, SARDH 
10 11 367 11 531 34 164 3 1 No CUGBP2 
10 51 456 51 828 63 372 3 3 Gain 
FAM21A, FAM21B, ASAH2, 
SGMS1 
10 72 253 72 310 14 57 1 2 No SGPL1 
13 18 514 18 613 13 98 3 1 No DKFNp686A1627 
14 34 999 35 148 15 150 1 1 No INSM2, GARNL1 
15 18 421 25 688 572 7 266 4 1 Yes 26 genes 
15 20 307 26 209 620 5 902 3 1 Yes 22 genes 
15 21 240 26 209 566 4 969 3 1 Yes 14 genes 
15 90 016 90 381 96 365 3 1 No SLCO3A1 
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CHR From-kb To-kbP NSNP Length CN Nind ACRD Genes 
19 12 868 12 942 11 73 1 1 No 
GCDH, SYCE2, FARSA, 
CALR, RAD23A, 
GADD45GIP1, DAND5 
20 41 032 41 177 36 145 1 1 Gain PTPRT 
22 48 777 49 525 141 748 1 1 
Gain 
and 
loss 
32 genes including 
SHANK3 
NOTE: CHR – Chromosome, From-kb – Start of CNV in kilobases from ptel, To-kb – End of 
CNV in kilobases from pten. Positions according to NCBI build 36 NSNP – Number of SNPs in 
the CNV region, Length – Length of CNV in kilobases, CN – Copy number, ACRD – Presence of 
CNV in Autism Chromosome Rearrangement database. 
5.5.8 Genome-wide expression profiling 
We used Affymetrix U133 2.0 Plus chips to establish genome-wide expression 
profiles for 10 male individuals with autism (FIN-EXPR). Age-matched male 
individuals with no diagnosis of ASDs were used as controls. After reannotation of 
the probes according to Entrez and normalization, we identified a total of 325 
differentially expressed genes at the p=0.01 level with fold change ranges between -
2.24 to +4.14 (Figure 2a, publication V). Of these, 92 were upregulated and 233 
downregulated. At p=0.05 significance level, a total of 1286 genes were 
differentially expressed. Hierarchical clustering using the differentially expressed 
genes resulted in the clear separation of autism cases and controls, which were split 
into two clusters (Figure 2b, publication V). Due to the limited number of samples 
available for gene expression profiling, we chose not to evaluate the differentially 
expressed genes in traditional ways. Instead, we chose to use the results for pathway 
analysis to evaluate the data together with the GWAS data. 
5.5.9 Pathway-analysis of GWA and expression data 
We used non-parametric pathway algorithm developed in-house to identify GO-
categories which were enriched in differentially expressed or associated genes. 
Pathway analysis of gene expression data was performed by ranking all of the genes 
on the absolute fold change. SNP data was ranked based on the uncorrected p-value 
from the association analysis. All three GWA-datasets (CF-GWAS, FIN-GWAS and 
AGRE-GWAS), and two expression datasets (the Finnish expression dataset (FIN-
EXPR) and a publicly available dataset (GEO-EXPR)) were included in the pathway 
analyses. Very little overlap was observed between the GO-categories from the 
different datasets (Table 26). 
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Table 26. Top 10 regulated GO-categories in the datasets included in this study. 
GO-category Category description p 
CF-GWAS 
  
GO:0016528       sarcoplasm       0.001 
GO:0016529       sarcoplasmic reticulum       0.001 
GO:0043193       positive regulation of gene-specific transcription       0.001 
GO:0032583       regulation of gene-specific transcription       0.001 
GO:0001525       angiogenesis       0.003 
GO:0048514       blood vessel morphogenesis       0.003 
GO:0008168       methyltransferase activity       0.003 
GO:0001568       blood vessel development       0.004 
GO:0016741       transferase activity, transferring one-carbon groups       0.004 
GO:0035107       appendage morphogenesis       0.006 
FIN-GWAS 
  
GO:0005764       lysosome       0.0038 
GO:0000323       lytic vacuole       0.0038 
GO:0005773       vacuole       0.0069 
GO:0031968       organelle outer membrane       0.0073 
GO:0019888       protein phosphatase regulator activity       0.0078 
GO:0019867       outer membrane       0.0081 
GO:0046483       heterocycle metabolic process       0.0088 
GO:0016810       
hydrolase activity, acting on carbon-nitrogen (but not 
peptide) bonds       
0.0119 
GO:0019208       phosphatase regulator activity       0.0139 
GO:0018193       peptidyl-amino acid modification       0.0171 
AGRE-GWAS 
  
GO:0032870       cellular response to hormone stimulus       0.0001 
GO:0005819       spindle       0.0002 
GO:0000278       mitotic cell cycle       0.0019 
GO:0007067       mitosis       0.002 
GO:0043434       response to peptide hormone stimulus       0.0023 
GO:0000087       M phase of mitotic cell cycle       0.0025 
GO:0000279       M phase       0.0031 
GO:0051329       interphase of mitotic cell cycle       0.0033 
GO:0005179       hormone activity       0.0037 
GO:0009725       response to hormone stimulus       0.0059 
FIN-EXPR 
  
GO:0051640 organelle localization 0.0006 
GO:0000242 pericentriolar material 0.0007 
GO:0004715 non-membrane spanning protein tyrosine kinase activity 0.0008 
GO:0031532 actin cytoskeleton reorganization 0.0011 
GO:0001515 opioid peptide activity 0.0012 
GO:0010573 vascular endothelial growth factor production 0.0021 
GO:0008156 negative regulation of DNA replication 0.0022 
GO:0010574 regulation of vascular endothelial growth factor production 0.0022 
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GO-category Category description p 
GO:0034464 BBSome 0.0024 
GO:0032350 regulation of hormone metabolic process 0.0026 
GEO-EXPR 
  
GO:0007019 microtubule depolymerization 0.0003 
GO:0031646 positive regulation of neurological system process 0.0004 
GO:0050806 positive regulation of synaptic transmission 0.0005 
GO:0031111 
negative regulation of microtubule polymerization or 
depolymerization 
0.0006 
GO:0050000 chromosome localization 0.0007 
GO:0051963 regulation of synaptogenesis 0.0008 
GO:0051303 establishment of chromosome localization 0.0009 
GO:0046459 short-chain fatty acid metabolic process 0.0009 
GO:0051971 positive regulation of transmission of nerve impulse 0.0011 
GO:0050807 regulation of synapse organization and biogenesis 0.0011 
NOTE: CF-GWAS – Central Finland GWAS, FIN-GWAS – Finnish replication GWAS, AGRE-
GWAS – Autism Genetic Research Exchange GWAS, GEO-EXPR – Gene Expression Omnibus 
expression dataset GSE6575. 
5.5.10 Discussion 
Previous studies have shown that the genetic architecture of ASDs is highly 
heterogeneous. We have previously shown that the Finnish population is stratified, 
with allele frequencies differing drastically between subisolates. To reduce genetic 
heterogeneity in our sample, we limited our study sample to families from the 
internal isolate of CF and a subset of individuals in this dataset can be 
genealogically linked to two large pedigrees. We have previously performed a dense 
microsatellite linkage study in the larger extended pedigree, in which no haplotypes 
shared among nuclear families were identified. In this study we wanted to follow up 
these findings using a denser set of markers as well as an increased sample size. 
First, we used dense, genome-wide SNP data to identify regions shared IBD in these 
distantly related individuals. We sought regions resembling either a dominant or 
recessive model within the extended pedigrees. However, no regions of interest were 
identified, suggesting that genetic risk factors are not shared across individuals in 
these pedigrees. The lack of shared haplotypes seems surprising, and even more 
surprising, IBD sharing data suggest that these families share less of their genome 
IBD compared to the other families used who were not linked genealogically but 
had two grandparents from CF. These results are in line with findings in other 
studies where identified mutations have often been de novo and specific to nuclear 
families. Homozygosity mapping has been primarily successful in closely 
consanguineous families where parents have been first or second cousins (Morrow 
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et al. 2008). The lack of increased IBD sharing between individuals in the large 
pedigrees agree with the lack of highly penetrant rare alleles enriched in these 
pedigrees. This data, combined with the results of the homozygosity- and shared 
segment analyses strongly agree with the hypothesis of de novo, family-specific risk 
variants. The methodology used in this study is poorly suited for identification of 
rare mutations unique to single families. These variants can only be revealed by 
genome-wide resequencing of affected individuals. 
We tested for common genetic risk factors within the CF dataset, and tried to 
replicate findings in two other datasets - one from the rest of Finland and the other 
from the US population. Suggestive support from both Finnish datasets was 
observed for a total of four variants, of which the functionally most interesting are 
located in DISC1 and TEX261. DISC1 has been linked to schizophrenia and 
neurocognitive phenotypes, and we have previously shown that markers in DISC1 
are associated with ASD in the Finnish families (Kilpinen et al. 2008). It should be 
noted, however, that the families used in the DISC1 study comprise a significant 
subset of the families in the CF-GWAS and replication material, and so the 
association observed in DISC1 here cannot be viewed as an independent replication. 
The best results in our previous DISC1 study were obtained with a microsatellite 
marker located only 77 kb from the SNP associated with ASDs in this study.  
TEX261 is reported to be induced by NMDA stimulation in the mouse hippocampus, 
modulating the NMDA receptor-mediated signaling cascade and resulting in cell 
death (Taniura et al. 2007). The NMDA receptors, located at many excitatory 
glutamate synapses in the central nervous system, are interesting in autism studies as 
they are involved in biological processes linked to brain development, excitatory 
neurotransmission and synaptic plasticity. Overexpression of NMDA receptors in 
the forebrain of mice results in enhanced learning and memory capabilities in 
various behavioral tasks, and have therefore even been suggested to be a possible 
target for treating learning and memory disorders (Tang et al. 1999).  
All GWA datasets, including the AGRE dataset, showed evidence for suggestive 
association at 2p16.1 in haplotype analysis. The haplotype does not overlap with any 
coding genes, and is located close to the end of the BCL11A gene, which is involved 
in B and T lymphocyte development, and is expressed in erythroid cells (Satterwhite 
et al. 2001; Sankaran et al. 2008) Mice deficient in Bcl11a lack B cells and have 
alterations in several types of T cells (Liu et al. 2003). The closest gene upstream is 
FANCL, located over 2 Mb from rs9309326. The gene encodes an ubiquitin ligase 
implicated in Fanconi anemia etiology (Meetei et al. 2003). Mice deficient in Pog, 
the mouse homolog of FANCL, display deficient proliferation of germ-cells 
(Agoulnik et al. 2002). The haplotype could modify the expression of these genes, or 
overlap with unknown small non-protein coding genes. 
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It should be noted that for all of these loci except for the marker in DISC1, different 
alleles or haplotypes showed association within the different datasets. The 
inconsistent allele frequency findings in the CF and replication datasets could 
indicate either that the findings are false positives, or that the SNPs tag causal 
variants present on different haplotypes in the different datasets and are not the risk 
variants themselves. As only a limited number of common susceptibility variants 
have been identified in autism, susceptibility variants could differ among families. 
Although these datasets are limited, recent studies have shown that if the phenotype 
of interest is controlled by common risk factors enriched in an isolate, they can be 
identified in a study design identical to the one used here, where a limited number of 
distantly related individuals and carefully matched population controls are used 
(Kallio et al. 2009). 
We also assessed CNVs in these datasets. No enriched CNVs were identified in the 
Central Finland families, but two large duplications were identified in the extended 
pedigrees, further supporting the role of rare, family specific variants even within 
these sets of distantly related individuals. Interestingly, many of the CNV-ROIs 
identified here have been previously reported in ACRD. The ACRD uses a similarly 
conservative approach for the inclusion of putative ASD related CNVs where 
variants only identified in ASD cases but not in controls are included. Although the 
distribution of CNVs in normal populations still needs to be more carefully 
characterized, the presence of identical CNVs in our dataset and the ACRD further 
support the role of these CNVs in the etiology of ASDs.  
The data from the GWA analysis, together with findings from other ASD studies, 
support the role of several rare, family specific variants. However, we wanted to 
take the GWAS dataset a step further from traditional GWA data analysis, which is 
usually confined to association or haplotype analysis. We attempted to identify GO-
categories that link the “grey zone” of results, which are suggestive results that do 
not reach genome-wide significance. As we also had access to two expression 
datasets, we were able to rank the evidence from these analyses based on the number 
of datasets supporting the role of the identified biological processes. Although 
different genetic variants in these datasets could cause disruptions of separate genes 
that result in a similar phenotype, the genes should affect common biological 
pathways. However, very little overlap was observed between the GO-categories. 
It should be noted that the analysis of GO-categories also presents limitations. The 
GO-categories provide a far from complete picture of true biological function, 
because the majority of gene functions are still incompletely characterized. 
However, GO-categories comprise the most extensive systematic annotation of 
available data concerning gene function, and despite its limitations, it is currently the 
best option available for system-biology analysis. More thoroughly annotated 
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pathway-collections such as the Kyoto Encyclopedia of Genes and Genomes 
(KEGG)-database exist, but they are mainly focused on metabolic pathways, and 
provide only limited information of the neuronal processes, of greatest interest in 
this study. 
In summary, the primary result of the GWA analysis is that there are no enriched 
high impact mutations in the ASD-families originating from a subisolate in a 
founder population. This is in agreement with other studies, where rare, family-
specific mutations have been identified and where common variants have only been 
identified in large samples (Wang et al. 2009). Further, the combination of GWAS 
and expression data did not yield evidence for overlapping biological processes 
among the most associated GO-categories. 
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6 CONCLUDING REMARKS AND FUTURE PROSPECTS 
When this study was initiated, knowledge of the genetics of idiopathic ASDs had 
been obtained from linkage studies and observation of large, microscopically 
detectable chromosomal aberrations. Linkage studies typically comprised of 50-150 
families or affected sib pairs, and resulted in candidate regions on almost every 
chromosome (Yang and Gill 2007). Potential reasons for the heterogeneity of results 
are the different clinical categories used, various statistical approaches taken, and 
partial overlap of study samples. Although some of the linkage regions will prove to 
be false positives caused by small samples sizes, the findings most likely also 
represent the substantial genetic heterogeneity underlying ASDs. The success of risk 
variant identification within linkage peaks has been poor in general, but some 
interesting candidate genes have been identified. These include EN2 and CNTNAP2 
at 7q36 (Gharani et al. 2004; Benayed et al. 2005; Cheh et al. 2006; Alarcon et al. 
2008; Arking et al. 2008; Bakkaloglu et al. 2008; Turunen et al. 2008), RELN and 
MET at 7q21-22 (Persico et al. 2001; Bonora et al. 2003; Skaar et al. 2005; 
Campbell et al. 2006; Campbell et al. 2007), and HTR3C at 3q27 in this study. The 
majority of families included in the linkage studies have been included in 
association studies, but so far these studies have only been used to test for 
association between ASDs and common variants. To evaluate the role of linkage 
regions in these families, the linkage regions should be further characterized using 
the genome-wide SNP data through homozygosity and haplotype sharing analysis 
within families. As generation of SNP data has been both laborious and costly, all 
possible approaches should be used to utilize this data as effectively as possible. 
The chromosomal abnormalities reported in ASDs further support the hypothesis of 
genetic heterogeneity in these disorders. Deletions and duplications have been 
reported on almost every chromosome. Rare chromosomal rearrangements have 
resulted in the identification of risk variants in functionally interesting genes, such 
as NLGNs, NRXN1 and SHANK3, which in turn implicate synaptic dysfunction in 
the etiology of ASDs. A significant step forward in the genetic characterization of 
ASDs was taken when genome-wide BAC arrays made it possible to identify 
submicroscopic lesions. It soon became evident that CNVs contribute to autism 
susceptibility (Sebat et al. 2007; Szatmari et al. 2007; Marshall et al. 2008), but 
again shared CNVs were the exception rather than the rule. Genome-wide SNP 
genotyping and simultaneously offered the opportunity to test for association and the 
presence of CNVs resulting in numerous novel loci. The results of linkage studies, 
rare mutations and numerous large and small chromosomal aberrations point to rare, 
high penetrance variants unique to single families. 
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However, some candidate gene studies, together with the recently published GWASs 
in ASDs point to the presence of common variants in the etiology of the disorders as 
well. In the first published GWAS, variants located between CDH9 and CDH10 on 
5p14.1 were identified and the finding was replicated in two independent datasets. 
This agrees well with findings in other complex disorders where common variants 
have low risk ratios and a large number of individuals are needed to reliably identify 
susceptibility variants. Furthermore, the cadherins being neuronal cell-adhesion 
molecules fit well with the emerging evidence of the role of cell-adhesion 
molecules, such as NLGNs and NRXNs in ASDs. In another GWAS, replicated 
association was identified to an adjacent region, 5p15, close to SEMA5A (Weiss et 
al. 2009). In that study, the genome-wide SNP data was also used for linkage 
analysis and significant linkage was identified on 6q27 and 20p13. The fact that the 
linkage peaks did not overlap with the association peak could suggest that the 
linkage peaks contain rare, highly penetrant risk alleles. This agrees with results 
obtained in this study where strong linkage has been identified, but the GWAS did 
not reveal association at the linkage peaks. The presence of common variants 
associated with autism in HTR3C identified in this study only explain a part of the 
observed linkage, which suggests that the linkage peaks could contain rare and 
common risk variants. Accumulating evidence from both this study, and others 
strongly suggests that there are only few common variants predisposing for ASDs. 
This would agree with multiple studies reporting de novo genetic variants as 
predisposing factors. Further, a minority of individuals with ASDs have children, 
resulting in strong negative selection against these de novo variants in the 
population. The presence of common variants could however help explain the 
observed incomplete penetrance of rare variants and CNVs. The common variants 
could modify the expressivity of the observed rare, high penetrance mutations 
resulting in apparent nonsegregation of these variants in families and the presence of 
these variants in unaffected parents. 
In this study, we wanted to utilize the advantages offered by a well characterized 
family set from an isolated population to pinpoint genetic risk factors for ASDs. We 
have focused on clinically well characterized small subgroups to limit genetic 
heterogeneity. This approach has proved successful at least in the case of AS where 
the linkage signal on 3p14-24 has been replicated in an independent family set. The 
family set used in the AS study was the smallest in this thesis, but it consisted of 
large families with multiple affected individuals providing substantial power for 
linkage analysis. The results of the population stratification study (IV) showed that 
even though Finns display reduced genetic heterogeneity compared to other 
European populations, significant substructure can be observed within the 
population. To take advantage of this substructure, in study V we concentrated on a 
family set originating from an internal isolate in an attempt to enrich shared genetic 
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risk factors. We have shown using GWA data that even if shared ancestors can be 
genealogically linked, this does not necessarily mean that families share any high 
impact genetic risk variants or haplotypes. In fact, our data suggest the opposite in 
that the individuals in the two genealogically linked extended pedigrees share no 
more of their genome IBD than healthy controls collected from the same geographic 
region. There are no systematic studies of the prevalence of ASDs in different parts 
of Finland, but there is evidence available of specific geographic regions with higher 
prevalence. The ASD prevalence in Finland is also similar to that in other countries 
(Kielinen et al. 2000). The lack of increased IBD sharing together with the expected 
frequency of ASDs in Finland provide evidence against founder mutations enriched 
in this isolate. These facts, together with the results of study V provide convincing 
evidence that even in the Finnish population, genetic susceptibility factors for ASDs 
are de novo, undergo strong negative selection and are unique in nuclear families 
and not shared among distantly related individuals.  
Linkage and association analyses detect different predisposing factors. Linkage 
analysis evaluates the co-segregation of haplotypes with phenotypes within families, 
whereas association analysis in the simplest form compares allele frequencies 
between cases and controls. Linkage analysis is more efficient for detection of rare 
variants, whereas association analysis is more suited for the identification of 
common variants. The results obtained by these methods are dependent on the 
makeup of the genetic risk factors for the phenotype under study. The results of the 
WTCCC‟s landmark paper on the association analysis of seven disorders nicely 
illustrate the effects that the underlying genetic architecture has on the probability of 
identifying risk variants (WTCCC 2007). For all phenotypes, 2000 cases and 3000 
shared controls were used. Some disorders, such as coronary artery disease, type 1 
diabetes and rheumatoid arthritis, resulted in clear candidate regions. For other 
disorders, such as bipolar disorder and hypertension, no genome-wide significant 
variants were identified. It is probably not a coincidence that one of the phenotypes 
resulting in only suggestive association signals was a neuropsychiatric disorder. 
Phenotypes such as coronary artery disease and type 1 diabetes have clear biological 
markers which can be used to establish a diagnosis. For neuropsychiatric 
phenotypes, the definition of the phenotype is based on observations of the patient, 
and although diagnostic criteria are clearly outlined in diagnostic manuals, the 
subjective opinions of clinicians may play a role in the diagnosis. It is also obvious 
that the GWA approach will be fruitful for phenotypes where many common, shared 
variants confer susceptibility to the disorder even if risk alleles individually confer 
only a marginal increase in risk. For such phenotypes, increasing sample-sizes will 
reveal new, even smaller effect variants, as has been done for many phenotypes 
including metabolic phenotypes, height and weight (Lettre et al. 2008; Weedon et al. 
2008; Aulchenko et al. 2009; Thorleifsson et al. 2009). Several studies, including 
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this study, have shown that the genetic risk factors for autism are not predominantly 
of this type, but consist more prominently of rare, high impact alleles unique to 
small subsets of families. 
The studies of the genetics of ASDs, including this one, have usually contributed 
individually only small pieces of the puzzle. However, when put together in the right 
context, the genetic picture of autism has never looked as clear as it does today. For 
idiopathic autism, the available data suggests that rare, family specific variants 
might compose the most significant genetic risk factors and a smaller, although 
apparent role is attributed to common, possibly modifying genetic factors. Existing 
knowledge that includes known genetic syndromes, chromosomal abnormalities, 
CNVs and coding mutations account for 10-20% of ASD cases (Abrahams and 
Geschwind 2008). Developing methodologies for more sophisticated CNV analysis 
and the gathering of data containing less variability will make it possible to identify 
smaller CNVs. Next-generation sequencing technologies will enable massive 
resequencing projects of genes involved in neuronal development, thereby making it 
possible to identify rare variants present in only one or a few families. The 
bioinformatic challenges will, however, increase tremendously as larger amounts of 
datapoints for each individual are produced. The differentiation of rare benign 
variants from variants increasing risk of disorders will require massive, well-
characterized control data, which will become available from projects such as the 
1000 genome project. A proof-of-principal study of the feasibility of massive 
resequencing has already provided new genes associated with X-linked MR (Tarpey 
et al. 2009). However, the same study also identified loss of function mutations in 
individuals with no clinical phenotype. Therefore future resequencing studies should 
be well designed to be able to correctly interpret the large amount of data and rule 
out benign polymorphisms, even if they are rare in the population. 
The small number of identified mutations suggests that the majority of genetic risk 
factors for ASDs remain to be discovered. Several aspects of genetic analysis remain 
largely uncharacterized, such as methylation and microRNA profiling as well as 
pathway and transcription factor analysis. These could provide important new 
insight into the genetic architecture of ASDs in a similar way that the 
groundbreaking studies of the role of CNVs have done recently. Finally, it should be 
noted that the identification of a genetic variant is a mere first step in the 
understanding of the underlying biology. Identifying genetic factors for ASDs is 
only the beginning of the long path of validating the findings functionally in order to 
identify biologically relevant processes. The identification of these processes and 
pathways will advance the understanding of the pathogenesis of ASDs and hopefully 
in the future also provide diagnostic markers or even serve as a starting point for 
providing a cure for these disorders.  
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